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Abstract 
Trypanosoma brucei spp. are protozoan parasites that cause Human African 
Trypanosomiasis in humans, and Nagana in cattle. These diseases are mostly 
fatal if left untreated and there is an urgent need for safe, effective drugs that 
can be easily administered. T. brucei has a complex cell cycle, the regulation of 
which appears to be divergent compared to other model eukaryotes. This implies 
that the regulators of the T. brucei cell cycle could be exploited as a source of 
novel drug targets. One such cell cycle regulator of interest is T. brucei polo-like 
kinase (TbPLK), a serine/threonine protein kinase thought to diverge from its 
canonical functions in eukaryotic mitosis and be mainly involved in the 
duplication of the parasite’s cytoskeletal structures. This study sought to 
investigate how the activity and localisation of TbPLK is regulated in procyclic 
form (PCF) and bloodstream form (BSF) parasites. More specifically, the 
importance of two threonine residues (T198 and T202) within the activating T-
loop of the N-terminal kinase domain and the C-terminal polo-box domain (PBD), 
which in other organisms plays a key role in PLK localisation and activity, was 
investigated. 
An ectopic TbPLK expression assay was employed in PCF cells, whereby 
expression of wild-type (WT) TbPLK resulted in cell cycle defects, whilst 
expression of a kinase dead variant did not. A number of TbPLK 
mutants/truncations were expressed, and the resulting growth and cell cycle 
phenotypes were compared with those of WT and kinase dead TbPLK, to assess if 
they demonstrated kinase activity in vivo. The expressed proteins were also N-
terminally tagged with YFP to track their localisation. Results showed that T198, 
and possibly T202, phosphorylation is essential for TbPLK kinase activity, in 
agreement with published data (Yu et al, 2012). In vitro studies did not identify 
any auto-inhibitory role for the PBD on TbPLK activity which is in contrast to 
what is known in other organisms. On the other hand, the PBD was found to be 
required for TbPLK localisation similar to its homologues in other organisms. 
However, a putative His-Lys pincer in the PBD was found to not be required for 
TbPLK activity and localisation. All the full-length TbPLK variants localised in a 
dynamic manner in agreement with previous studies (Ikeda & de Graffenried, 
2012). Truncation studies also revealed that TbPLK possesses a functional 
 
xvii 
nuclear localisation signal (NLS) motif and a destruction box, the biological 
importances of which are yet to be determined.  
Efforts were also made to translate these studies on TbPLK regulation to the 
mammalian stages of the parasite. In the absence of notable TbPLK expression 
phenotypes in BSF cells, attempts were made to establish an RNAi 
complementation assay. The 3’ UTR of endogenous TbPLK was targeted via RNAi 
so that TbPLK variants could be ectopically expressed unhindered, and assessed 
for their ability to complement TbPLK RNAi. T198 was found to be important for 
TbPLK kinase activity similar to what was found in PCF parasites. Evidences of 
differential regulation of TbPLK between the two life cycle stages were also 
seen. It seems that the putative His-Lys pincer is required for TbPLK activity in 
BSF cells, which is in contrast to what is seen in PCF parasites. Altogether, 
despite TbPLK’s divergent functions, some of the ways by which it is regulated 
appear to be conserved. 
A second aim of this study was to identify novel protein kinases (PKs) which 
regulate the T. brucei cell cycle by screening part of a kinome-wide RNA 
interference (RNAi) library of BSF cell lines, that has recently been established 
(Jones et al. 2014). The cell lines had already been assessed for proliferation 
defects upon RNAi induction by using an Alamar blue viability assay. In this 
study, the cell lines which displayed proliferation defects were further screened 
for cell cycle defects using growth curves and DAPI staining, to identify as yet 
uncharacterised protein kinases required for T. brucei cell cycle regulation. 50 
PKs had been shown to be required for viability in vitro and were screened for 
potential cell cycle roles. Of these, 25 were identified as potential cell cycle 
regulators, 15 of which were detected for the first time. The majority of the hits 
were deemed to be involved in either just cytokinesis, or cytokinesis in 
combination with kinetoplast duplication or mitosis, with surprisingly few in 
G1/S. Knockdown of a number of these putative cell cycle PKs induced cell death 
signifying their potential as drug targets. Indeed, one of the hits, CLK1, was 
genetically validated as a potential drug target in a mouse model. The 
identification of these putative cell cycle kinases has also provided valuable 
starting points by which the signalling pathways that regulate the cell division 
cycle of these parasitic organisms can be elucidated. 
Chapter 1 
 
1 
1 Introduction 
1.1 The African Trypanosomiases  
Trypanosoma brucei spp. are the causative agents of the African 
trypanosomiases known to affect humans, livestock and wild animals. African 
trypanosomes are vector-borne parasites and are exclusively transmitted by the 
tsetse fly (Glossina species). These parasitic protozoa belong to the order 
Kinetoplastida, which also includes Trypanosoma cruzi, the causative agent of 
Chagas disease in South America, and Leishmania spp. which is responsible for 
the Leishmaniases in much of the tropical and subtropical world. The two 
morphologically indistinct Trypanosoma brucei sub-species, T. b. rhodesiense 
(found in East and Southern Africa) and T. b. gambiense (West and Central 
Africa) cause sleeping sickness in humans (also known as human African 
trypanosomiasis, or HAT). T. b. rhodesiense is considered as a host-range variant 
of the non-human infective sub-species, T. b. brucei, which causes Nagana in 
livestock (Sternberg & Maclean 2010); it expresses the serum-associated 
resistance (SRA) gene which confers its human infectivity (see section 1.1.1). T. 
b. gambiense can be divided further into at least two groups which differ in 
population genetic structure, virulence in experimental rodents and similarity to 
T. b. brucei (Sternberg & Maclean 2010). T. congolense, T. vivax, T. evansi and 
T. equiperdum are other important etiological agents of animal African 
trypanosomiasis (AAT). HAT and AAT affect people and livestock living in 36 sub-
Saharan countries, which correspond to an area of more than 9 million km2, 
equivalent to a third of Africa's total land area (WHO/TDR 2012).  
The two human-infective T. brucei sub-species cause diseases that follow 
distinct clinical courses. Rhodesian sleeping sickness is a more acute form of the 
disease with rapid onset of the late stages. This is in contrast to the more 
common Gambian sleeping sickness (over 98% of reported cases overall according 
to the WHO), which is more chronic in nature, with the disease lasting for 
months to years. A bite from an infected tsetse fly (sometimes causing a primary 
lesion or a chancre to develop at the bite site which lasts for up to 5-15 days) 
leads to the development of the first of the two stages of the diseases - the 
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early, or the haemolymphatic stage, where the parasites proliferate in the 
bloodstream and the lymphatic tissues. During this period, patients present with 
febrile illness lasting 1–7 days, together with enlarged lymph nodes and several 
other nonspecific symptoms such as malaise, headache, arthralgia, generalized 
weakness, and weight loss (Kennedy 2004). The parasites can then go on to 
invade multiple organs including the spleen, liver, skin, cardiovascular system, 
endocrine system, eyes and eventually the central nervous system (CNS) 
(Kennedy 2004).  
CNS invasion marks the onset of the late meningo-encephalitic stage of sleeping 
sickness. Symptoms of neurological involvement include mental disturbances 
such as irritability, lassitude, apparent changes in personality, sometimes 
including violence, hallucinations, suicidal tendencies, and mania; evidence of 
motor system involvement such as seizures, muscle fasciculation and sometimes 
paralysis; disorders of the sensory system and the characteristic sleep pattern 
disturbances. If left untreated, the disease progresses to its final stage which is 
characterised by coma, systemic organ failure and eventually death (Kennedy 
2004). In the acute Rhodesian form of the disease, CNS involvement occurs 
within weeks following the infective bite, while in the Gambian form, CNS 
involvement does not occur for months or years after the initial infection. At this 
point, it is important to note that disease progression does not always occur with 
such predictable outcomes. Variability in clinical manifestations of trypanosome 
infections, with regards to clinical symptoms, disease severity and duration of 
illness, involving both forms of the sub-species, has been reported. It is now 
known that both host and parasite genetics and mixed infections of different 
parasite clones can influence the clinical outcomes of the infection, with reports 
of trypanotolerance in both humans and livestock (Murray et al. 1982; Naessens 
et al. 2003). This can mean that sleeping sickness is not always fatal when left 
untreated as had been previously believed (for reviews, see Sternberg & Maclean 
2010; Morrison 2011; La Greca & Magez 2011).            
T. b. gambiense and T. b. rhodesiense possess varying transmission cycles. 
Though T. b. gambiense parasites have been isolated from domestic and wild 
animals, humans are still considered as their main reservoir host (Maudlin 2006). 
On the other hand, T. b. rhodesiense is zoonotic with antelopes, hyenas, lions, 
sheep and cattle found to act as reservoir hosts, thus maintaining prevalence of 
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the disease (Maudlin 2006). The distribution of HAT incidence is focal, as it 
depends on the distribution of the tsetse fly, and that of suitable mammalian 
hosts, occurring within the range of the vector. Incidences tend to occur in 
localised breakouts, generally following certain types of human activity such as 
mass migration or man-made developments, resulting in the establishment of 
favourable breeding grounds for flies (Steverding 2008) or, as is the case for T. 
b. rhodesiense, trading of infected livestock (Fèvre et al. 2001). Following the 
huge epidemics in the late 19th century, the colonial regimes implemented 
rigorous control programs, bringing down the incidence of HAT to almost zero by 
the 1960s. However, political unrest during the post-independence period saw a 
steep rise in incidences through the next thirty years, leading up to devastating 
epidemics in the 1980s and 1990s. In 2008, an estimated 1.78 million disability 
adjusted life years (DALYS) were lost across Africa due to sleeping sickness 
(Fèvre et al. 2008). In 2009, the World Health Organization (WHO) reported 9878 
new cases of HAT, representing a steady decline compared to more than 17600 
in 2004 and almost 38000 in 1998. The real number of cases is, however, likely 
to be at least three times higher than those reported, as outbreaks tend to occur 
among the rural poor and during civil strife rendering surveillance and diagnosis 
difficult to achieve in its entirety (Odiit et al. 2005; Simarro et al. 2011). 
Nevertheless, the decline in disease incidences below the significant 10,000 
cases per year has allowed renewed hope for achieving eradication of the 
disease. In 2012, the WHO set a roadmap aiming for HAT elimination by 2020 – to 
bring down the incidence of the disease to fewer than 1 case per 10,000 of the 
population in at least 90% of the areas where cases exist (Maurice 2013). This 
inspired the London Declaration on Neglected Tropical Diseases where donors, 
the World Bank, pharmaceutical companies, government agencies and the WHO 
jointly committed to aiding WHO’s roadmap through initiating a collaborative 
disease eradication programme. The challenge then remains to ensure sustained 
surveillance, vector control and drug availability with eradication and not just 
elimination as the end-point, elimination being the point in time when vertical 
intervention approaches are no longer cost-effective (Simarro et al. 2011). 
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1.1.1 Natural resistance against T. brucei 
The sera from humans and other primates was first noted for their trypanolytic 
properties in 1902 (Laveran 1902). Normal human serum was found to be able to 
kill T. b. brucei whilst not harming the human infective T. b. rhodesiense and T. 
b. gambiense. This remarkable human innate response involves trypanocidal 
factors which associate with serum complexes in normal human sera and are 
termed trypanosome lytic factors (TLFs). Two TLFs, TLF1 and TLF2, have now 
been defined as multi-subunit complexes with separate modes of uptake (Barth 
1989; Hajduk et al. 1989; Raper et al. 1996). Nevertheless, they share their 
modes of trypanosome lysis which is mediated by one of their subunits - the 
pore-forming toxin, apolipoprotein L-1 (ApoL1; Vanhamme et al. 2003). 
Following uptake of TLF1 or TLF2 into the trypanosome, ApoL1 enters the 
endocytic pathway where it is progressively acidified, causing it to dissociate 
from the original TLF1/TLF2 complex and to insert into endosomal membranes 
(Pérez-Morga et al. 2005). The bacterial colicin-like pore-forming domain of 
ApoL1 then triggers an influx of chloride ions from the cytoplasm causing 
osmotic-swelling of the lysosome and activating compensatory entry of chloride 
ions from the extracellular medium. The swollen lysosome eventually occupies 
the whole cell body ultimately compromising the outer plasma membrane and 
killing the parasite. This model along with other proposed mechanisms have 
been discussed in detail by Pays et al. 2006.   
TLF1 is a lipid-rich subtype of serum-derived high-density lipoprotein (HDL) -
HDL3 and is composed of apolipoprotein-A1 (ApoA1; Tomlinson et al. 1997), a 
serine-protease-like protein, haptoglobin-related protein (Hpr; Smith et al. 
1995; Tomlinson et al. 1997), and ApoL1. Uptake of the TLF1 complex is 
mediated via Hpr. Hpr binds to haemoglobin (Hb) to form the Hpr-Hb complex 
which is then recognised by the T. b. brucei sub-species receptor, TbHpHbR 
(Widener et al. 2007; Vanhollebeke et al. 2008). TbHpHbR, a GPI-anchored 
glycoprotein thought to supply the bloodstream form (BSF; mammalian life cycle 
stage; see section 1.2.1) T. brucei parasites with haem for growth, is unable to 
distinguish between host-derived haptoglobin (Hp)-Hb and TLF1-Hpr-Hb 
complexes, enabling TLF1 uptake by the parasites (Vanhollebeke & Pays 2010).  
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The TLF2 complex is composed of IgM, ApoA1, Hpr and ApoL1 (Tomlinson et al. 
1997; Raper et al. 1999) but, unlike TLF1, is mainly internalized in a manner 
independent of TbHpHbR . It has been suggested that TLF2 is the dominant lytic 
factor in normal human sera and its entry is mediated via low-affinity/high 
capacity interactions with VSGs (variant surface glycoproteins) whose rapid 
turnover and recycling through the endocytic system may explain the efficiency 
of TLF2-mediated killing (Vanhollebeke & Pays 2010). 
Whilst T. b. brucei is susceptible to the innate trypanocidal activity of ApoL1, T. 
b. rhodesiense and T. b. gambiense have developed ways to evade it. T. b. 
rhodesiense expresses SRA, a member of the VSG family shown to localise within 
the endocytic system (De Greef et al. 1989; Vanhamme et al. 2003). Through 
coiled-coiled interactions mediated via its N-terminal domain, SRA binds to 
ApoL1 thus sequestering it and enabling its degradation via proteolytic cleavage  
(Vanhamme et al. 2003; Stephens & Hajduk 2011; Alsford et al. 2013). Hosts 
which express variant forms of ApoL1 are able to circumvent SRA-mediated T. b. 
rhodesiense resistance to human serum; this has been found to be the case with 
people of West African descent, although at the cost of a higher susceptibility to 
developing kidney disease (Genovese et al. 2010). T. b. gambiense, which does 
not express SRA, has developed multiple strategies to avoid ApoL1-mediated 
killing. Group 1 T. b. gambiense parasites feature reduced uptake of TLF1-bound 
ApoL1 via downregulated expression of (Kieft et al. 2010), and, single amino-
acid substitutions to (Symula et al. 2012; Higgins et al. 2013) its HpHb receptor 
(TbgHpHbR). The comparative importance of these two strategies, i.e. the 
neutralisation of ApoL1 and reduced uptake of TLF1, and how this group avoids 
TLF2-mediated lysis are questions that are yet to be addressed. Group 2 
parasites, which display variable resistance against normal human serum, are 
unimpeded in their ability to internalise TLF1, yet are still resistant to ApoL1. 
This suggests that Group 2 parasites employ alternative means by which they are 
able to neutralise ApoL1 toxic activity (Capewell et al. 2011). 
The natural host resistance mechanisms against T. b. brucei highlight the 
opportunities which receptor-mediated endocytosis provide in delivering toxins 
to human-infective trypanosomes. The high-rate of uptake and the essentiality 
of endocytosis could be exploited to design novel therapeutics which could be 
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engineered to specifically enter parasites through this route (Alsford et al. 2013; 
Stijlemans et al. 2011).     
1.1.2 Current therapies against HAT 
Currently, there are no vaccines available for prophylactic immunisation, thus 
rendering chemotherapy as the only means available for combating HAT. Unless 
complete eradication is achieved, the issue of the lack of effective, safe and 
easy-to-administer drugs will still remain. To date only five drugs have been 
registered for treatment against HAT which have been summarised in Table 1-1 
(for recent review see Babokhov et al. 2013).  
Table 1-1 Drugs registered for treatment against HAT. 
Suramin, the oldest trypanocidal drug that has been in use since the early 1920s, 
is a naphthylamine–benzamide urea derivative, similar to trypan blue, that is 
used to treat early stage Rhodesian sleeping sickness (Barrett et al. 2007; 
Steverding 2010). Some degree of kidney damage is common following 
administration and adverse effects include cutaneous lesions, anaphylactic 
shock, renal failure and neurotoxicity (Kaur et al. 2002; Bitton et al. 1995). In 
the case of the Gambian form of the disease, the diamine, pentamidine, is the 
preferred drug of choice. This drug, in comparison, is better tolerated but can 
cause side effects such as hypo- or hyperglycemia and hypotension, 
nephrotoxicity, leucopenia and liver enzyme abnormalities (Sands et al. 1985; 
Doua & Yapo 1993). Suramin and pentamidine are both unable to cross the 
blood-brain barrier (BBB) efficiently and, therefore, cannot be used to treat 
CNS-stage disease. Until recently, melarsoprol has been the mainstay drug for 
treatment against late-stage HAT. This drug is an organo-arsenic compound and 
is, therefore, highly toxic. Side effects following administration are very 
common. 5-10% of treated patients develop post-treatment reactive 
encephalopathy (PTRE) which is a severe condition with fatality rates close to 
 Stage 1 Stage 2 
T. b. rhodesiense Suramin Melarsoprol 
T. b. gambiense 
Pentamidine Melarsoprol 
Eflornithine 
NECT 
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50% among those affected (Barrett et al. 2007; Burri 2010). Melarsoprol is 
dissolved in propylene glycol which, in itself causes irritation at the site of 
injection, and needs to be administered over a 10-day period (Kuepfer et al. 
2012). Intensive use of this drug has led to a growing problem of resistance with 
several foci reporting treatment failures of up to 30% of those treated. Yet, 
melarsoprol is the only available option for effective treatment of late stage 
Rhodesian HAT. In contrast, further treatment options are now available against 
T. b. gambiense. These include eflornithine and the recently developed 
nifurtimox-eflornithine combination therapy (NECT). Adverse reactions to 
eflornithine are similar to those of other cytotoxic drugs that are used to treat 
cancer, the severity of which depends on the length of treatment and the 
general condition of patient. Reports of eflornithine treatment failures (Burri 
2010; Balasegaram et al. 2009) have led to the development of combination 
therapies with the view of maintaining the efficacy of this drug. The result of 
this is NECT, with proven higher efficacy compared to monotherapies. 
Nifurtimox, an orally administered drug used to treat Chagas’ disease, had 
previously been used for compassionate treatment of relapsed HAT. Following 
successful trials where the two drugs were used in combination to treat HAT 
(Priotto et al. 2006; Priotto et al. 2007), nifurtimox and eflornithine have now 
been added to WHO’s Essential List of Medicines for the treatment of HAT. The 
trypanocidal mechanisms of action of these drugs, apart from eflornithine, are 
yet to be fully elucidated. A recent RNA interference target sequencing (RIT-seq) 
study employing high-throughput sequencing of a drug-selected RNA interference 
(RNAi) library, has helped unearth new players responsible for the mode of 
action of these drugs while, at the same time, corroborating previous studies 
(Alsford et al. 2012).  
As a highly charged molecule, it had been speculated that suramin would have 
high-affinity to serum proteins allowing its uptake via receptor-mediated 
endocytosis  and intralysosomal accumulation (Vansterkenburg et al. 1993). 
Consequently, a variety of targets had been proposed for suramin (McGeary et 
al., 2008; Stein, 1993). The RIT-seq study identified the invariant surface 
glycoprotein , ISG75, as a key protein contributing to suramin efficacy in 
addition to proteins which affect ISG75 copy number and members of the 
endocytic apparatus (Alsford et al. 2012; Alsford et al. 2013). Altogether, this 
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study supports the importance of receptor-mediated endocytosis of suramin and 
its targeted accumulation in lysosomes in its efficacy in a BSF stage-specific 
manner (Natesan et al. 2007; Alsford et al. 2012). However, no receptor for 
suramin has been found beyond ISG75 and, consequently, the final target of this 
drug still remains elusive.   
Pentamidine, an aromatic diamidine, one of the most successful classes of drugs 
with anti-protozoal activity, has been in use since the 1930s. Other members of 
this class are diminazene aceturate, a first-line treatment against AAT, and 
DB75, the active compound of the new drug candidate, pafuramidine (DB289). 
Pafuramidine was meant to be a new line of treatment targeting early-stage HAT 
and, unlike already available treatments, was to be administered orally. 
However, toxicity issues meant that phase III clinical trials had to be 
discontinued (Paine et al. 2010). Pentamidine is a nucleic acid binding compound 
and is transported into the parasite via the P2 adenosine/adenine transporter 
encoded by the TbAT1 gene in addition to high-affinity pentamidine transporter 
(HAPT1) and low-affinity pentamidine transporter (LAPT1) (de Koning & Jarvis 
2001; de Koning 2001). Recent research identified HAPT1 to be the 
aquaglyceroporin, TbAQP2 (Baker et al. 2013; Munday et al. 2014). Once 
transported, pentamidine has been shown to localise to the mitochondrion 
where it is thought to mediate its trypanocidal activity via disruption of 
kinetoplast DNA and/or mitochondrion membrane potential (Alsford et al. 2012; 
Baker et al. 2013). Resistance against pentamidine is a well-documented 
phenomenon and strongly coincides with cross-resistance to melarsoprol, 
highlighting the shared pathway by which diamidines and arsenicals are taken up 
by the parasite (Baker et al. 2013).  
Melarsoprol is a melaminophenyl arsenical drug thought to act by forming a 
stable adduct with trypanothione known as Mel-T. The RIT-seq screen identified 
a cohort of proteins which directly or indirectly regulate the levels of 
trypanothione suggesting that Mel-T itself is toxic to the parasite (Alsford et al. 
2012). Separate studies have also linked melarsoprol’s mode of action to energy 
metabolism (Denise & Barrett 2001). It is highly likely that, similar to 
pentamidine, melarsoprol targets a number of essential intracellular processes; 
this is supported by the fact that resistance against these compounds mainly 
focuses on blocking uptake of the drugs (Baker et al. 2013). Similar to 
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pentamidine, melarsoprol uptake is dependent on the TbAT1 encoding P2 
aminopurine transporter and TbAQP2 (HAPT1) (Munday et al. 2014).  
Eflornithine or D,L-a-difluoromethylornithine (DFMO), originally developed as an 
anti-neoplastic, is the only drug for which a defined mode of action is known 
(Barrett et al., 2007). Developed in 1981, this drug is an analogue of the amino 
acid, ornithine, which acts as an inhibitor of the enzyme ornithine decarboxylase 
– an enzyme required for polyamine biosynthesis. Lack of polyamine availability 
causes a trypanostatic effect and requires immunological action for complete 
elimination of the parasites (Barrett et al., 2007). Eflornithine therapy is, 
therefore, unsuitable for patients with suppressed immune systems. Eflornithine 
activity has been found to be limited in T. b. rhodesiense and the more rapid 
turnover of ornithine decarboxylase in this sub-species has been thought to be 
the reason for it (Iten et al. 1995; Iten et al. 1997). 
Administration of these drugs is not straight-forward. All of them need to be 
administered intravenously, which requires technically trained staff and multiple 
visits to a health centre. For melarsoprol and eflornithine, hospitalization is 
mandatory due to the possibility of adverse reactions. In areas where HAT is 
endemic, access to health facilities is often difficult sometimes preventing 
timely access to the appropriate drugs. With no vaccines available, there is a 
pressing need for the development of safe and easy-to-administer novel drugs, 
especially in the treatment of CNS-stage HAT – an area of research that has 
failed to successfully advance in recent years, as evidenced by the fact that the 
latest novel drug was developed some 50 years ago.   
1.1.3 Drug development and new treatment prospects 
Reports of trypanotolerance in cattle, mice and humans gives hope that 
vaccination against trypanosomes is possible as it demonstrates the ability of 
hosts to successfully mount immune responses against these parasites (Courtin et 
al. 2008). The same reports also indicate the importance vaccines will play in 
eradicating HAT and AAT as trypanotolerant mammals will continue to act as 
reservoirs of the parasite. As mentioned earlier, there are no current vaccines 
against HAT, and attempts to develop a clinically effective one is a long way-off 
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(La Greca & Magez 2011). This is mainly attributed to the remarkable immune 
evasion strategy of antigenic variation which trypanosomes have adopted (see 
section 1.2.1) where regular switching of trypanosomes’ outer surface protein, 
VSG, prevents mammalian hosts from mounting an effective response. It has 
been argued that the use of in-bred murine models could give rise to artefacts, 
thus becoming a hindrance in vaccine development and that alternatives might 
need to be considered (La Greca & Magez 2011). With the development of an 
efficient vaccine out of reach, the only viable means through which the 
available anti-HAT therapeutics can be improved upon are by countering the 
limitations of current drugs or by developing new ones.  
One of the disadvantages of treating late-stage HAT with melarsoprol is that it is 
highly toxic and that it is poorly soluble in water, requiring its solubilisation in 
propylene glycol, thereby restricting its administration through the intravenous 
route. In an attempt to counter these issues, melarsoprol was complexed with 
cyclodextrin molecules which was shown to increase its oral bioavailability and 
reduce its toxic effects (Rodgers et al. 2011). Plans to test this complex in a 
phase II is currently underway (Rodgers et al. 2011).   
Fexinadazole, the most promising drug candidate against HAT to have entered 
clinical trials, is a member of the nitroimidazole class of drugs. Nitroimidazoles 
have long been used to treat infectious diseases with notable examples such as 
nifurtimox, metrinidazole (anti-bacterial) and benzidazole (Chagas disease). 
Fexinadazole was identified by Drugs for Neglected Diseases initiative (DNDi) in 
their extensive compound mining efforts to identify further nitroimidazoles with 
anti-trypanosomal activity, and was shown to treat the early and late stages of 
both acute and chronic forms of the disease (Torreele et al. 2010). Genotoxicity, 
which was the leading concern against a related nitroimidazole, megazol, was 
found to not be an issue with fexinadazole (Torreele et al. 2010; Tweats et al. 
2012). The drug, which is orally administered, was well tolerated by healthy 
individuals in the first in-human studies that were conducted (Tarral et al. 2014) 
and is currently undergoing a pivotal phase II/III comparative study assessing its 
efficacy against late stage HAT. If successful, fexinadazole will be the first orally 
administered drug against HAT, the use of which, due to its potential efficacy 
against all forms and stages, has the added advantage of removing the 
requirement for staging the disease in the clinic. 
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The boron-containing oxaborole carboxamides, are another class of compounds 
providing promising new drug candidates against HAT. Also orally bioavailable, 
two lead compounds were able to kill T. b. gambiense and T. rhodesiense in 
vitro, cross the BBB and also recover acutely and chronically infected mice, 
suggesting that these compounds could be used to treat both stages and forms of 
HAT (Nare et al. 2010). Further optimisation studies, which focussed on 
improving the pharmacokinetic properties of the lead series, with particular 
emphasis on improving the extent and duration of brain exposure, yielded the 
compound SCYX-7158, which entered phase I clinical trials in 2012 (Jacobs et al. 
2011).    
Another preclinical candidate of note is DB829 which came to light as a result of 
continued screening of novel diamidines and prodrugs to improve on the toxicity 
observed during phase I clinical trials testing pafuramidine (DB289). DB829 was 
able to cure mice with late stage T. b. brucei infections and was also active 
against T. b. rhodesiense in vitro and T. b. gambiense in vivo (Wenzler et al. 
2009; Wenzler et al. 2013) thus making it, along with its prodrug, DB868, ready 
for phase I clinical trials.  
Other compounds of promise have also been identified and have been reviewed 
briefly recently (Babokhov et al. 2013). The challenges of developing novel drugs 
lie with the difficulty of generating small-molecules that specifically target 
genetically validated biomolecules, are pharmacologically sound and are able to 
convey therapeutic effects. This has caused some to challenge the presently 
accepted drug development pipeline which disconnects pharmacology from the 
early stages of target identification and validation (Moellering & Cravatt 2012). A 
chemoproteomics approach has been suggested where the vast libraries of small 
molecules with drug-like properties can be taken advantage of and exploited to 
accelerate drug discovery in the post-genomic era. In this approach, proven 
inhibitors of specific protein classes can be used to mine a proteome for 
identification and validation of new targets (Beroza et al. 2002). This was the 
basis of a recent study, which identified and validated a previously 
uncharacterised protein kinase, TbCLK1, as a potent drug-target using 
hypothemycin, a fungal product known to target protein kinases with a CDXG 
motif. Hypothemycin itself, due to dangers of non-specific binding to host 
kinases, cannot be developed as a new drug against HAT but provides a start 
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point for TbCLK1-specific drug development (Nishino et al. 2013). Such 
chemoproteomic approaches could be promising in enabling future drug 
development against HAT. 
Novel developments are also being made in improving the current models that 
are used to test the efficacy of new compounds against the second stage of the 
disease. The current established model is plagued by long screening periods and 
hinders the process of defining structure activity relationships which often 
require iterative rounds of chemical synthesis. By capitalising on recent 
expansions in applying in vivo imaging to a broad range of biological studies, 
Myburgh and colleagues developed a serial, non-invasive bioluminescent imaging 
system to monitor parasitaemia, thereby reducing the drug screening time by 
two-thirds of the time taken by previous late-stage drug screening models 
(Myburgh et al. 2013; McLatchie et al. 2013). The development of such models 
greatly contributes towards drug evaluation programmes.  
1.2 Trypanosoma brucei life cycle, cellular structure and 
biology 
1.2.1 T. brucei life cycle and differentiation 
1.2.1.1 Bloodstream stages 
The life cycle of T. brucei involves the parasite progressing through a number of 
different developmental stages within their vector and mammalian hosts 
(Vickerman 1985) entailing morphological restructuring and biochemical 
adaptation (Figure 1-1). As an infected tsetse fly takes a blood meal from a 
mammalian host, it injects non-dividing metacyclic trypomastigotes into the 
underlying connective tissue. The parasites then quickly enter the bloodstream 
and the lymphatic tissue, following which they undergo morphological changes 
and differentiate into rapidly proliferative long slender trypomastigotes. At peak 
parasitaemia, some BSF long slender trypomastigotes differentiate into non-
dividing short stumpy form parasites pre-adapting them for survival in the insect 
vector. 
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At these BSF stages the parasites exhibit cyclical antigenic variation, a host 
survival strategy which is common among bacterial, viral and eukaryotic 
pathogens. Trypanosomes possess the most comprehensive system of antigenic 
variation so far described. The trypanosome cell surface is thickly coated with 
densely packed, homodimeric VSGs. This protective coat shields other, more 
vulnerable, invariant cell surface membrane epitopes from targeted host 
immune response. Successive waves of VSG-specific immune response only 
succeed in eliminating part of the parasite population as new cells expressing 
switched VSGs emerge, thus prolonging an infection for months to even years in 
a host, thereby favouring transmission (for recent reviews, see Taylor & Rudenko 
2006; Stockdale et al. 2008; Morrison et al. 2009). Only one, of about 15 
exclusive VSG expressions sites (ES), is active at a time and only a single VSG, 
assembled from an archive of >1600 silent VSG genes and pseudogenes (Marcello 
& Barry 2007), is expressed at a time. VSG switching occurs at a rate of 10-2 per 
cell cycle, spontaneously and stochastically, independent of the host immune 
response (Lythgoe et al. 2007). VSG mosaicism, where the expressed VSG is a 
product of segmental gene conversions from two or more VSG donors, adds 
another layer of variation that can be achieved from a limited archive of VSG 
genes (Marcello & Barry 2007; Hall et al. 2013). 
BSF parasites solely rely on glycolysis of host glucose for carbon supply and 
subsequent ATP production. Reflecting this, BSF parasites feature a tubular 
mitochondrion which lacks cristae and is unable to undergo oxidative 
phosphorylation, thus limiting metabolic options available to the parasite (Coley 
et al. 2011). However, the availability of abundant nutrients from the 
bloodstream of the host enables BSF parasites to multiply extensively via binary 
fission. 
Differentiation is the key feature of any parasitic organism which invades 
multiple hosts during its life cycle; it is characterised by substantial 
transcriptome alterations, bringing about morphological and biochemical 
changes thus adapting the parasite to survive the subsequent destination host 
environment. Stumpy form BSF parasites are metabolically pre-adapted to 
survive in the tsetse fly vector where glucose is scarce and alternative carbon 
sources, such as amino acids, have to suffice. Therefore, they are equipped with 
mitochondria featuring well developed cristae and functional Krebs cycle, 
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respiratory chain and oxidative phosphorylation enzymes. These metabolic 
changes, in addition to variations in other cellular features such as cell 
structure, protein transport, proteolysis and translation, are reflected in the 
differential gene expression found between slender and stumpy BSF parasites 
described by recent comparative transcriptome analyses (reviewed in Rico et al. 
2013). 
A fine balance needs to be struck between immune evasion via antigenic 
variation and differentiation to quiescent transmissible forms to achieve both 
infection chronicity and transmissibility (MacGregor et al. 2012). This balancing 
act includes density-dependent differentiation induction as one of its key 
players. Similar to bacterial quorum sensing mechanism, differentiation in the 
mammalian bloodstream from slender to stumpy trypomastigotes has been 
shown to involve density-sensing, induced by an unidentified parasite-derived 
molecule termed Stumpy Induction Factor (SIF) (Vassella et al. 1997). Upon 
reaching the ideal density within the bloodstream, the slender to stumpy 
differentiation pathway is induced. The downstream pathways following 
differentiation induction are only just being unravelled. Some negative 
regulators have been identified, namely, ZFK (Vassella et al. 2001), MAPK5 
(Domenicali-Pfister et al. 2006), TOR4 (Barquilla et al. 2012), RDK1 and RDK2 
(Jones et al. 2014). Also, in vitro-adapted T. brucei monomorphic cell-lines have 
been shown to differentiate to a stumpy-like form in response to hydrolysable 
cell-permeable cAMP analogues (Vassella et al. 1997; Laxman et al. 2006; 
Barquilla et al. 2012) suggesting the importance of the cAMP signalling pathway 
in regulating the slender to stumpy differentiation pathway of trypanosomes in 
mammalian bloodstreams. Indeed, a recent genome-wide RNAi study identified a 
host of proteins linked to cAMP analogue processing, signal transduction and 
regulatory effector molecules to be involved in the differentiation-inducing 
cAMP analogue response pathway. Further in vivo analyses using pleomorphic 
cell lines confirmed the physiological relevance of some of these factors 
(involving kinases, phosphatases and effectors) in promoting density-dependent 
differentiation of slender trypomastigotes to stumpy form bloodstream parasites 
(Mony et al. 2014).  
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1.2.1.2 Insect stages 
The T. brucei life cycle continues when a tsetse fly takes a blood meal from an 
infected mammal. Entry into the insect midgut brings about a dramatic change 
in the environment for the parasite with a drop in temperature and an alteration 
in the chemical environment inducing their differentiation (Engstler & Boshart 
2004; MacGregor & Matthews 2010). Within the insect posterior midgut, ingested 
stumpy-form trypomastigotes, which have been shown to express PAD1, a citrate 
transporter required to transduce a citrate and/or cis-aconitate signal, then 
differentiate to procyclic form (BSF) trypomastigotes, while ingested BSF slender 
trypomastigotes either first transform into stumpy forms in the anterior midgut 
or die (Vickerman et al. 1988). This differentiation from stumpy form to PCF has 
been shown to be regulated by a phosphatase cascade (Szöor et al. 2006; Szöor 
et al. 2010). PCF trypomastigotes are able to replicate via binary fission and 
progressively lose their VSG coat (Bülow et al. 1989; Overath et al. 1983) which 
is then replaced by an equally dense coat of two classes of procyclins – EP 
(dipeptide repeats; EP1, EP2 and EP3) and GPEET (protease-resistant 
pentapeptide) (Roditi et al. 1987; Roditi & Clayton 1999). GPEET expression is 
transient and is down-regulated when PCF trypomastigotes mature (Knüsel & 
Roditi 2013). PCF trypomastigotes are characterised by increased cell length, 
kinetoplast repositioning, extensive mitochondrial branching, further increase in 
Krebs cycle associated enzymes and respiratory chain proteins and reduced 
endocytosis. When mature, PCF trypomastigotes invade the ectoperitrophic 
space, via active penetration of the peritrophic membrane, from where they 
migrate, via a marathon journey through the oesophagus, mouthparts and 
salivary ducts, to the salivary glands (Vickerman et al. 1988). Throughout this 
journey, they undergo a number of differentiation events thereby progressing 
through up to 11 further developmental stages (Figure 1-1; Rotureau & Van Den 
Abbeele 2013).  
Once in the peritrophic matrix, PCF trypomastigotes elongate to form non-
proliferative long mesocyclic trypomastigotes which then migrate to the anterior 
part of the insect’s midgut. The parasites then migrate to the proventriculus 
where the mesocyclic cells become thinner and take on the epimastigote 
morphological form (the kinetoplast is positioned between the nucleus and the 
anterior end of the cell unlike trypomastigotes where the kinetoplast is 
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positioned on the opposite side of the nucleus). These long dividing 
epimastigotes then begin to undergo asymmetric division, each producing a long 
and a short epimastigote, whilst migrating upstream from the proventriculus to 
the salivary glands of the insect via the foregut and the proboscis (Van Den 
Abbeele et al. 1999). This migratory stage from the midgut to the salivary glands 
acts as a pronounced bottleneck as only between 0-5 parasites succeed in 
accomplishing it which results in the amplification of rare variants that are 
subsequently disseminated into the mammalian host population (Oberle et al. 
2010). Once in the salivary glands, the short epimastigotes remain attached to 
the epithelium (attached epimastigote), via dendritic outgrowths of the 
flagellum termed ‘flagellopodia’ and hemidesmosome-like junctional complexes, 
and elongate (Vickerman 1985; Tetley & Vickerman 1985; Vickerman et al. 
1988). Epimastigotes in the salivary glands are also characterised by a switch in 
their surface coats from procyclins to brucei alanine-rich proteins (BARP; 
Urwyler et al. 2007). At this stage the attached epimastigotes proliferate via two 
distinct cycles simultaneously whilst remaining attached to the salivary gland 
epithelium – 1) producing two equivalent cells which occurs at the early phase of 
the infections ensuring rapid colonisation; 2) asymmetric division producing a 
daughter cell which matures into a non-dividing infective metacyclic 
trypomastigote (Rotureau et al. 2012) featuring a metacyclic VSG (mVSG) 
surface coat that is expressed in ways distinct from BSF VSG coats (Tetley et al. 
1987; Ginger et al. 2002). These infective metacyclics are subsequently released 
into the saliva, ready for transmission into mammalian hosts. MKK1 and the RNA-
binding proteins, RBP6, ALBA 3 and ALBA4, remain the sole identified putative 
regulators/effectors of trypanosome differentiation in the insect stages (Subota 
et al. 2011; Morand et al. 2012; Kolev et al. 2012). 
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Figure 1-1 Schematic representing morphological changes during a T. brucei life cycle. MG – 
midgut; FG – foregut; PV – proventriculus; SG -  salivary glands (SG); long-short – asymmetrical 
division of long dividing epimastigotes generating short and long epimastigotes; epi-epi – cell 
division generating two equal attached epimastigotes; epi-trypo - asymmetrical division of 
attached epimastigotes generating attached epimastigotes and metacyclic trypomastigotes. 
Adapted from Ooi & Bastin 2013. 
1.2.2 Structure of T. brucei cell 
The T. brucei cell body is vermiform in shape, 19-25 µm long, with defined 
anterior and posterior ends along a long axis. Its cell surface is characterised by 
the plasma membrane, the associated glycocalyx (defined by the several integral 
and peripheral proteins, glycoproteins, including GPI-anchored glycoproteins, 
such as the VSGs in BSF parasites, and glycolipids) and the underlying 
subpellicular corset of microtubules. The subpellicular corset is an array of 
microtubules which nucleate at randomly distributed sites, are regularly spaced, 
are arranged helically along the long axis of the cell and have the same polarity 
with their positive ends facing the posterior end of the cell (Sherwin & Gull 
1989; Robinson et al. 1995; Gull 1999). The corset is extremely stable which can 
be attributed to the microtubules being linked to each other and the plasma 
membrane by cross-bridges featuring microtubule-associated proteins (MAPs) 
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(Sherwin & Gull 1989). The corset accommodates two specialised regions, which  
are definitive trypanosome cytoskeletal features.  
At one point, along the length of the microtubule array, a gap exists which 
accommodates the bead-like filament part of the flagellum attachment zone 
(FAZ; Figure 1-2). The FAZ is responsible for the attachment of the single 
flagellum to the main cell body via a series of punctate transmembrane 
junctions (Bastin et al. 2000), thus forming an undulating membrane between 
the cell body and flagellum. To the left of this filament (when the cell is viewed 
from the posterior end of the cell) is an extremely stable set of four 
microtubules (the microtubule quartet; MtQ; Figure 1-2) which remains 
associated with the cell endoplasmic reticulum (ER) throughout the length of the 
cell (Sherwin & Gull 1989) and is also considered as part of the FAZ. The 
microtubules of the MtQ, which nucleate between the basal and pro-basal bodies 
(described later) at the posterior end of the cell, have opposite polarity to the 
rest of the subpellicular microtubules (Lacomble et al. 2009). Following 
nucleation, the MtQ wraps around the other specialised region found in the 
corset, the flagellar pocket, before traversing the length of the cell.  
The flagellar pocket is a small invagination within the pellicular membrane from 
which the flagellum exits the cytoplasm (Figure 1-2). It is a vase-like structure 
which covers only 5% of the cell surface, is the most posterior structure on the 
outside of the cell and is the sole site of endo/exocytosis including vital 
processes such as VSG recycling (Engstler et al. 2004). In line with its specific 
roles in membrane traffic interchange, the flagellar pocket membrane is 
characterised by a distinct proteome (Field & Carrington 2009). The lumen of 
the flagellar pocket asymmetrically surrounds the flagellum as it just emerges 
following nucleation from the mature basal body (Figure 1-2; Lacomble et al. 
2010). As the flagellum exits the flagellar pocket, its membrane along with those 
of the flagellar pocket and cell surface are constricted together by the flagellar 
pocket collar (Figure 1-2; FPC). Once the flagellum exits the cytoplasm, it is 
surrounded by its own membrane which is functionally distinct to the plasma 
membrane and the flagellar pocket membrane (Oberholzer et al. 2011).    
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Figure 1-2 Overview of the T. brucei flagellum. Lower panel - Scanning electron micrograph of 
a T. brucei PCF cell with the direction of cell propulsion shown (arrow). Top panel - Diagram 
depicting flagellum emergence from the flagellar pocket at the posterior end of the cell (boxed 
region in lower panel). Cross sections of the basal body (A), transition zone (B) and two points of 
the emerging flagellum (C and D) depicting microtubule patterns are shown. Adapted from 
Langousis & Hill 2014. 
The mature basal body and its tightly associated pro-basal body are the only 
recognisable microtubule organising centres (MTOC) found in a trypanosome cell 
and are located immediately under the flagellar pocket membrane. It is from the 
mature basal body that the microtubular core of the flagellum, the axoneme, 
nucleates (Figure 1-2). At the distal end, the mature basal body is characterised 
by nine peripheral triplet microtubules with no central pair (Figure 1-2A). As the 
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proximal end of the mature basal body, which marks the origin of the axoneme, 
invades the flagellar pocket, the peripheral microtubules become doublets thus 
forming the transition zone (Figure 1-2B). At the basal plate, where the 
transition zone ends, the two central pair microtubules nucleate and the 
canonical 9+2 (nine doublet microtubules that are symmetrically arranged 
around a central pair of singlet microtubules) axoneme begins which is then 
continued all the way along the flagellum (Figure 1-2C and D; Lacomble et al. 
2009). Trypanosome axonemes possess components such as the inner and outer 
dynein arms, the radial spokes which connect the peripheral doublets to the 
central pair, the nexin links which are associated with peripheral doublets and 
the projections of, and connections between, the central pair of microtubules, 
all of which are well conserved axonemal features found in other eukaryotic 
organisms (Bastin et al. 2000). ATP-dependent dynein motors that are attached 
to one of the tubules of a doublet walk along the adjacent doublet generating 
sliding forces responsible for the movements of the flagellum.  
The flagellum also features an extra axonemal accessory in the form of a 
paracrystalline structure called the paraflagellar rod (PFR; Figure 1-2) which is 
attached directly to both the axoneme (via outer arm dyneins to the peripheral 
doublets 4-7 when numbered according to convention; Hughes et al. 2012) and 
the FAZ. The PFR, along with the axoneme, is essential for flagellar motility 
(Hughes et al. 2012). The lattice-like structure of the PFR can be divided into 
three distinct zones: proximal, intermediate and distal. The proximal domain 
mediates PFR linking to the FAZ via distinct filaments (Portman & Gull 2010). A 
few studies have now been performed characterising the proteome of the PFR 
and interactions between its components (Pullen et al. 2004; Portman et al. 
2009). Protein components of the PFR can be classified as those that are vital for 
structural viability, those involved in adenine nucleotide signalling and 
metabolism, those involved in calcium signalling and those with as yet unknown 
function altogether suggesting a role for the PFR in acting as a regulatory and 
metabolic platform for the sensory and motility functions of the flagellum 
(Portman & Gull 2010).  
The flagellar basal bodies are anchored to a differentiated region of the 
mitochondrial membrane, and subsequently the kinetoplast, through a series of 
filaments known as the tri-partite attachment complex (TAC; Figure 1-2; 
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Ogbadoyi et al. 2003). The T. brucei kinetoplast – the definitive feature of the 
Kinetoplastida order – is an intricately structured nucleoid in which the genome 
of the single mitochondrion is condensed into a 100 nm thick, 650 nm wide disc 
(Klingbeil & Englund 2004). These continuous links between the kinetoplast, 
basal bodies and the flagellum act as guide ropes enabling connection of 
kinetoplast segregation to the replication and segregation of the rest of the 
cytoskeletal elements. 
Closely associated to the exit point of the flagellum from where the FAZ is seen 
to begin and adjacent to the Golgi apparatus, is a hook-shaped structure termed 
the bilobe (Figure 1-3). The bilobe, which appears to be unique to 
trypanosomes, was serendipitously discovered (He et al. 2005) and has only been 
linked to Golgi biogenesis so far (de Graffenried et al. 2008). The cytoplasmic 
region between the flagellar pocket and the centrally positioned nucleus is home 
to single copy organelles such as the Golgi apparatus and the lysosome where 
protein degradation occurs (Figure 1-3).  
 
Figure 1-3 Schematic representation of trypanosome cell architecture depicting the location of 
the major structural features of the trypanosome cell. Adapted from Matthews 2005. 
The precise positioning of these single copy organelles points to the importance 
of strict regulation of organellar and cytoskeletal replication and duplication in 
trypanosomes. This study has focussed on cell cycle regulation in T. brucei. 
Before gaining a background in T. brucei cell cycle events and regulation, what 
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is already known about this subject in other better studied eukaryotic models, 
shall be briefly looked into first. 
1.3 The cell cycle and its regulation 
1.3.1 General eukaryotic cell cycle events 
A typical eukaryotic cell cycle can be subdivided into four phases –G1, S, G2 and 
M phases. During G1 phase, the cell, in response to environmental conditions, 
decides whether to proliferate, quiesce, or differentiate. Under favourable 
conditions, determined by the ready availability of nutrients and an appropriate 
cell size, the cell proceeds to S phase when DNA replication occurs. This is 
followed by another gap phase, G2 phase, when the cell grows even further and 
is primed for mitotic cell division. During M phase, or mitosis, replicated DNA 
and organelles segregate and cells divide to produce viable daughter cells which 
then re-enter G1 phase. When conditions are not favourable to enter S phase, 
progression through the cell cycle is arrested and G1 cells enter the quiescent G0 
phase, where they remain metabolically active but no longer proliferate without 
external stimuli. For some cell types, this quiescent stage is irreversible. 
The major events of M phase in eukaryotes are broadly categorized into four 
stages. Mitosis begins with prophase during which chromosomes condense to 
form sister chromatids and spindle assembly is initiated following localisation of 
the duplicated centrosomes at opposite sides of the nucleus (see Hirano 2000 for 
review of chromosome cohesion, condensation and separation during the cell 
cycle). This is followed by an intermediate pro-metaphase, during which the 
chromosomes bind to the mitotic spindle. This process of attachment and 
alignment of the chromatids to the centre of the metaphase plane is mediated 
through the kinetochore - a complex of proteins bound to the centromeres of the 
chromatids. The cell is now said to have reached metaphase. Anaphase 
commences with the disruption of the link between the chromatids. Active 
remodelling of the spindle structure moves the chromatids towards the opposite 
ends of the pole. By this point, cytoplasmic division, or cytokinesis, would 
already have begun (Pollard 2010). Meanwhile, mitosis progresses through to 
telophase when nuclear DNA decondenses to form two separate nuclei.  
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Cytokinesis can, in general, be described to occur in three stages – initiation, 
furrow ingression and abscission. In animal cells, cytokinesis is initiated via 
signalling events leading to the formation of a contractile actin-myosin ring 
which promotes division of the cells along the cleavage plane (Barr & Gruneberg 
2007). This is followed by abscission which causes an irreversible fission of the 
plasma membrane between the dividing cells producing two daughter cells 
(Guizetti & Gerlich 2010).  
Progression through the various stages in the right order is essential for the 
viability of progeny. Although the T. brucei cell cycle events broadly follows the 
scheme described for general eukaryotes, the parasite cell replication displays 
many unique features and is characterised by strict regulation of its organelle 
positioning. This is to enable faithful replication, segregation and localisation of 
its nuclear/kinetoplast genome and that of its single copy major organelles, 
some of which feature only in trypanosomatids.  
1.3.2 T. brucei cell cycle events and co-ordination 
Sherwin and Gull first described the order of T. brucei cell cycle events in PCF 
parasites through the use of immuno-fluorescence and electron microscopy 
(Sherwin & Gull 1989) and this work still informs much of our current knowledge 
of this subject today. In BSF parasites, the order of events have been found to 
be largely similar with variations in the kinetics and the length of the cell cycle 
(about 6 hours for BSF compared to 8.5 hours for PCF parasites; Hammarton et 
al. 2007). Variations in morphology also occur which shall be pointed out as the 
cell cycle events are described and have been summarised in Figure 1-4. 
The earliest microscopically detectable cell cycle events begin with the 
maturation of the pro-basal body at the G1/S transition where it elongates to 
form the transition zone and basal plate (Sherwin & Gull 1989; Lacomble et al. 
2010). A new flagellum begins to extend from the newly mature basal body 
which is now associated with a duplicated pro-basal body positioned anterior to 
the new flagellum/basal body complex (Lacomble et al. 2010). Once the new 
flagellum exits the existing flagellar pocket, the extension of the paraflagellar 
rod is initiated. The tip of the new flagellum goes on to physically connect with 
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the old flagellum via a transmembrane mobile junction termed the ‘flagellar 
connector’ (Briggs et al. 2004; Vaughan & Gull 2008), an association which is 
crucial for the spatial organisation of the new cellular structures. In BSF cells, 
this tethering of the new flagellum is achieved by the distal tip of the new 
flagellum being embedded in an indentation of the cell body called the groove, 
but does not last as long as it does in PCF parasites (Hughes et al. 2013). 
Following penetration into the flagellar pocket and the association with the 
flagellar connector by the new flagellum, the new basal body complex 
subtending the new flagellum, is repositioned via a rotational movement around 
its old counterpart in an anti-clockwise direction (Lacomble et al. 2010). This 
movement causes the new basal body and associated flagellum to take on a 
more posterior position in the cell. One of the consequences of this rotational 
movement is the formation of the new flagellar pocket which is formed by the 
partitioning of the existing flagellar pocket (Farr & Gull 2012). The force 
required for the rotational movement of the new basal body/flagellum complex 
has been linked to the nucleation of the new microtubule quartet, which 
precedes pro-basal body extension or new pro-basal body formation, as it 
extends in a helical pattern around the basal body/flagellum complex before 
inserting into the subpellicular microtubule corset (Lacomble et al. 2010). 
Basal body replication, in addition to replication of the TAC and remodelling of 
the kDNA/TAC (Ogbadoyi et al. 2003), de novo synthesis of a new Golgi body (He 
et al. 2004; He et al. 2005; Selvapandiyan et al. 2007), duplication of the bilobe 
(He et al. 2005) and growth and duplication of the FPC (Bonhivers et al. 2008),  
all coincide with kinetoplastid DNA (kDNA) S phase (Sherwin & Gull 1989). 
Nuclear and kinetoplast replication are two independent events with the kDNA S 
phase seeming to occur just before the initiation of nuclear S phase.  The 
kinetoplast replication and division cycle, which has been shown to occur in five 
distinct morphological stages (Gluenz et al. 2011), is shorter compared to 
nuclear replication, and ends before the initiation of nuclear mitosis (Woodward 
& Gull 1990). Segregation of replicated kDNA is coupled with basal body 
segregation (Robinson & Gull 1991) mediated via the interlinking TAC complex. 
Inhibition of basal body segregation in turn inhibits kinetoplast segregation. 
Kinetoplast segregation coincides with the branching of the mitochondrion which 
does not completely detach until after the end of mitosis (Tyler et al. 2001). 
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Initiation of nuclear mitosis follows kinetoplast segregation and occurs without 
chromosome condensation or nuclear envelope breakdown (Galanti et al. 1998; 
Ogbadoyi et al. 2000). Bipolar spindle generation does not involve MTOCs, such 
as centrioles, but instead is co-ordinated via chromatin dependent pathways. As 
the nucleus elongates, it repositions towards the anterior of the basal bodies and 
straddles the axis of the mature flagellum and the growing new flagellum next 
to it. As a result, once the two nuclei separate they take on a linear ‘KNKN’ 
configuration relative to the positions of the kinetoplasts (when taken from the 
posterior to the anterior) (Robinson et al. 1995). Each daughter nucleus is thus 
localised next to a flagellum/basal body which is essential for accurate 
segregation during cytokinesis. At this point too, differences emerge between 
PCF and BSF cell division. In BSF cells, the kinetoplast is maintained at the 
posterior end of the cell throughout the cell cycle and such nuclear repositioning 
events are not seen (Tyler et al. 2001). The resulting organelle configuration is 
‘KKNN’ which is in contrast to that found in PCF parasites. 
Unlike mammalian cells, cytokinesis in T. brucei occurs via ingression of a 
cleavage furrow  which occurs longitudinally and continues unidirectionally (from 
anterior to posterior), along the helical axis of the cell (reviewed in Hammarton 
et al. 2007). Also, cytokinesis in T. brucei can be divided into four distinct stages 
- division fold generation (or initiation), division furrow ingression, pre-
abscission and abscission (Wheeler et al. 2013). Initiation of cytokinesis occurs at 
a point near to the distal end of the new flagellum. An invagination of the cell 
body is generated between the two flagella which continues to deepen. Both the 
posterior and the anterior ends of the cell remain attached via the flagellar 
connector until the pre-abscission stage (Briggs et al. 2004; Wheeler et al. 
2013). However, in BSF parasites only the posterior ends of the nascent daughter 
cells remain attached as the new flagellum seems to disconnect from the cell 
body soon after division fold generation (Hughes et al. 2013; Wheeler et al. 
2013). Furrow ingression continues dividing replicated organelles equally. 
Disconnection of the two flagella from the flagellar connector releases the 
anterior ends of the daughter cells in PCF parasites. In the pre-abscission stage, 
the posterior ends of the nascent daughter cells of BSF and PCF stages remain 
connected to each other via a thin membrane linking the two, termed the 
‘cytoplasmic bridge’ (Wheeler et al. 2013). The cytoplasmic bridge differs 
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morphologically between PCF and BSF cells, i.e., in breadth and in volume 
(Wheeler et al. 2013). Final re-modelling and resolution of the new posterior end 
then facilitates final abscission (Farr & Gull 2012; Wheeler et al. 2013). 
 
Figure 1-4 Morphogenesis of the bloodstream and procyclic forms of T. brucei through the cell 
division cycle. Major morphogenetic cell cycle events are shown alongside cartoon 
representations of the associated cell morphologies. Adapted from Wheeler et al. 2013. 
1.3.3 Eukaryotic cell cycle regulation 
It is crucial that cell cycle events occur in their correct sequence and are well-
timed to ensure the production of viable progeny. Therefore, progression 
through the cell cycle, i.e. entry and exit from one phase to another, is strictly 
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regulated. There are checkpoints where control mechanisms verify whether the 
previous phase of the cell cycle has been accurately completed before entry into 
the next phase. These checkpoints ensure vital processes such as genomic DNA 
replication, at the S/M transition, or chromosome segregation, at the 
M/cytokinesis transition, have been completed faithfully and accurately. Events 
which drive the cell cycle forward involve the sequential activation and 
inactivation of cyclin-dependent kinases (Cdks). Cyclins bind Cdks and activate 
them. Activation of checkpoints, which stall the cell cycle, requires modulation 
of Cdk activities. Cdks are serine/threonine protein kinases featuring conserved 
catalytic cores which include an ATP-binding pocket, a PSTAIRE-like cyclin-
binding domain and an activation loop (also known as the T-loop) motif, whilst 
cyclins, which have been classified into many different types, are more diverse 
and are mainly characterised by their cyclin box which mediates binding to Cdks 
(Lim & Kaldis 2013). 
Yeasts possess only one major Cdk (CDC28 in Saccharomyces cerevisiae and 
Cdc2 in Schizosaccharomyces pombe; collectively CDK1; Beach et al. 1982). 
Yeast CDK1 is able to regulate the diverse cell-cycle transitions (G1/S, S and 
G2/M phases) by associating with different cell-cycle stage-specific cyclins. In 
higher organisms, specialised multiple homologues of yeast Cdk1 perform the 
multiple functions of yeast Cdk1 (Malumbres & Barbacid 2005; Malumbres & 
Barbacid 2009). Approximately 20 Cdk-related proteins have now been 
discovered which regulate cell-cycle events in higher eukaryotes via complex 
combinations with different cyclins (Satyanarayana & Kaldis 2009). Cyclins are 
synthesised and degraded at specific-points during the cell-cycle while different 
types of cyclins pair with specific Cdks. Cyclins confer substrate specificity and 
regulation (such as activation, inactivation, localisation and binding of subunits) 
to Cdk-cyclin complexes. However, further analyses on these complexes have 
shown that wide-spread redundancies do occur (Satyanarayana & Kaldis 2009).  
Many Cdk-cyclin complexes, along with their roles in driving the cell cycle, have 
been well characterised in mammalian cells and yeast (for reviews see 
Malumbres and Barbacid, 2005; Malumbres and Barbacid, 2009). In mammalian 
cells, a subset of Cdk-cyclin complexes remains at the front-line of cell cycle 
control by directly regulating cytoskeletal events which promote progression 
through the cell cycle. The Cdks and cyclins that are directly involved in 
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mammalian cell cycle include three interphase CDKs (Cdk2, Cdk4 and Cdk6), a 
mitotic CDK (Cdk1) and ten cyclins that belong to four different classes (the A-, 
B-, D- and E-type cyclins) (Malumbres & Barbacid 2009). It is important to note 
that some of these Cdk-cyclin pairs only act within specific cellular contexts 
(Malumbres & Barbacid 2009). Additional layers of control factors orchestrate 
the cytoskeletal events required for the replication and segregation of all 
cellular components and cytokinesis. Detailed summaries outlining cell cycle 
regulation in model organisms and T. brucei, within the various stages, can be 
found in the next section and its sub-sections 
1.3.4 T. brucei cell cycle regulation 
T. brucei possesses eleven homologues of Cdks, termed cdc2-related kinases 
(CRKs): CRK1-4 and CRK6-12 (Parsons et al., 2005; Hammarton, 2007). Ten 
different T. brucei cyclins (CYCs; CYC2-11) have also been identified 
(Hammarton, 2007). Six of these (CYC2, CYC4, CYC5, CYC7, CYC10 and CYC11) 
resemble the budding yeast PHO80 cyclin, which is involved in signalling 
phosphate starvation, and three cyclins (CYC3, CYC6 and CYC8) are homologous 
to the mitotic B-type cyclins found in mammals (Hammarton 2007). The last, 
CYC9, resembles cyclin C transcriptional cyclins (Hammarton, Monnerat, et al. 
2007). The publication of the ‘TriTryp’ (T. brucei, T. cruzi and Leishmania major 
- Berriman et al., 2005; El Sayed et al., 2005; Ivens et al., 2005) genome has 
enabled the extensive use of RNAi in investigating how the T. brucei cell-cycle is 
regulated via the various CRK:CYC interactions in addition to the roles played by 
T. brucei homologues of many other major cell-cycle regulators. 
1.3.4.1 G1/S transition 
During G1 phase, cells follow environmental cues to decide whether to 
proliferate, differentiate, quiesce or undergo apoptosis. Following favourable 
stimuli, once sufficient nutrients and growth factors are available, the decision 
is made to commit to the cell cycle and the cells transition from G1 phase to S 
phase. In mammalian cells, binding of D-type cyclins to Cdk4 and/or Cdk6 
activates the kinases, initiating the phosphorylation of the retinoblastoma 
protein, which leads to the release of the E2F transcription factors and 
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subsequent expression of E2F responsive genes (Dyson 1998; Weinberg 1995; 
Sherr & Roberts 1999; Sherr & Roberts 2004). These include E- and A-type cyclins 
(Sherr & Roberts 1999). Activation of Cdk2 by cyclin E further activates E2F 
mediated transcription which drives the G1/S transition. Cdk2 activation by A-
type cyclins triggers DNA replication and entry into S phase (Coverley et al. 
2000; Petersen et al. 1999). Deregulation of G1/S transition is a hallmark of 
cancer in metazoans (Massagué 2004). 
In T. brucei, not much is understood regarding the molecular pathways which 
drive cells into the S-phase. A number of putative regulators have been 
identified. RNAi of CYC2 (also called cyclin E1) and CYC4 has revealed that they 
play a major and minor role in the G1/S transition, respectively (Hammarton et 
al. 2004; Li & Wang 2003). RNAi of CRK1 alone, and in combination with CRK2, 
CRK4 and CRK6, indicated a primary role of CRK1 and accessory roles of CRK2, 
CRK4 and CRK6 for progression into S phase (Tu & Wang 2004; Tu & Wang 2005). 
CRK1 has been shown to interact with CYC2 forming, what is thought to be, the 
primary CRK-cyclin pair for promoting the G1/S transition (Gourguechon et al. 
2007). RNAi of CYC2 (in PCF cells and not in BSF cells) also displayed a ‘nozzle’ 
phenotype characterised by elongation of the posterior end of the cells thereby 
linking G1/S transition to morphogenesis (Hammarton et al. 2004). The joint 
knockdown of CRK1 and CRK2 generated a similar morphological phenotype 
indicating that CRK1, CYC2 and CRK2 are involved in the same pathway 
modulating PCF cell morphogenesis. Using yeast-two hybrid screens, CRK1 was 
also shown to interact with CYC4, CYC5 and CYC7, in addition to CYC2 (Liu et al. 
2013). Similar to CRK1, CYC2 and CYC4, RNAi of CYC5 and CYC7 also led to cells 
being blocked from transitioning into S phase, indicating a more complicated 
regulatory scheme for G1/S transition in T. brucei cells (Liu et al. 2013). In 
addition, the yeast-two hybrid experiments also revealed that CYC2 can interact 
with six other CRKs (CRK2, CRK3, CRK6, CRK8, CRK10 and CRK12) in addition to 
CRK1 (Liu et al. 2013). However, the physiological relevance of these 
interactions in T. brucei is yet to be determined. 
1.3.4.2 G2/M transition 
During G2 phase, the cell assesses the state of chromosome replication and 
prepares to undergo mitosis and cytokinesis. B-type cyclins are key for 
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progression through the G2/M boundary. In mammals, activation of Cdk1 by 
cyclin B, the protein kinase that sets the mitotic state (for example, by 
promoting chromosome condensation and nuclear envelope breakdown), leads to 
entry and progression through mitosis. To prevent early entry into mitosis, Cdk1 
is maintained in an inactive state via the phosphorylation activities of Wee1 and 
Myt1 (Dunphy 1994). Dephosphorylation of Cdk1 via Cdc25 during G2 phase 
activates it, thus promoting mitotic entry (Kumagai & Dunphy 1991). Cdc25 is 
activated by Polo-like kinase (PLK) which also promotes degradation of the Cdk1 
inhibitor Wee1 (Archambault & Glover 2009). Human PLK1 is activated by Aurora 
A kinase in G2 phase, which ultimately constitutes the pivotal event driving G2/M 
transition. 
RNAi of the Cdk1 homologue in T. brucei, CRK3, established its role in regulating 
mitotic entry, possibly through binding with CYC6 (also termed CYCB2; 
demonstrated in PCF and BSF cells; (Hammarton et al. 2003; Tu & Wang 2004; Li 
& Wang 2003). CRK3 has also been shown to form a complex with CYC2 
(demonstrated in PCF cells; Van Hellemond et al. 2000), however, whether this 
complex directly regulates mitotic entry is yet to be shown. In addition, CRK9 
and CYC8 have also been shown to be required for the G2/M transition (Li & 
Wang 2003; Gourguechon & Wang 2009). T. brucei does possess homologues of 
Wee1 and PLK. Recently, Wee1 was shown to be essential for PCF cell 
proliferation and to be able to rescue Wee1 deficient yeast mutants suggesting 
that T. brucei does possess a functional homologue of Wee1 (Boynak et al. 
2013). Depletion of Wee1 via RNAi in PCF cells generated zoids suggesting 
defects in mitosis. Studies characterising TbPLK have found no evidence for its 
localisation in the nucleus and role in mitosis (Chapter 3). In all, the pathways 
by which these factors collectively promote the G2/M transition are yet to be 
fully understood.  
1.3.4.3 Spindle assembly and chromosome segregation 
Chromosome segregation requires the setting of the bipolar mitotic spindle 
which is made of microtubule bundles. In mammalian cells, the mitotic spindle 
nucleates either from MTOCs or via chromatin-mediated pathways (Walczak & 
Heald 2008; Meunier & Vernos 2012). In yeast, spindle pole bodies (SPB) act as 
the nucleation site for spindle fibres (McIntosh & O’Toole 1999). Maintenance of 
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these spindle fibres requires the joint activities of microtubule motors, such as 
kinesin-5, kinesin-14 and the kinesin-13 microtubule depolymeriser, mitotic 
centromere-associated kinesin (MCAK), in addition to the phosphorylation 
activities of Aurora kinases on these motor proteins (Carmena et al. 2012; 
Waitzman & Rice 2014; Moore & Wordeman 2004). The spindle assembly 
checkpoint (SAC) ensures timely activity of the APC ligase until proper 
attachment of the mitotic spindle to kinetochores before progression into 
anaphase (Kops & Shah 2012). APC ligase activation promotes cleavage of sister 
chromatids and degradation of B-type cyclins (in turn inactivating Cdk1 and 
promoting mitotic exit). 
Trypanosomes are acentrosomal. The bipolar spindle is therefore likely to be 
mediated via chromatin-dependent pathways (Ogbadoyi et al. 2000; Li 2012). 
Aurora B kinase (AUK1) and MCAK homologues in trypanosomes have been found 
to be essential for spindle assembly and/or spindle microtubule dynamics in (Tu 
et al. 2006; Li & Wang 2006). In addition, AUK1 forms a unique chromosomal 
passenger complex (CPC) with two novel proteins, CPC1 and CPC2 (Li, Lee, et al. 
2008; Li, Umeyama, et al. 2008). The CPC has been shown to display dynamic 
localisation during mitosis and cytokinesis (Earnshaw & Cooke 1991; Cooke et al. 
1987). In other organisms, the CPC targets Aurora B to its substrates (Carmena et 
al. 2012). Whether the CPC in T. brucei plays a similar role is yet to be 
ascertained. T. brucei also possesses homologues of tousled-like kinase (TLK; 
TbTLK1 and TbTLK2) which in other eukaryotes are essential for activating 
Aurora B activity (Yeh et al. 2010; Silljé et al. 1999). TbTLKs have been found to 
be required for spindle assembly and chromosome segregation and although a 
substrate for AUK1, do not appear to be an activator of it (Li, Umeyama, et al. 
2008; Li et al. 2007). T. brucei possesses orphan kinesins (TbKINA and TbKINB) 
which also appear to regulate spindle assembly (Li, Lee, et al. 2008). TbKif13-2, 
a member of the kinesin-13 family was found to possess microtubule 
depolymerase activity (Chan & Ersfeld 2010). Additionally, several other proteins 
have also been reported to be involved in mitosis and chromosome segregation, 
such as TbNOP86 (Boucher et al. 2007), TbAGO1 (Durand-Dubief & Bastin 2003), 
and the small ubiquitin-like modifier (SUMO; Liao et al. 2010). Trypanosomes 
express all the components of the APC/C, of which, only two APC/C subunits, 
APC1 and Cdc27, are essential for trypanosome mitosis (Kumar & Wang 2005). In 
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addition, homologues of separase and the components of the cohesin complex of 
which SMC3, SCC1, and separase were all shown to be essential for chromosome 
segregation (Bessat & Ersfeld 2009; Gluenz et al. 2008).  
 
1.3.4.4 Mitotic exit and cytokinesis 
Mitotic exit requires the inactivation of the Cdk1-cyclin B complex which is 
achieved via its degradation by the anaphase promoting complex (APC) ligase. 
Activation of the APC is achieved by PLK (Archambault & Glover 2009). In yeasts, 
the SIN (septation initiation network) or MEN (mitotic exit network) pathways 
replace the role played by the mammalian APC ligase in promoting mitotic exit 
and are initiated by PLK. These SIN/MEN pathways involve a number of proteins 
which are also conserved in mammals and T. brucei such as PLK, Mps One Binder 
1 (MOB1) and nuclear DBF1-related (NDR) kinases.    
Cytokinesis involves a number of cytoskeletal events involving components of the 
cytoskeleton and the cell membrane. The core regulatory pathways are well 
conserved amongst eukaryotes. In mammalian cells, cytokinesis requires the 
definition of the cleavage plane by the central spindle. The phosphorylating 
activities of Aurora kinase and PLK are required at the central spindle and 
midbody (Archambault & Glover 2009). They regulate the centralspindlin 
complex recruitment of the guanine nucleotide exchange factor, Ect2, to the 
midbody. Ect2 then goes on to activate the small GTPase, RhoA, which leads to 
formation of the actinomyosin contractile ring.  
In T. brucei the cleavage furrow for cytokinesis is likely to be defined by the 
new FAZ and flagellum (Kohl et al. 2003; Wheeler et al. 2013). Mechanistic 
division of the cell is mediated via the ingression of this cleavage furrow which 
involves major remodelling of cytoskeletal components such as the subpellicular 
corset (Wheeler et al. 2013). CRK9 has been suggested to play a role in 
cytokinesis in PCF parasites. Depletion of CRK9 in BSF cells, on the other hand, 
did not seem to have any effect on their growth (Gourguechon and Wang, 2009). 
Other factors that have been shown to be involved in T. brucei cytokinesis such 
as the SIN/MEN homologues TbPLK, MOB1 and NDR kinases (Hammarton, Kramer, 
et al. 2007; Hammarton et al. 2005; Ma et al. 2010), the RHO kinase, TRACK 
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(Rothberg et al. 2006), components of the trypanosome CPC – AUK1, CPC1 and 
CPC2 (Li, Lee, et al. 2008; Li & Wang 2006; Tu et al. 2006), the MAP, AIR9 (May 
et al. 2012), to name a few (see Li 2012 for an extended list); it is however, 
quite likely that not all of these proteins are direct regulators of cytokinesis. 
Initiation of cytokinesis is usually associated with the mitotic exit checkpoint in 
order to ensure accurate inheritance of the replicated nuclei by daughter cells. 
In T. brucei PCF cells this checkpoint is missing making the generation of “zoids” 
(0N1K cells) possible as a result of unregulated cell division. This dissociation 
between mitotic exit and cytokinesis initiation has not been found to be the case 
in BSF parasites (Hammarton et al. 2003; Tu & Wang 2005).    
1.4 Research Aims 
Much is yet to be understood about how the cell cycle is regulated in T. brucei. 
Studies characterising various aspects of the cell cycle have identified 
divergence in T. brucei compared to other organisms. PLK is one such example. 
The only PLK homologue found in T. brucei, TbPLK, has been found to possess no 
mitotic role yet and features a dynamic localisation instead of a nuclear one. 
Detailed studies have now already provided clues to TbPLK function in T. brucei 
cytokinesis, and replication and segregation of cytoskeletal elements, in BSF and 
PCF parasites, respectively. One of the aims of this project was to characterise 
how TbPLK is regulated. The main thrust of the studies was to ascertain if the 
key regulatory features, as understood in other eukaryotes, have been conserved 
for TbPLK. Investigations were made in PCF (Chapter 3) and BSF cells (Chapter 
4). 
Since cell cycle progression is essential for T. brucei survival and has been shown 
to diverge from what has been demonstrated in mammalian cells, cell cycle 
regulators of T. brucei make attractive drug targets. It was hypothesised that 
due to the divergence in T. brucei cell cycle regulation there are novel cell cycle 
regulatory protein kinases that are yet to be discovered. Uncovering such novel 
kinases has been the second aim of this project. The establishment of a kinome-
wide RNAi library (Jones et al. 2014) has enabled a simple screen where kinases 
which affect T. brucei growth following their knockdown via RNAi, were 
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investigated for potential cell cycle roles, via microscopic analysis of DAPI 
stained cells (Chapter 5). 
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2 Materials and Methods 
2.1 Cell Culture  
2.1.1 Bacterial cell culture 
2.1.1.1 Bacterial strains 
Escherichia coli (E. coli) strains were used for the purposes of cloning and 
protein expression in this study (Table 2-1).  
Strain Genotype Comments 
XL1-Blue 
recA1 endA1 gyrA96 thi-
1 hsdR17 supE44 relA1 
lac [F´ proAB 
lacIqZΔM15 Tn10 
Tetracyline (Tet)r] 
Host strain used for plasmid storage 
(via glycerol stocks), propagation and 
purifications. 
BL21 DE3 
pLysS 
F– ompT hsdSB (rB–, mB–) 
dcm gal λ(DE3) pLysS 
Chloramphenicol (Cam)r 
Used for isopropyl β-D-thio-
galactopyranoside (IPTG) inducible 
expression of a target gene driven by 
the T7 promoter. Contains pLysS 
plasmid encoding T7 lysozyme which 
inhibits T7 polymerase, preventing 
basal expression from the T7 
promoter, without interfering with 
the level of expression achieved 
following IPTG induction. 
Table 2-1 E. coli strains used in this study. 
2.1.1.2 Bacterial culture and media 
Bacterial strains were routinely cultured in Luria-Bertani broth (LB-broth; 86 mM 
NaCl, 10 gL-1 tryptone and 5 gL-1 yeast extract, adjusted to pH 7 and 
autoclaved), with shaking at 180-220 rpm or on LB-agar plates (LB-broth 
supplemented with 15 gL-1 agar and autoclaved) at 37oC. 12-16 hours of 
incubation were typically required to obtain stationary phase liquid cultures or 
single colonies on plates. As required, media were supplemented with 
antibiotics, which were stored as 1000 X stock concentrations at -20oC (Table 2-
2). 
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Antibiotic Final concentration Dissolved in 
Ampicillin (Amp) 100 µg ml-1 70 % ethanol 
Kanamycin (Kan) 25 µg ml-1 dH2O 
Chloramphenicol (Cam) 25 µg ml-1 50 % ethanol 
Table 2-2 Antibiotics used when culturing bacterial strains. 
In order to determine the cell density of a liquid bacterial culture, 1 ml was 
pipetted into a cuvette and the OD600 nm was measured using a 
spectrophotometer (Shimadzu Biospec-mini DNA/RNA/protein analyser). 
2.1.1.3 Storage of bacterial strains 
For long term storage of bacterial strains, pellets from 10 ml overnight liquid 
cultures were obtained via centrifugation (3000 g, 10 minutes at 4oC) and 
subsequently resuspended in 1 ml LB containing 2 % peptone and 40 % glycerol 
before storing them at -80oC.  Frozen strains were revived by streaking a small 
amount of glycerol stock onto LB-agar plates and incubating at 37oC overnight so 
that single colonies were obtained.   
2.1.2 T. brucei cell culture 
2.1.2.1 T. brucei strains 
427 Lister T. b. brucei parasites, adapted for in vitro culturing, and their 
derivatives were used in this study  as described in Table 2-3.  
Life-cycle stage Genotype Comments 
PCF Lister 427 Wild-type 
BSF Lister 427 Wild-type 
PCF Lister 427 pHD449 
Zeor. Features constitutive 
expression of the tet repressor 
(TetR). Allows tet-inducible 
expression of genes of 
interest(Wirtz & Clayton 1995; 
Biebinger et al. 1997). 
BSF Lister 427 pLew13 pLew90 
Hygr. Neor. Features 
constitutive expression of T7 
RNA polymerase and T7 
promoter driven TetR. Allows 
tet-inducible expression of 
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genes of interest and 
constitutive expression of 
proteins (including selectable 
markers) that are under the 
control of T7 promoter (Wirtz 
et al. 1999). 
BSF 2T1 
Single ribosomal RNA 
(rRNA) spacer targeted for 
homologous recombination via 
the introduction of an 
incomplete hygromycin-
resistance marker. Enables 
consistent robust regulated 
expression of constructs 
introduced (Alsford & Horn 
2008). 
Table 2-3 T. brucei strains used in this study. 
2.1.2.2 T. brucei culture and media  
T. brucei PCF strains were cultured in the presence of 5 % CO2 at 27
oC in 
complete semi-defined media (SDM)-79 medium (Brun et al. 1979). Cells were 
routinely diluted to maintain mid-log phase growth (1 x 106 – 1 x 107 cells ml-1).  
SDM-79 was prepared by dissolving one pot of SDM-79 powder (Invitrogen; makes 
5 L) and 10 g Na(CO3)2 in 4.5 L dH2O before adjusting its pH to 7.3 with NaOH. 
This incomplete medium was then filter-sterilised and stored as 450 ml aliquots 
in sterile bottles at 4oC. The incomplete SDM-79 was routinely supplemented 
with heat-inactivated tetracycline-free fetal bovine serum (Gibco) to a final 
concentration of 10 % (v/v) and 500 Uml-1 penicillin and 50 µg ml-1 streptomycin 
and pre-warmed to 27oC before use.  
T. brucei BSF strains were cultured in the presence of 5 % CO2 at 37
oC in Hirumi's 
modified Iscove's medium (HMI)-9 (Hirumi & Hirumi 1989) or, for 2T1 cells which 
were used to generate the kinome-wide RNAi library described in Chapter 5, in 
HMI-11 (Jones et al. 2014). Cells were routinely diluted to maintain mid-log 
phase growth (1 x 105 – 1 x 106 cells ml-1).  
HMI-9 was prepared by dissolving one pot of HMI-9 powder (Invitrogen; makes 5 
L) in 3.8 L dH2O following which 71.5 µl β-mercaptoethanol and 200 ml 75 gL
-1 
Na(CO3)2 solution was mixed in before adjusting its pH to 7.4 with NaOH. This 
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incomplete medium was then filter-sterilised and stored as 400 ml aliquots in 
sterile bottles at 4oC. The incomplete HMI-9 was routinely supplemented with 
heat-inactivated tetracycline-free fetal bovine serum (Gibco) to a final 
concentration of 20 % (v/v) and 500 Uml-1 penicillin and 50 µg ml-1 streptomycin 
and pre-warmed to 37oC before use. In the case of HMI-11, 10 % (v/v) heat-
inactivated tetracycline-free fetal bovine serum was used to supplement 
incomplete HMI-9 instead.   
As needed, drugs were added to maintain selection for cells with successfully 
integrated constructs or, in the case for tetracycline, to induce expression of 
RNAi or a target protein. Different concentrations were used for drugs when 
supplementing HMI-11 to culture cell lines belonging to the kinome-wide RNAi 
library. Table 2-4 summarises details of the drugs used.   
Drug 
Final concentration in medium (µg ml-1) 
Company 
PCF (SDM-79) BSF (HMI-9) BSF (HMI-11) 
Hygromycin (Hyg) 50  5  2.5  Invitrogen 
Neomycin (Neo) 10  2.5  - Calbiochem 
Blasticidin (BSD) 20  10  10  InvivoGen 
Phleomycin (Phleo) - 2.5  0.5  InvivoGen 
Zeocin (Zeo) 10  - - Calbiochem 
Puromycin (Puro) - - 0.2  InvivoGen 
Tetracycline (tet) 1  1  1  Sigma 
Table 2-4 Drugs used when culturing T. brucei strains. 
In order to determine the cell density of a culture, 10 µl of cell suspension was 
loaded onto a Neubauer Improved haemocytometer. In order to ensure accuracy 
(limited to between 1 x 105 to 1 x 106 cells ml-1), at times, the cell suspension 
was first diluted before loading onto the haemocytometer. Cells in the four 
outer quadrants of the haemocytometer, each representing 1 mm2, were 
counted using phase contrast microscopy and the original cell density of the 
culture was determined by using the following calculation:    
cells ml-1 = average number of cells/mm2 x dilution factor x 104. 
For downstream applications, trypanosomes were harvested via centrifugation 
(PCF parasites – 600 X g; BSF parasites – 1500 X g) for 10 minutes. When needed, 
harvested cells were also washed before use. BSF parasites were washed in 
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sterile trypanosome dilution buffer (TDB; 20 nM Na2HPO4, 2 mM NaH2PO4.2H2O, 
80 mM NaCl, 5 mM KCl, 1 mM MgSO4.7H2O, 20 mM glucose and adjusted to pH 
7.4), whilst PCF parasites were washed sterile in phosphate-buffered saline (PBS; 
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4 , 1.8 mM KH2PO4 and adjusted to 
pH7.4). 
2.1.2.3 Storage of T. brucei strains 
For the purposes of long-term storage, glycerol stock stabilates of cultures were 
made. Cells from, typically, 10 ml (to make 4 stabilates) of mid-log phase 
cultures, were harvested (PCF parasites - 600 g, 10 minutes; BSF parasites 1500 
g, 10 minutes) to obtain pellets. The pellets were then resuspended in 4 ml fresh 
culture medium (without selective drugs) supplemented with 10 % (v/v) sterile 
glycerol (filter-sterilised after adding glycerol and stored at 4oC) and placed as 1 
ml aliquots into cryotubes. The stabilates were first allowed to freeze overnight 
in an insulated container at -80oC before being transferred to liquid nitrogen.    
When needed, stabilates removed from liquid nitrogen were allowed to thaw 
gently at room temperature before the contents were transferred into 10 ml of 
the appropriate pre-warmed culture media. The cells were allowed to recover 
without selective drugs for a day before such drugs were added. Cells were 
typically subpassaged 3-4 times before their use in experiments. 
2.1.2.4 Mouse infections 
ICR mice were inoculated with appropriate T. brucei cell numbers (as 
determined by the severity of infection expected). The inoculum volume was 
adjusted to 500 µl in trypanosome dilution buffer (TDB; 20 nM Na2HPO4, 2 mM 
NaH2PO4.2H2O, 80 mM NaCl, 5 mM KCl, 1 mM MgSO4.7H2O, 20 mM glucose and 
adjusted to pH 7.4). RNAi was induced by offering doxycycline-hyclate (Sigma 
Aldrich D9891 - 5 g) laced sugar water (0.2 g/L doxycycline-hyclate plus 50 g/L 
sucrose). Mice with parasitaemia above 1 x 108 cells/ml were humanely culled. 
All animal work was conducted in accordance with Home Office regulations by 
licensed animal handlers.  
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2.2 Genetic manipulation  
2.2.1 Transformation of bacterial cells 
2.2.1.1 Generating competent E. coli cells 
Competent bacterial cells were generated in the lab. In order to do this, cells 
from an appropriate overnight culture were diluted 1/500 into 50 ml fresh LB-
broth supplemented with the appropriate antibiotics and incubated at 37oC with 
shaking at 200 rpm until the cell density reached OD600 nm 0.6. The culture was 
then cooled on ice for 10 minutes before harvesting the cells via centrifugation 
(957 g, 15 minutes at 4oC). The resulting pellet was then, via gentle vortexing, 
resuspended in 16 ml ice-cold sterile RF1 buffer (100 nM RbCl, 50 mM 
MnCl2.4H2O, 30 mM CH3COOK, 10 mM CaCl2.2H2O and 15 % (v/v) glycerol 
adjusted to pH 5.8 with acetic acid). The suspension was then incubated on ice 
for 15 minutes before harvesting the cells (775 g, 15 minutes at 4oC). The 
resulting pellet was resuspended in 4 ml cold RF2 buffer (10 mM 3-(N-
morpholino) propanesulfonic acid (MOPS), 10 mM RbCl, 75 mM CaCl2.4H2O and 15 
% (v/v) glycerol, adjusted to pH 6.8 with NaOH) and incubated on ice for 1 hour. 
200 µl aliquots were frozen rapidly in a dry ice/ethanol slurry before being 
transferred to -80oC for long term storage. 
2.2.1.2  Transformation of competent E. coli cells 
Competent E. coli cells were transformed with plasmid DNA or ligation products 
as part of cloning and protein expression protocols. 100 µl aliquots of competent 
cells were thawed on ice before incubating the required amount (25 – 50 µl cells 
per construct) with β-mercaptoethanol (0.85 µl per 100 µl cell suspension) on ice 
for 5 minutes. To these cells, DNA (5 µl ligation product or 10-50 ng plasmid 
DNA) was added and incubated on ice for a further 20 minutes. The cells were 
then heat-shocked (42oC for 42 s) and allowed to recover by adding LB-broth 
(pre-warmed to 42oC; 900 µl per 100 µl competent cells) and incubating the cells 
with shaking (200 rpm) at 37oC for 30-90 minutes. 100 µl of the cell suspension 
were then plated aseptically onto an LB-agar plate supplemented with 
appropriate drugs which was then incubated overnight at 37oC to obtain single 
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colonies. As controls, an aliquot of cells incubated with dH2O (instead of DNA), 
and another aliquot of cells which were plated untransformed onto antibiotic 
free LB-agar plates, were also included in transformation experiments.  
2.2.2 Transfection of T. brucei cells  
Transfections of T. brucei cells were performed using the AmaxaTM 
NucleofectorTM Technology (Lonza). Cells (5 x 106 PCF cells/3 x 107 BSF cells per 
construct/control) from parental cultures at mid-log phase were harvested 
(section 2.1.2.2). The supernatant was then decanted ensuring no residual 
medium was left before resuspending the cell pellet with 100 µl Amaxa Human 
T-cell Nucleofector solution (supplemented as per the manufacturer’s 
instruction). The resulting cell suspension was then mixed by slow pipetting with 
5-10 µg linearised and purified DNA (section 2.3.2.10; or 5-10 µl dH2O to set up a 
mock transfection as a negative control) and transferred to a cuvette supplied 
with the kit. The cuvette was then placed into the NucleofectorTM cuvette holder 
and the X-001 program was applied. The transfected cells were then 
immediately transferred into pre-warmed media (10 ml complete SDM-79 
supplemented with 15 % instead of 10 % (v/v) fetal bovine serum for transfected 
PCF parasites or 30 ml complete HMI-9 for BSF parasites) containing drugs 
selective for the parental strain. After this step, the protocol varied between 
the two life cycle stages. 
The 10 ml cell suspension of transfected PCF cells was immediately split into 3 x 
3.3 ml cultures and allowed to recover for 16 hours (27oC, 5 % CO2). To each 
flask, the drugs selective for the transfected constructs were then added. 1/10 
and 1/100 dilutions of each flask were then plated as 100 µl aliquots per well 
into 96-well plates. The plates were incubated for 10 days before the culture 
volumes from a set of usually six selected positive wells were gradually 
increased to allow analysis of cell lines (when possible) and the generation of 
stabilates (section 2.1.2.3). Wells were selected for further culturing only when 
less than 20 % of the wells contained viable parasites after the selection period. 
In the case of BSF parasites, immediately after the transfection, 1 ml aliquots 
per well of neat, 1/10 and 1/100 dilutions of the 30 ml cell suspension were 
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plated into 24-well plates and the cells were allowed to recover for 6-12 hours 
(37oC, 5 % CO2). 1 ml complete HMI9/HMI11 medium containing 1 X 
concentration of drugs selective for the parental cell line and 2 X concentration 
of drugs selective for the transfected constructs was pipetted into each well. 
The plates were then incubated for 7 days before volumes from usually six 
selected positive wells were gradually increased to allow analysis of cell lines 
(when possible) and the generation of stabilates (section 2.1.2.3). Wells were 
selected for further culturing only when less than 25 % of the wells contained 
viable parasites after the selection period.  
2.3 Molecular Biology – DNA preparation and 
manipulation 
2.3.1 DNA Preparation  
2.3.1.1 Extraction of plasmid DNA from E. coli 
Plasmid DNA from 5 ml overnight liquid cultures of E. coli strains was purified 
using the QIAprep Spin Miniprep kit (Qiagen) in accordance with the 
manufacturer’s protocol. Plasmid DNA was always eluted using 30-50 µl dH2O. 
Table 2-5 outlines plasmids that were previously generated/obtained and used in 
this study. 
Plasmid Details Source 
pGL202 
Hygr. Also known as pHD675. T. brucei 
expression vector featuring PARP-
promoter modified to include tet 
operators (TetO) which drives the 
expression of a gene of interest in a tet-
inducible manner. Linearised with NotI 
allowing integration into the rRNA gene 
array.   
(Biebinger et al. 1997) 
pGL605 
Bleor. Also known as p2T7ti:GFP. T. 
brucei RNAi vector featuring opposing 
promoters allowing the generation of 
dsRNA in a tet-inducible manner. NotI 
site mutated, therefore, requires 
linearisation with EcoRV instead prior to 
transfection into T. brucei parasites to 
allow integration into the rRNA gene 
(LaCount et al. 2000) 
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array. 
pHG314/315
/316 
BSDr/Bleor/Hygr, respectively. T. brucei 
dual promoter expression vector 
featuring T7 promoters and terminators 
asscoiated with the resistance gene and 
Tet-inducible, RNA polymerase promoter 
driven-expression of gene of interest. 
Linearised with NotI to allow integration 
into the rRNA gene array. 
Cross lab 
(http://tryps.rockefel
ler.edu/trypsru2_plas
mids.html). 
pET28a+ 
Kanr. Bacterial 6His-tagged protein 
expression vector. 
Novagen 
pGEX-5X1 
Ampr. Bacterial GST-tagged protein 
expression vector. 
GE Lifesciences 
pGL1278 
Ampr. Hygr. Inducible ty-tagged TbPLK 
expression vector; pGL202 backbone. 
(Hammarton et al. 
2007) 
pGL1279 
Ampr. Hygr. Inducible ty-tagged TbPLK 
N169A expression vector; pGL202 
backbone. 
(Hammarton et al. 
2007) 
pHG3 
Kanr. Inducible 6His-tagged TbPLK 
expression vector; pET28a(+) backbone. 
(May 2010) 
pHG4 
Kanr. Inducible 6His-tagged TbPLK N169A 
expression vector; pET28a(+) backbone. 
(May 2010) 
pHG123 
Kanr. Inducible 6His-tagged TbPLK T198V  
expression vector; pET28a(+) backbone. 
(May 2010) 
pHG153 
Kanr. Inducible 6His-tagged PBD431 (431-
763 aa) expression vector; pET28a(+) 
backbone. 
(May 2010) 
pHG152 
Kanr. TbPLK H704A H706A cloned into 
pSC-A. 
(May 2010) 
pHG157 
Kanr. Inducible 6His-tagged TbPLK T198A 
expression vector; pET28a(+) backbone. 
(May 2010) 
pHG329 
Bleor. Inducible YFP-tagged PBD (468-763 
aa) expression vector; pLew100 
backbone.  
de Graffenried lab. 
Table 2-5 Plasmids used in this study. 
2.3.1.2  Extraction of genomic DNA from T. brucei  
Genomic DNA from T. brucei was either extracted using the DNeasy blood and 
tissue kit (Qiagen) following the manufacturer’s instructions or a simple ‘mini-
prep’ procedure using LiCl (Medina-Acosta & Cross 1993). For genomic extraction 
using the DNeasy kit, 5 x 106 cells were harvested and washed once (section 
2.1.2.2) before applying the protocol. For genomic extraction using the ‘mini-
prep’ procedure, 1 x 107 – 1 x 108 cells were harvested and washed once before 
applying the protocol. Briefly, cell pellets were resuspended in 150 µl TELT 
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buffer (50 mM TrisCl at pH 8; 62.5 mM EDTA at pH 9; 2.4 M LiCl and 4 % (v/v) 
Triton X-100) and incubated for 5 minutes at room temperature before adding 
150 µl of phenol:dH2O (1:1) and separating the phases via centrifugation (13,000 
g for 5 minutes). The aqueous phase was then transferred to separate tube to 
which 300 µl of 100 % ethanol was added. The mixture was mixed gently before 
being incubated for 5 minutes at room temparature. The precipated DNA was 
pelleted via centrifugation (13,000 g for 10 minutes) and then washed with 1 ml 
100 % ethanol. The DNA was then allowed to air-dry before being resuspended in 
100 µl TE buffer (10 mM TrisCl at pH 8 and 1 mM EDTA at pH 8) with 2 ngµl-1 
pancreatic ribonuclease and incubating it at 37oC for 30 minutes. 
2.3.1.3 Determination of DNA concentration 
The concentration of prepared DNA samples was measured using a NanoDrop 
1000 Spectrophotometer (Thermo Scientific) by measuring absorbance at OD260 
nm. 
2.3.2 DNA manipulation 
2.3.2.1 Agarose gel electrophoresis 
In order to prepare an agarose gel, 0.7-1 % (w/v) agarose was added to 0.5 % 
Tris-borate-EDTA (TBE) buffer (44.6 mM Tris-base, 44.5 mM boric acid and 1 mM 
EDTA) and the mixture then heated in a microwave until all agarose dissolved. 
The solution was allowed to cool before adding SYBR® Safe DNA Gel Stain 
(Invitrogen, 1/30,000 dilution). The solution was then poured into a prepared gel 
cast following which a suitable gel-comb was set in place to make wells. The gel 
was then allowed to set at room temperature. Once set and the comb removed, 
the gel was immersed into an appropriate gel tank filled with 0.5 % TBE. DNA 
samples were prepared by adding DNA loading buffer (6 X stock solution: 0.25 % 
(w/v) xylene cyanol, 0.25 % (w/v) bromophenol blue and 15 % Ficoll) to a final 
concentration of 1 X. The DNA samples were then loaded into the wells of the 
agarose gel. 10 µl of 1 kb Plus DNA Ladder (Invitrogen; 0.052 µg ml-1 in 1 X DNA 
loading buffer) were added to one lane in order to allow size estimation of 
sample DNA bands. The gels were typically electrophoresed for 30-45 minutes at 
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100 V before bands were visualised using the GelDoc (BioRad) system and the 
associated Quantity One Software (BioRad). 
2.3.2.2 Polymerase chain reaction (PCR) 
PCR was used to amplify genes or parts of a gene from purified plasmid/genomic 
DNA (section 2.3.1) or from E. coli colonies harbouring plasmids (colony PCR; 
sections 2.3.2.6 and 2.3.2.7). The PCR was also used to introduce mutations into 
genes on plasmids (site-directed mutagenesis; section 2.3.2.3).  
In this study, two different polymerases, Taq DNA Polymerase (NEB) and the 
proof reading polymerase, Phusion™ High-Fidelity DNA Polymerase (Finnzymes), 
were used. Taq polymerase was used to test primer pairs (Table 2-7) for their 
ability to successfully amplify the required product and for colony PCR. Phusion 
polymerase was used to amplify genes or gene fragments with high-fidelity for 
subsequent cloning. Table 2-6 shows the composition of reaction mixes for each 
enzyme. 
 Reagents 
Polymerase 
Taq Phusion® 
Buffer 1 X Taq PCR mix* 1 X Phusion PCR mix** 
dNTPs included in Taq PCR mix 0.2 mM 
Forward primer 20 ng 20 ng 
Reverse primer 20 ng 20 ng 
DNA*** 5-10 ng 5-10 ng 
Enzyme 1 U 0.4 U 
Final volume 20 µl 20 µl 
Table 2-6 Amounts of components added to make up one PCR reaction. 
*Composed of: 113 µg ml-1 BSA, 45 mM Tris (pH 8.8), 11 mM (NH4)2SO4, 4.5 mM 
MgCl2, 0.047 % (v/v) β-mercaptoethanol, 4.4 µM EDTA (pH 8) and 1 mM dNTPs 
(Invitrogen). 
**Provided with the enzyme as a 5 X stock solution 
***Prepared plasmid/genomic DNA or a small portion of an E. coli colony.  
For Taq polymerase reactions, the PCR programme was set as follows: 
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 1 cycle of 95oC for 30 s (for amplification from DNA) or 1 cycle of 95oC for 
5 minutes (for colony PCR to ensure cell lysis) 
 30 cycles of 95oC for 50 s; Tm for 50 s; 72
oC for 1 minute, where Tm was 
adjusted depending on the primers used. 
 1 cycle of 72oC for 5 minutes 
For Phusion polymerase reactions, the PCR programme was set as follows: 
 1 cycle of 98oC for 30 s 
 35 cycles of 98oC for 10 s; Tm for 30 s; 72
oC (Te) for 15 s, where Tm was 
adjusted depending on the primers used and Te was calculated by allowing 
15-30 s per 1 kb of amplified product. 
 1 cycle of 72oC for 10 minutes 
Primer 5’ → 3’ sequence and restriction site Details 
OL2138 
           Nhel 
CCAAGCTAGCATGCACGCAACCGCTGAGAC            
Sense primer to 
amplify TbPLK (from 
base 4). 
OL2139 
           XhoI 
GGTTCTCGAGCTAAATATCACGGTTTTGTATG 
Antisense primer to 
amplify TbPLK (up to 
the final base). 
OL2142 
         BamHI 
CCAAGGATCCACGCAACCGCTGAGACGTG            
Sense primer to 
amplify TbPLK (from 
base 4). Designed 
specifically for 
cloning into pGEX-
5X1. 
PR318  
           Nhel 
GTGACTCGAGCTAGTAGAAGAGTGTGGTAGG            
Antisense primer to 
amplify TbPLK (up to 
base 936) 
PR368 
         BamHI 
ACAAGGATCCCACGCAACCGCTGAGACGTG 
Sense primer to 
amplify TbPLK (from 
base 4). 
PR369 
         BamHI 
ACTGGGATCCGCGGTGAGCATCCCGTCACC 
Sense primer to 
amplify TbPLK (from 
base 1291). 
PR385 
         BamHI  
CGACGGATCCAAGGAAAAGAAATG 
Sense primer to 
amplify 3’UTR of 
TbPLK (from the 
base which is 1 base 
upstream of the stop 
codon). 
PR386 
         HindIII 
CGTCAAGCTTCCTTCGCCCCTTCTC 
Antisense primer to 
amplify 3’ UTR of 
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TbPLK (up to the 
base which is 549 
bases upstream of 
the stop codon). 
PR403 
          XhoI 
GATACTCGAGCTAAGCACTGTTAATGGGG 
Antisense primer to 
amplify TbPLK (up to 
base 1290). 
PR404 
         BamHI 
GTTAGGATCCAGTTCACGCCGCCGTCAG 
Sense primer to 
amplify TbPLK (from 
base 937). 
Table 2-7 PCR primers used in this study for gene cloning. 
1 µl samples, made up to 10 µl volume with dH2O, of all PCR reactions were 
electrophoresed via agarose gel electrophoresis to verify appropriate 
amplification. 
2.3.2.3 Site-directed mutagenesis 
Site-directed mutagenesis was performed using the Quikchange II Site-directed 
Mutagenesis kit (Agilent) and mutagenised plasmid mixes were transformed into 
XL1-Blue supercompetent cells according to the manufacturer’s instructions. The 
primers used to introduce mutations are given in Table 2-8. Plasmid DNA was 
prepared (section 2.3.1.1) from selected colonies obtained, tested via small-
scale restriction digests (section 2.3.2.4) and analysed via DNA sequencing to 
verify the introduction of the desired mutation and the absence of any unwanted 
mutations in the sequence of the gene of interest (section 2.3.2.9). Table 2-9 
describes plasmids that were successfully mutated via site-directed mutagenesis 
in this study.  
Primer 5’ → 3’ sequence Details 
PR387 
CGCGCCATTTGTGGCGCCCCCAATTATATCGCACC
G 
Sense primer to 
introduce T202A 
mutation into TbPLK 
T198A. 
PR388 
CGGTGCGATATAATTGGGGGCGCCACAAATGGCG
CG 
Antisense primer to 
introduce T202A 
mutation into TbPLK 
T198A. 
PR389 
CGCGACATTTGTGGCGACCCCAATTATATCGCACC
GG 
Sense primer to 
introduce T202D 
mutation into TbPLK 
T198D. 
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PR390  
CCGGTGCGATATAATTGGGGTCGCCACAAATGTC
GCG 
Antisense primer to 
introduce T202D 
mutation into TbPLK 
T198D. 
PR391 
CGCGCCATTTGTGGCGACCCCAATTATATCGCACC
G 
Sense primer to 
introduce T202D 
mutation into TbPLK 
T198A. 
PR392  
CGGTGCGATATAATTGGGGTCGCCACAAATGGCG
CG 
Antisense primer to 
introduce T202D 
mutation into TbPLK 
T198A. 
PR393 
CGCGACATTTGTGGCGCCCCCAATTATATCGCACC
G 
Sense primer to 
introduce T202A 
mutation into TbPLK 
T198D. 
PR394 
CGGTGCGATATAATTGGGGGCGCCACAAATGTCG
CG 
Antisense primer to 
introduce T202A 
mutation into TbPLK 
T198D. 
PR395 
CGCACTATTTGTGGCGCCCCCAATTATATCGCACC
G 
Sense primer to 
introduce T202A 
mutation into TbPLK. 
PR396 
CGGTGCGATATAATTGGGGGCGCCACAAATAGTG
CG 
Antisense primer to 
introduce T202A 
mutation into TbPLK. 
PR397 
CGCACTATTTGTGGCGACCCCAATTATATCGCACC
GGAG 
Sense primer to 
introduce T202D 
mutation into TbPLK. 
PR398 
CTCCGGTGCGATATAATTGGGGTCGCCACAAATA
GTGCG 
Antisense primer to 
introduce T202D 
mutation into TbPLK. 
PR409 
CGCACTATTTGTGGCGAGCCCAATTATATCGCACC
GGAG 
Sense primer to 
introduce T202E 
mutation into TbPLK. 
PR410 
CTCCGGTGCGATATAATTGGGCTCGCCACAAATAG
TGCG 
Antisense primer to 
introduce T202E 
mutation into TbPLK. 
Table 2-8 Primers used for site-directed mutagenesis. Bases shown in bold highlight mutations 
that are to be introduced. 
Original 
gene 
Parent plasmid* 
Primers used** 
Mutation 
introduced 
Resulting 
plasmid Sense 
Anti-
sense 
TbPLK T198A pHG393  PR387 PR388 T202A pHG438 
TbPLK T198D pHG395  PR389 PR390 T202D pHG439 
TbPLK T198A pHG393  PR391 PR392 T202D pHG440 
TbPLK T198D pHG396  PR393 PR394 T202A pHG441 
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TbPLK pHG389  PR395 PR396 T202A pHG442 
TbPLK pHG389  PR397 PR398 T202D pHG443 
TbPLK pHG389  PR409 PR410 T202E pHG460 
*For details of plasmids used, see Table 2-11. 
**For details of primers used, see Table 2-8. 
Table 2-9 Details of mutations introduced into TbPLK genes including parent plasmids and 
primers used, and the resulting plasmids that were generated. 
2.3.2.4 Restriction endonuclease digests    
To verify plasmid identity and for cloning experiments, DNA samples were 
digested with selected restriction endonucleases (NEB). 
Plasmid DNA was routinely checked and verified via small-scale digests before 
further work. To 1 µl (typically 0.2-0.5 µg) of the Mini-prep product (section 
2.3.1.1), 10 U of the selected restriction endonuclease(s), 1 µg µl-1 bovine-serum 
albumin and 1 µl of the appropriate buffer were added as prescribed by the 
manufacturer’s protocol. This reaction mixture was then made up to 10 µl with 
dH2O before incubating it for 30-60 minutes at the appropriate temperature in 
accordance with the manufacturer’s guidelines.    
For cloning and for plasmid linearisation (prior to transfection into T. brucei), 
plasmid DNA was subjected to large scale restriction endonuclease digestion. For 
cloning, typically 20 µl (4-8 µg) of the Mini-prep product (section 2.3.1.1), 20 U 
of the selected restriction endonuclease(s), 1 µg µl-1  bovine-serum albumin and 
10 µl of the appropriate buffer was added. For linearisation, 10 µg of the Mini-
prep product (section 2.3.1.1), 20-60 U of the selected restriction endonuclease, 
1 µg µl-1 bovine-serum albumin and 10 µl of the appropriate buffer were added. 
These reaction mixtures were then made up to 100 µl with dH2O before 
incubating them for 16 hours at the appropriate temperature.    
All digest products were analysed via agarose gel electrophoresis (section 
2.3.2.1) before being used for downstream applications. In the case of small-
scale digests, all 10 µl of the digest products were analysed whilst in the case of 
large-scale digests, 0.5–1 µl samples that were made up to 10 µl volume with 
dH2O, were analysed. 
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2.3.2.5 DNA extraction from agarose gels 
For the purpose of cloning, the required DNA fragments were visualised under 
blue light following electrophoresis (section 2.3.2.1) and were excised from the 
gel using clean scalpels . The gel slices were then solubilised and DNA was 
extracted from them using the QIAquick Gel Extraction kit (Qiagen) in 
accordance with manufacturer’s guidelines. DNA was eluted in 30 µl dH2O. 
2.3.2.6 Cloning of amplified genes/fragments into generic cloning vectors 
Phusion polymerase-amplified products (section 2.3.2.2) were always first 
cloned into the pSC-B-Amp/Kan blunt cloning vector (Stratgene) following the 
manfacturer’s instructions before they were sub-cloned into the appropriate 
final destination vector (section 2.3.2.7). A set of colonies were then screened 
for the presence of the gene/fragment of interest within pSC-B-Amp/Kan 
(section 2.3.2.2). At least two of the colonies confirmed to have an insert were 
then analysed via small-scale restriction digests (section 2.3.2.4) and 
subsequently by DNA sequencing to confirm the presence of the desired 
gene/fragment (section 2.3.2.9). Table 2-10 describes the genes/fragments that 
were amplified in this project along with the resulting plasmids that were 
generated following the cloning of these amplified products into pSC-B-
Amp/Kan. 
Sequence amplified Template DNA 
Primers used*** pSC-B-
Amp/Kan 
plasmid Sense 
Anti-
sense 
KD pGL1278*  OL2142 PR318 pHG304 
KD N169A pGL1279*  OL2142 PR318 pHG376 
TbPLK pGL1278*  PR368 OL2139 pHG379 
TbPLK N169A pGL1279*  PR368 OL2139 pHG380 
KD pGL1278*  PR368 PR318 pHG381 
KD N169A pGL1279*  PR368 PR318 pHG382 
TbPLK T198A pHG157*  PR368 OL2139 pHG383 
TbPLK T198V pHG123* PR368 OL2139 pHG384 
TbPLK T198D pHG163* PR368 OL2139 pHG385 
TbPLK H704A H706A pHG152* PR368 OL2139 pHG386 
PBD431 pGL1278* PR369 OL2139 pHG387 
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PBD431 H704A H706A pHG152*  PR369 OL2139 pHG388 
TbPLK 3’UTR BSF 427 genomic DNA PR385 PR386 pHG444 
TbPLK ΔPBD431 pGL1278*  PR368 PR403 pHG447 
TbPLK ΔKD+PBD431 pGL1278*  PR404 PR403 pHG448 
TbPLK ΔKD pGL1278*  PR404 OL2139 pHG449 
TbPLK T198D T202D pHG439**  OL2138 OL2139 pHG463 
TbPLK T198A T202D pHG440**  OL2138 OL2139 pHG464 
TbPLK T202A pHG442**  OL2138 OL2139 pHG465 
TbPLK T202D pHG443**  OL2138 OL2139 pHG466 
TbPLK T202E pHG460**  OL2138 OL2139 pHG467 
*For details of plasmids used, see Table 2-5. 
**For details of plasmids used, see Table 2-9. 
***For details of primers used, see Table 2-7. 
Table 2-10 TbPLK gene fragments amplified with details of templates and primers used. Also 
included are the names of the resulting plasmids when the amplified fragments were cloned into 
the generic blunt cloning vector pSC-B-Amp/Kan. KD – kinase domain; PBD – Polo-box domain. 
2.3.2.7 Subcloning 
DNA ligation was used to insert restriction endonuclease digested fragments into 
a recipient plasmid.  
First, appropriate large-scale restriction digests (section 2.3.2.4) were 
performed to cut the desired fragment out of the donor plasmid (insert) and to 
cut the destination vector backbone (vector). Digests were electophoresed on 
agarose gels to separate the fragments, and the required fragments were 
excised from the gel under blue light using a clean scalpel blade. DNA was then 
purified from the gel slices obtained (section 2.3.2.5) and the concentrations of 
the purified products were ascertained (section 2.3.1.3). 
In order to set up a ligation reaction, the relative amounts of purified insert and 
vector DNA was then determined using the formula: 
[(ng vector X kb insert)/(kb vector)] X molar ratio of insert:vector = ng insert   
Chapter 2 
 
52 
where the molar ratio of 3:1 (insert:vector) was routinely used. Volumes used 
were such that the vector and insert would collectively measure less than 8 µl. 
Also, a vector only reaction was set up as a negative control. 
Typically, 10 µl ligations reactions were set up. 1 X T4 DNA ligase buffer (NEB) 
and 0.4 U T4 DNA ligase (NEB) were added to the insert and vector DNA and the 
final volume was then made up to 10 µl with dH2O. The reaction mixture was 
then incubated, either for 1 hour at room temperature or for 16 hours at 4oC, 
before transforming the resulting products into XL1-Blue cells (sections 2.1.1.1 
and 2.2.1.2). 
The colonies obtained were then screened via PCR (section 2.3.2.2) to 
determine whether they likely harboured the desired final plasmid.  Plasmid DNA 
was extracted from PCR-positive colonies and further analysed via small-scale 
restriction digests (section 2.3.2.4). 
Sub-cloning reactions that were carried out in this project have been described 
in Table 2-11. 
Plasmid 
Fragment 
subcloned 
from 
Final 
destination 
vector 
Restriction 
sites used 
Details 
pHG321 pHG304* pGEX-5XI** BamHI+XhoI 
Ampr. KD cloned into 
pGEX-5X1 to generate 
GST-tagged protein.  
pHG341 pHG329**  pGL202**  HindIII+BamHI 
Ampr. Bleor. YFP cloned 
into pGL202 (pHD675). 
pHG342 pHG329**  pHG316**  HindIII+BamHI 
Ampr. Hygr. YFP cloned 
into pHG316 
(pLew100v5). 
pHG366 
fragment 
generated by 
annealing 
complement
-ary primers, 
PR364 and 
PR365*** 
pHG341 
BamHI+BclI 
overhangs in 
fragment 
cloned into 
BamHI site in 
pHG341 
Ampr. Bleor. MCS 
introduced into pHG341 
to allow N-terminal 
YFP-tagged 
overexpression of target 
protein in PCF T. brucei 
parasites. 
pHG367 
fragment 
generated by 
annealing 
complement
ary primers, 
pHG342 
BamHI+BclI 
overhangs in 
fragment 
cloned into 
BamHI site in 
Ampr. Hygr. MCS 
introduced into pHG342 
to allow N-terminal 
YFP-tagged 
overexpression of target 
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PR366 and 
PR367*** 
pHG342 protein in BSF T. brucei 
parasites. 
pHG378 pHG376* pGEX-5XI** BamHI+XhoI 
Ampr. KD N169A cloned 
into pGEX-5X1 to 
generate GST-tagged 
protein. 
pHG389 pHG379*  pHG366 BamHI+XhoI 
Ampr. Hygr. TbPLK 
cloned into pHG366 (see 
above). 
pHG390 pHG380*  pHG366 BamHI+XhoI 
Ampr. Hygr. TbPLK 
N169A cloned into 
pHG366 (see details for 
pHG366). 
pHG391 pHG381*  pHG366 BamHI+XhoI 
Ampr. Hygr. KD cloned 
into pHG366 (see details 
for pHG366). 
pHG392 pHG382*  pHG366 BamHI+XhoI 
Ampr. Hygr. KD N169A 
cloned into pHG366 (see 
details for pHG366). 
pHG393 pHG383*  pHG366 BamHI+XhoI 
Ampr. Hygr. TbPLK 
T198A cloned into 
pHG366 (see details for 
pHG366). 
pHG394 pHG384*  pHG366 BamHI+XhoI 
Ampr. Hygr. TbPLK 
T198V cloned into 
pHG366 (see details for 
pHG366). 
pHG395 pHG385*  pHG366 BamHI+XhoI 
Ampr. Hygr. TbPLK 
T198D cloned into 
pHG366 (see details for 
pHG366). 
pHG396 pHG386*  pHG366 BamHI+XhoI 
Ampr. Hygr. TbPLK 
H704A K706A cloned 
into pHG366 (see details 
for pHG366). 
pHG397 pHG387*  pHG366 BamHI+XhoI 
Ampr. Hygr. PBD431 
cloned into pHG366 (see 
details for pHG366). 
pHG398 pHG388*  pHG366 BamHI+XhoI 
Ampr. Hygr. PBD431 
H704A K706A cloned 
into pHG366 (see details 
for pHG366). 
pHG399 pHG315** pHG367 HindIII+NotI 
Ampr. Switched 
resistance cassette of 
pHG367 from Hygr to 
Bleor (see details for 
pHG367). 
pHG402 pHG379*  pHG399 BamHI+XhoI 
Ampr. Bleor. TbPLK 
cloned into pHG366 (see 
details for pHG366). 
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pHG403 pHG380*  pHG399 BamHI+XhoI 
Ampr. Bleor. TbPLK 
N169A cloned into 
pHG366 (see details for 
pHG366). 
pHG404 pHG381*  pHG399 BamHI+XhoI 
Ampr. Bleor. KD cloned 
into pHG366 (see details 
for pHG366). 
pHG405 pHG382*  pHG399 BamHI+XhoI 
Ampr. Bleor. KD N169A 
cloned into pHG366 (see 
details for pHG366). 
pHG406 pHG383*  pHG399 BamHI+XhoI 
Ampr. Bleor. TbPLK 
T198A cloned into 
pHG366 (see details for 
pHG366). 
pHG407 pHG384*  pHG399 BamHI+XhoI 
Ampr. Bleor. TbPLK 
T198V cloned into 
pHG366 (see details for 
pHG366). 
pHG408 pHG385*  pHG399 BamHI+XhoI 
Ampr. Bleor. TbPLK 
T198D cloned into 
pHG366 (see details for 
pHG366). 
pHG409 pHG386*  pHG399 BamHI+XhoI 
Ampr. Bleor. TbPLK 
H704A K706A cloned 
into pHG366 (see details 
for pHG366). 
pHG410 pHG387*  pHG399 BamHI+XhoI 
Ampr. Bleor. PBD431 
cloned into pHG366 (see 
details for pHG366). 
pHG411 pHG388*  pHG399 BamHI+XhoI 
Ampr. Bleor. PBD431 
H704A K706A cloned 
into pHG366 (see details 
for pHG366). 
pHG450 pHG447*  pHG366 BamHI+XhoI 
Ampr. Hygr. ΔPBD431 
cloned into pHG366 (see 
details for pHG366). 
pHG451 pHG448*  pHG366 BamHI+XhoI 
Ampr. Hygr. ΔKD+PBD431 
cloned into pHG366 (see 
details for pHG366). 
pHG452 pHG449*  pHG366 BamHI+XhoI 
Ampr. Hygr. ΔKD cloned 
into pHG366 (see details 
for pHG366). 
pHG456 pHG314**  pGL605**  SnaBI 
Ampr. Switched 
resistance cassette from 
Bleor to BSDr (see 
details of pGL605 in 
Table 2-5).  
pHG457 pHG444*  pHG456 HindIII+BamHI 
Ampr. BSDr. TbPLK 
3’UTR cloned into 
pHG456 to induce RNAi. 
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pHG468 pHG463* pET28a+**  NheI+XhoI 
Kanr. TbPLK T198D 
T202D cloned into 
pET28a+ to generate 
His-tagged protein. 
pHG469 pHG464*  pET28a+**  NheI+XhoI 
Kanr. TbPLK T198A 
T202D cloned into 
pET28a+ to generate 
His-tagged protein. 
pHG470 pHG465*  pET28a+**  NheI+XhoI 
Kanr. TbPLK T202A 
cloned into pET28a+ to 
generate His-tagged 
protein. 
pHG471 pHG466*  pET28a+**  NheI+XhoI 
Kanr. TbPLK T202D 
cloned into pET28a+ to 
generate His-tagged 
protein. 
pHG472 pHG467*  pET28a+**  NheI+XhoI 
Kanr. TbPLK T202E 
cloned into pET28a+ to 
generate His-tagged 
protein. 
*For details of plasmids used, see Table 2-10 
**For details of plasmids used, see Table 2-5 
***For further details, see section 2.3.2.8. 
Table 2-11 Details of plasmids generated in this study following subcloning and modification. KD 
comprises of bases 4-936 (2-312 aa) of TbPLK; PBD431 comprises of bases 1292-end (431-763 aa) of 
TbPLK; ΔPBD431 comprises of bases 4-1291 (1-430 aa) of TbPLK; ΔKD+PBD431 comprises of bases 
937-1291 (313-430 aa) of TbPLK; ΔKD comprises of bases 937-end (313-763 aa) of TbPLK.  
2.3.2.8 Addition of multiple cloning sites 
In order to add multiple cloning sites into the plasmids pHG341 and pHG342, 
linker DNA sequences were generated using primers PR364+PR365 and 
PR366+PR367, respectively (Table 2-12). 
To do this 0.5 µg each of the sense and antisense primers, diluted with dH2O to a 
final volume of 100 µl, were heated at 95oC for 2 minutes and then allowed to 
cool at room temperature. These linker sequences (inserts) were then subcloned 
into pHG341 and pHG342 (vectors) as described in section 2.3.2.7.  
Primer 5’ → 3’ sequence Details 
PR364  BamHI   MluI      XhoI     HpaI   BclI 
Sense primer to 
introduce a multiple 
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GATCCACGCGTCTCGAGGTTAACT cloning site into the 
BamHI site of 
pHG341 
PR365 
   BclI    HpaI      XhoI      MluI   BamHI 
GATCAGTTAACCTCGAGACGCGTG 
Antisense primer to 
introduce a multiple 
cloning site into the 
BamHI site of 
pHG341 
PR366 
BamHI   ApaII     XhoI      HpaI   BclI 
GATCCGGGCCCCTCGAGGTTAACT 
Sense primer to 
introduce a multiple 
cloning site into the 
BamHI site of 
pHG342 
PR367 
   BclI    HpaI     XhoI      ApaII   BamHI 
GATCAGTTAACCTCGAGGGGCCCG 
Sense primer to 
introduce a multiple 
cloning site into the 
BamHI site of 
pHG342 
Table 2-12 Primers used to generate linker sequences for adding multiple cloning sites into 
pHG341 and pHG342.  
2.3.2.9 DNA sequencing  
DNA samples were sequenced by the University of Dundee sequencing service 
(http://www.dnaseq.co.uk/home.html).  The primers that were routinely used 
for sequencing have been listed in Table 2-13. 
Primer 5’ → 3’ sequence Details 
M13 forward GTAAAACGACGGCCAGT            
Sense primer to 
sequence insert 
in pSC-B. 
M13 reverse GGAAACAGCTATGACCATG 
Antisense 
primer primer 
to sequence 
insert in pSC-B. 
OL87 CTGCAGGCGCACCTCCCTGCTG 
Antisense 
primer to 
sequence up to 
the 3’ end of 
the MCS in 
pGL202 
(pHD675).  
OL88  TAGGGGTTATCGGGTAGGGATC 
Sense primer to 
sequence from 
the 5’ end of 
the MCS in 
pGL202 
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(pHD675). 
OL2223 CAGTTCACGCCGCCGTCAGC 
Sense primer to 
sequence 
TbPLK (from 
base 936). 
OL2224 GCCACCCGCACACAAACC 
Sense primer to 
sequence 
TbPLK (from 
base 1516). 
OL3035 GCATGGACGAGCTGTACAAG 
Sense primer to 
sequence 
GFP/YFP 
Table 2-13 Primers used for sequencing. 
2.3.2.10 Purification of linearised DNA for transfection into T. brucei 
To purify linearised DNA (section 2.3.2.4), ½ volume chloroform:isoamyl alcohol 
(24:1) and ½ volume phenol were added to the digested DNA and the mixture 
vortexed before centrifugation (17968 g, for 2 minutes at room temperature) to 
separate the lower organic phase from the upper aqueous layer containing the 
DNA. The top layer was carefully pipetted into a new tube to which 1 volume of 
chloroform:isoamyl alcohol was added before the mix was vortexed and 
centrifuged as described above. This step was repeated once more following 
which the top layer was decanted, and 1/10 volume 3 M CH3COONa and 1 volume 
isopropanol were added. The tube was gently mixed causing the DNA to 
precipitate. To pellet the DNA, this mixture was centrifuged for 20 minutes, 
17968 g at 4oC. The pellet was then washed with 70 % ethanol and centrifuged as 
above to pellet the DNA. The ethanol was decanted and the DNA pellet was then 
dried under a sterile hood until no ethanol remained. The DNA pellet was then 
solubilised in dH2O to a final concentration of 1 µg µl
-1.Protein analysis, 
purification and biochemistry 
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2.4 Protein analysis, purification and biochemistry 
2.4.1 Polyacrylamide gel electrophoresis (PAGE) and 
Western Blotting 
2.4.1.1 Sodium dodecyl sulphate (SDS)-PAGE 
SDS-PAGE was used to size-separate proteins in denaturing conditions as a means 
of analysing protein preparations and cell lysates. Gels were then Coomassie 
stained (section 2.4.1.2) to visualise separated proteins or probed further with 
specific antibodies via Western-blotting (section 2.4.1.3).  
Typically, 12 % separating gels were used with a layer of 5 % stacking gel on top 
to focus samples before separation. In order to prepare the separating gel, all 
the reagents described in Table 2-14 (except TEMED and ammonium persulphate) 
were mixed together. TEMED and ammonium persulphate were added at the 
end, following which the solution was mixed again before being poured into a 
gel cassette (Invitrogen). A layer of isopropanol was then added on top to 
remove air bubbles. 
Reagent Volume 
30 %/0.8 % (w/v) Acrylamide/Bis acrylamide 6 ml 
10 % (w/v) SDS 250 µl 
1 M Tris HCl (pH 8.8) 9.4 ml 
dH2O 8.8 ml 
5 % (w/v) Ammonium persulphate 625 µl 
TEMED 6.25 µl 
Table 2-14 12 % Separating gel recipe. Final volume enough to make four 1 mm thick mini gels 
using Invitrogen gel cassettes.  
Once set, the isopropanol was decanted before pouring in the stacking gel. The 
stacking gel was prepared mixing in all the ingredients described in Table 2-15 as 
described above for the separating gel. Once poured into the cast as an overlay 
to the already set separating gel, gel combs were set into place to generate 
wells for loading protein samples. Once set, the combs were removed, and the 
cassettes were placed in gel tanks and immersed in 1 X Tris-Glycine-SDS Page 
Buffer (10 X stock; National Diagnostics) 
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Reagent Volume 
30 %/0.8 % (w/v) Acrylamide/Bis acrylamide 1 ml 
10 % (w/v) SDS 125 µl 
0.375 M Tris HCl (pH 6.8) 4.2 ml 
dH2O 6.3 ml 
5 % (w/v) Ammonium persulphate 1 ml 
TEMED 5 µl 
Table 2-15 4 % Stacking gel recipe. Final volume sufficient to make four 1 mm thick mini gels 
using Invitrogen gel cassettes. 
For analysis via Western blotting, protein samples or T. brucei cell pellets 
(prepared by harvesting cells and washing them once (section 2.1.2.2) were 
prepared by addition of 1 X Laemmli loading dye (final concentration; 25 mM 
Tris-HCl pH 6.8, 1 % SDS, 0.05 % bromophenol blue, 50 mM dithiothreitol (DTT)) 
where the final concentration of T. brucei cell samples was maintained at 1 x 
105 cellsµl-1. All samples were then heated at 95oC for 5-10 minutes before 
loading.  
Samples were loaded into the wells and electrophoresed for 1 hour at 200 V. 
Standard ladders were also electrophoresed with the samples to allow 
determination of the molecular weights of protein bands. For Coomassie 
staining, 10 µl of BenchMark™ Protein Ladder (Invitrogen; unstained, prepared 
according to manufacturer’s instructions) was used whilst for Western blotting, 
10 µl of Novex® Sharp Pre-stained Protein Standard (Invitrogen) was used. 
2.4.1.2 Coomassie staining 
Following electrophoresis, SDS-PAGE gels were incubated with Coomassie blue 
stain (0.25 % (w/v) Coomassie Blue-R250, 10 % (v/v) acetic acid and 45 % (v/v) 
methanol) for 1 hour, before being destained with 10 % (v/v) acetic acid,45 % 
(v/v) methanol. The destain solution was changed once after 30 minutes and 
destaining was continued until a background staining was reduced to acceptable 
levels. 
The gels were imaged under epi-white illumination using the Gel Doc™ system 
(Bio-Rad) and dried onto filter-papers using a Model 583 Gel Dryer (Bio-Rad).   
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2.4.1.3 Western blotting 
Once electrophoresed, proteins from an SDS-PAGE gel were transferred onto a 
blotting membrane such as PVDF or nitrocellulose by electro-transfer. PVDF 
transfer membrane (Perkin Elmer) or Hybond ECL nitrocellulose membrane were 
prepared by soaking them in 100 % methanol or transfer buffer (Tris-SDS-Glycine 
and 10 % (for one gel) or 20 % (for two gels) methanol), respectively. The XCell 
II™ Blot Module (Invitrogen) was assembled according to the manufacturer’s 
instructions and immersed in transfer buffer. The electrotransfer was carried out 
for 1.5 hours at 30 V. To visualize transferred proteins, the membrane was 
stained for 5 minutes with Ponceau reagent and destained to an appropriate 
level under running tap water. 
Following transfer and Ponceau staining, the membrane was blocked in PBS-T 
(0.5 % (v/v) Tween 20 in PBS) containing 5 % (w/v) Marvel skimmed milk powder 
(PBS-T milk), shaking, for either 16 hours at 4oC or for 1 hour at room 
temperature. The membrane was then given a quick rinse with PBS-T before 
being probed with the primary antibody (diluted in PBS-T milk; Table 2-16), 
shaking, either for 16 hours at 4oC or for 1 hour at room temperature. The 
membrane was then washed three times with PBS-T (1 x 15 minutes and then 2 x 
5 minutes) before being incubated with the secondary antibody (diluted in PBS-T 
milk; Table 2-17) for 1 hour, shaking , at room temperature. The membrane was 
then washed in PBS-T as earlier, before developing it using an enhanced 
chemiluminescence (ECL) HRP substrate (Super Signal® WestPico/Dura/Femto) 
to reveal antibody labeling according to manufacturer’s instructions. 
Chemiluminescence was visualized by exposing the developed membrane to an 
X-ray film and processing the film using an X-Omat automatic developer 
machine.    
Antibody Company/Gift from Dilution 
α-GFP mouse monoclonal (clone JL-8) Living Colors®, Clontech 1:400 
α -EF1α mouse monoclonal (clone CBP-KK1) Millipore 1:10,000 
α-TY-1 mouse monoclonal IgG1 (clone BB2) 
Mathews lab  
(Bastin et al. 1996) 
1:50 
α-PLK rabbit polyclonal 
de Graffenreid lab 
(Ikeda & de Graffenried 
2012) 
1:300 
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Table 2-16 Primary antibodies used for Western blotting 
Antibody Company Dilution 
α-mouse IgG-HRP conjugate Promega 1:10,000 
α-rabbit IgG-HRP conjugate Sigma 1:10,000 
Table 2-17 Secondary antibodies used for Western blotting. 
2.4.2 Bacterial recombinant protein production 
E. coli strains (Table 2-1) expressing recombinant proteins were generated by 
transforming BL21 DE3 pLysS cells (section 2.2.1) with expression plasmids 
(pET28a+ or pGEX-5X1 backbones to generate His-tagged or GST-tagged proteins, 
respectively) (see Table 2-11). Before transformation into the BL21 derived 
cells, the final pET28a+ or pGEX-5X1 constructed plasmids (section 2.3.2.7 and 
Table 2-11) were first transformed into XL1-Blue cells (section 2.2.1) to allow 
stable storage. The plasmids for transformation into BL21 DE3 pLysS cells were 
prepared from these XL1-Blue colonies and verified via small-scale digest. 
2.4.2.1 Protein expression 
For large scale protein production, overnight liquid cultures of the appropriate 
BL21 DE3 pLysS bacterial strain were diluted 1:100 in 400 ml LB-broth and 
allowed to grow at 37oC, shaking at 200 rpm until the density of the culture 
reached OD600 nm 0.6-1. If needed, cultures were then cooled to the appropriate 
temperature (optimised experimentally via small scale expression experiments 
and analysis of the insoluble and soluble fractions of the resultant cell pellets to 
ensure adequate expression levels of soluble protein) at which the cells were to 
be induced for protein production. In this study, expression of the described 
proteins from the pET28a+ and the pGEX-5X1 plasmids required induction with 1 
mM IPTG at 20oC for 18-20 hours. 
Cells were harvested via centrifugation (5285 g, 10 minutes at 4oC). The 
resulting pellets were then resuspended in 10 ml (per 400 ml liquid culture) ice-
cold lysis buffer supplemented with EDTA-free protease inhibitor cocktail 
(Roche). For His-tagged proteins, the buffer used was Buffer A (20 mM NaH2PO4 
pH 7.5, 0.5 M NaCl, 20 mM imidazole pH 7.5 and 5 mM β-mercaptoethanol). For 
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GST-tagged proteins, PBS was used. The pellets were then stored at -80oC for at 
least one hour in order to promote lysis.  
The frozen pellets were then thawed to room temperature before lysing the 
cells via sonication. The 10 ml lysates were sonicated using a Soniprep 150 
(MSE), on ice, with 10 blasts of 10 s, with at least 10 s rest in between each 
blast, at 30 % amplitude. The soluble fraction was then separated from the 
insoluble fraction via centrifugation (20000 g, 20 minutes at 4oC). 
2.4.2.2 His-tagged protein purification 
His-tagged proteins were purified using Ni-NTA agarose beads (Qiagen) by 
following a bench-top protocol. 0.5-1 ml of 50 % slurry (per soluble fraction 
originating from a 400 ml liquid culture) was prepared by washing the beads in 5 
ml buffer A. The beads were then harvested (500 g, 2 minutes) before incubating 
them with the soluble fraction for 1 hour at 4oC on a rotary mixer.  
The beads potentially bound with the target protein were then harvested as 
described above and washed four times with 10 ml ice-cold buffer A. The 
washed beads were then resuspended in 4 ml buffer B (as buffer A but with 250 
mM imidazole pH 7.5). Disposable polypropylene columns (Pierce) were set up 
with the provided polyethylene filter discs and prepared for use by washing 
them first with water, buffer A and finally with buffer B. The beads resuspended 
in buffer were then transferred into the prepared columns and allowed to settle. 
The resulting eluate was then allowed to drip through and be collected in a 
separate tube. A further 1 ml buffer B was added to the beads and the resulting 
eluate was also collected.  
To determine the efficiency of the purification, samples were collected at each 
stage of expression and purification, and analysed by SDS-PAGE and Coomassie 
staining. 
2.4.2.3 GST-tagged protein purification 
GST-tagged proteins were purified using glutathione sepharose beads (GE 
Healthcare) by following a bench-top protocol. 200 µl of glutathione sepharose 
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beads slurry (per 5 ml of soluble fraction) were prepared by washing them in 2 
ml PBS. The beads were then harvested (500 g, 5 minutes) before incubating 
them with 5 ml soluble fraction for 1 hour at room temperature on a rotary 
mixer.  
The beads potentially bound with the target protein were then harvested as 
described above and washed with 1 ml PBS, three times. Bound proteins were 
then eluted by resuspending the washed beads in 200 µl of glutathione elution 
buffer (10 mM glutathione, 50 mM Tris HCl pH 8) and incubating the mixture for 
10 minutes at room temperature on a rotary mixer. The beads were harvested as 
described above and the resulting supernatant collected as an eluate. These 
elution steps were repeated twice and the resulting eluates were pooled 
together at the end. 
To determine the efficiency of the purification, samples were collected at each 
stage of expression and purification, and analysed by SDS-PAGE and Coomassie 
staining. 
2.4.2.4 Determination of protein concentration and storage of purified 
proteins 
As soon as possible, buffers of the pooled eluates were exchanged with kinase 
storage buffer (40 mM Tris-Cl pH 7.6, 50 mM NaCl, 1 mM DTT, 10 % glycerol using 
Amicon® Ultra-15 Centrifugal Filter Devices (Millipore). The purified proteins 
were stored at -80oC. 
Following buffer exchange, protein concentrations were determined using a 
NanoDrop 1000 Spectrophotometer (Thermo Scientific). 
2.4.3 Kinase assays 
The kinase activities of purified recombinant proteins (section 2.4.2) were 
analysed using protein kinase assays.  
Equimolar amounts of recombinant proteins, made up to a volume of 20 µl with 
kinase assay buffer (KAB; 50 mM MOPS pH 7.4, 20 mM MgCl2 , 2 mM DTT, 10 mM 
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ethylene glycol tetraacetic acid (EGTA)), were added to 20 µl of kinase assay 
mixture (KAB supplemented with 5 μg of α-casein when needed, 4 μM ATP, and 
0.037 MBq [γ-32P] ATP) and incubated for 30 minutes at 30oC. Reactions were 
stopped by adding Laemmli loading buffer to a final concentration of 1 X and 
boiling for 5 minutes. Reaction mixtures were then electrophoresed by SDS-PAGE 
using 12 % gels, which were then Coomassie stained and dried before exposing 
them to a phosphorimager screen or an X-ray film (later processed using 
Typhoon Phosphorimaging system/X-Omat automatic developer machine, 
respectively).  
2.5 Microscopy 
5 x 105 – 1 x 106 T. brucei cells were harvested and washed (section 2.1.2.2), 
resuspended in the residual supernatant and spread onto glass microscope slides. 
The slides were then air-dried before placing them in methanol at -20oC for at 
least 20 minutes to fix the cells. When the slides were ready to be used, they 
were air-dried and the cells were rehydrated using PBS. The slides were 
mounted with Vectashield mounting medium (Vector labs) containing DAPI which 
was sealed with a cover-slip and the application of nail varnish.  
The fixed T. brucei cells were viewed under oil immersion using a Zeiss 
Axioscope fluorescent microscope at 1000 X magnification and  images were 
processed using Openlab (Perkin Elmer) version 5.5 software or Volocity 3D 
Image Analysis Software (Perkin Elmer). For cell-cycle analysis, the slides were 
viewed at 630 X magnification and the number of nuclei and kinetoplasts per cell 
were counted (at least 200 cells per sample). 
2.6 Flow cytometry 
Flow cytometry was used to characterise the DNA content of a particular T. 
brucei cell population. To prepare the cells, 5 x 106 to 1 x 107 cells were 
harvested (section 2.1.2.2) and washed once with PBS. The cells were then 
resuspended in the 300 µl PBS before carefully adding in 700 µl methanol whilst 
mixing gently to prevent cells clumping together. The fixed cells were left at 4oC 
for at least 16 hours (or up to a month) before harvesting the cells via 
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centrifugation (section 2.1.2.2) and washing them once in PBS. The cells were 
then resuspended in 1 ml PBS containing 10 µg ml -1 propidium iodide (PI) and 10 
µg ml -1 RNAse A, and incubated at 37oC for 45 minutes in the dark. The cell 
suspensions were then filtered with the aid of cell strainers (BD Biosciences) 
before analysing their DNA content using a FACSCalibur™  (BD Biosciences) and 
the detecter FL2-A. Data were analysed using FlowJo software (TreeStar).
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3 Regulation of T. brucei Polo-like kinase 
in procyclic form parasites 
3.1 Discovery of Polo and Polo-like kinases  
Fewer than 30 years ago the polo gene was discovered to be essential for mitosis 
in Drosophila melanogaster as its mutants displayed defective spindle pole 
formation (hence the name) and chromosomal arrangement (Sunkel & Glover 
1988). polo was soon found to encode a protein kinase which showed cyclical 
changes in distribution throughout the cell cycle (Llamazares et al. 1991) and to 
be part of a wider family of Polo-like kinases (PLK) that are highly conserved 
across the majority of the eukaryotic lineages. No homologues of this protein 
kinase have yet been identified in bacteria, archaea or plants. The PLK family 
can be divided into further three subfamilies: PLK1, PLK2 and PLK4, which have 
distinctive functions and evolutionary histories (Table 3-1; de Cárcer, Escobar, 
et al. 2011). 
The budding yeast, Saccharomyces cerevisiae, and the fission yeast, 
Schizosaccharomyces pombe, each possess only one PLK homologue: Cdc5 
(Kitada et al. 1993) and plo1 (Ohkura et al. 1995), respectively, both of which, 
in addition to mammalian Plk1 (Clay et al. 1993; Hamanaka et al. 1994) and 
Xenopus laevis Plx1 (Kumagai & Dunphy 1996), are Polo’s closest orthologues and 
together belong to the PLK1 subfamily. Mammals and X. laevis possess further 
four PLKs, which belong to PLK2 and PLK4 subfamilies (Table 3-1), and that are 
orthologous between species and paralogous within a species - Plk2/Plx2 
(originally Snk; Simmons et al. 1992; Duncan et al. 2001), Plk3/Plx3 (originally 
Fnk or Prk; Donohue et al. 1995; Li et al. 1996; Duncan et al. 2001), Plk4/Plx4 
(originally SAK; Fode et al. 1994; Eckerdt et al. 2011); and the recently 
described Plk5/as yet uncharacterised putative Xenopus Plx5 (de Cárcer, 
Manning, et al. 2011; de Cárcer, Escobar, et al. 2011; Andrysik et al. 2010). D. 
melanogaster has just one other PLK family member in addition to polo - SAK, an 
orthologue of Plk4 (Bettencourt-Dias et al. 2005), while Caenorhabditis elegans 
possesses four altogether: plc1-3 which belong to the PLK1 subfamily (Ouyang et 
al. 1999; Dan Chase et al. 2000; D Chase et al. 2000) and the PLK4 member, zyg-
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1 (O’Connell et al. 2001; Jana et al. 2012). Table 3.1 summarises the various 
sub-divisions within the wider PLK family (see de Cárcer, Manning, et al. 2011 
for review). PLKs are now understood to be major players in cell cycle 
regulation. The PLK1 subfamily is especially involved in mitosis and shall be the 
focus of this mini-review. Paralogues, such as PLK2-4 in mammals, perform 
specialised yet some overlapping functions in aiding cell proliferation owing to 
the higher levels of complexity associated with multi-cellular organisms (for 
reviews see Winkles & Alberts 2005; Archambault & Glover 2009; Zitouni et al. 
2014). They have also been found to play non-traditional roles that go beyond 
the cell cycle (de Cárcer, Escobar, et al. 2011). 
Sub-
families 
Organism 
D. melanogaster S. cerevisiae S. pombe C. elegans X. laevis Mammals 
PLK1 polo Cdc5 plo1 
plc1 
plc2 
plc3 
Plx1 Plk1 
PLK2     
Plx2 
Plx3 
Plx5 
Plk2 
Plk3 
Plk5 
PLK4 SAK   zyg-1  Plx4 Plk4 
Table 3-1 PLK family of kinases in selected organisms across various taxons. The names of PLK(s) 
in each organism are given and are assigned to their subfamily. Members of the PLK2 subfamily 
are only found in some bilaterian animals whilst those of PLK4 subfamily are found in all animals. 
Adapted from de Cárcer, Manning, et al. 2011. 
3.2 Cell cycle functions of PLK1 
Consistent with its mitotic functions, in humans, the mRNA and protein levels of 
PLK1 remain low throughout G1 phase, start to increase in the S and G2 phases 
and peak during mitosis before rapidly decreasing at the end of mitosis (Lee et 
al. 1995; Hamanaka et al. 1995; Uchiumi et al. 1997). Throughout interphase, 
PLK1 localises to the cytoplasm and the centrosomes, whilst during mitosis and 
cytokinesis, it concentrates to the kinetochores and the cytokinetic bridge, 
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respectively. Mammalian Plk1 and its well-studied orthologues, polo and Cdc5, 
have been found to be essential in mitotic entry, centrosome maturation and 
spindle assembly, chromatin segregation, mitotic exit and cytokinesis as 
described below.   
One of the major roles played by PLK1s is the promotion of mitotic entry. Entry 
into M phase requires nuclear translocation and activation of the Cdk1-cyclin B 
complex – widely regarded as the master regulator of mitosis (Malumbres & 
Barbacid 2005). The activity of this complex is affected by the phosphorylation 
state of Cdk1 which is determined by the inhibitory kinases, Wee1 and Myt1, and 
an antagonising phosphatase, CDC25. Dephosphorylation of Cdk1 at specific 
sites, achieved by simultaneous inhibition of Wee1 and Myt1 and activation of 
CDC25, activates the Cdk1/cyclin B complex which then phosphorylates a wide-
range of substrates triggering events during both the G2/M transition and 
progression through mitosis (Takizawa & Morgan 2000). PLK1s have been shown 
to bring about Cdk1 activation via their phosphorylation of Wee1, Myt1 and 
CDC25 (for reviews see Barr et al. 2004; van Vugt & Medema 2005; Petronczki et 
al. 2008) – a role which is conserved in humans (Booher et al. 1997; Watanabe et 
al. 2004) yeast (reviewed in Lee et al. 2005) and frogs (Kumagai & Dunphy 1996; 
Watanabe et al. 2004; Inoue & Sagata 2005). 
Defects in spindle formation were some of the phenotypes exhibited by the D. 
melanogaster polo mutants (Sunkel & Glover 1988) and human cells micro-
injected with α-Plk antibodies (Lane & Nigg 1996). In both cases, the PLK-
depleted cells presented with disorganised, mono- and multipolar spindles 
indicating the key role of PLK1s in generating functional bipolar spindles during 
mitosis. MTOCs mastermind the generation of mitotic spindles. Timely 
separation and maturation of MTOCs are essential for spindle generation, 
positioning and regulation at the poles of mitotic spindles (Mardin & Schiebel 
2012). These processes are characterised by migration of duplicated MTOCs to 
the poles of the cells and their growth by increased microtubule recruitment. 
This requires the additional recruitment of multiple MAPs, microtubule 
nucleators and motor proteins thus setting the stage for increased microtubule 
nucleation activity. MTOCs differ greatly in their structure and organisation in 
yeast (SPB) and mammals (centrosomes), yet the bipolar spindle assembly 
function of PLK1s at the MTOCs is one of their most conserved cellular roles 
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(Zitouni et al. 2014). In animal cells, PLK1s are key players in the centriole 
duplication cycle and promote centriolar cohesion in centrosomes during 
prophase whilst also contributing to centriole disengagement during mitotic exit 
(for reviews see Mardin & Schiebel 2012; Zitouni et al. 2014). Also, PLK1s are 
required for the recruitment of γ-tubulin ring complexes to mitotic MTOCs from 
yeast to metazoans. In budding yeast, cdc5 phosphorylates Spc72 to help anchor 
γ-tubulin ring complexes to the SPB (Snead et al. 2007; Maekawa et al. 2007). In 
Drosophila, polo regulates the MAP, Asp, which holds γ-tubulin ring complexes at 
the mitotic centrosome (do Carmo Avides & Glover 1999; Donaldson et al. 2001). 
In human cells, the phosphorylation of the centrosomal protein, Ninein-like 
protein (NLP), by Plk1 results in the inhibition of the dynein-dynactin-dependent 
transport of NLP, thus enabling the recruitment of other centrosomal proteins 
such as components of the γ-tubulin ring complexes to the centrosomes 
(Casenghi et al. 2003; Casenghi et al. 2005). In addition, by controlling the 
centrosomal localization of Aurora A kinase, mammalian Plk1 makes a further 
contribution towards centrosomal maturation. Phosphorylation of the 
centrosome-associated protein, Kizuna, by Plk1 was also shown to be essential 
for formation of functional mitotic centrosomes (Oshimori et al. 2006). PLK1s 
have also been shown to associate with other MAPs (Petronczki et al. 2008; 
Archambault & Glover 2009; Zitouni et al. 2014). Phosphorylation and 
dephosphorylation of microtubule-binding proteins changes their stabilisation 
activities on microtubules thus indirectly regulating microtubule motility and 
finally orchestrating spindle-dynamics during anaphase. 
Sister chromatids need to be correctly aligned before separation. To achieve 
this, spindle microtubules are attached to the kinetochores of the chromatids 
and then the SAC ensures that the onset of anaphase does not occur until the 
sister chromatids are correctly aligned and that their attachment to the spindle 
microtubules are under equal tension. PLK1s phosphorylate a number of distinct 
kinetochore substrates in a dynamic manner to stabilise kinetochore-microtubule 
attachment in order to satisfy the SAC (Petronczki et al. 2008; Archambault & 
Glover 2009). These include dynein (Bader et al. 2011), which is required for its 
recruitment to the kinetochore where it has been implicated in microtubule 
capture and correcting inappropriate microtubule attachments; CLIP-170 of the 
+TIP group of MAPs, which is required for its dynein/dynactin‐dependent 
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kinetochore localisation and timely formation of microtubule–kinetochore 
attachments (Li et al. 2010); the MAP, CLASP2, which increases its recruitment 
to the kinetochores stabilising kinetochore attachment to microtubules (Maia et 
al. 2012); and the kinesin-13 family of microtubule depolymerising enzyme 
members, MCAK (Zhang et al. 2011) and Kif2b (Hood et al. 2012), which are 
required for the correction of aberrant kinetochore-microtubule attachment. 
Cleavage and removal of cohesin, the cohesion complex which attaches sister 
chromatids together, is required for their separation during anaphase ensuring 
equal distribution of duplicated genomes to daughter cells at the end of mitosis 
and cytokinesis, and PLK1s have been shown to be required for this. For 
instance, phosphorylation of SCC1 and SA2 by mammalian Plk1 promotes their 
own cleavage and removal of cohesin complexes from chromosomal arms and the 
centromere (Sumara et al. 2002; Hauf et al. 2005; N. Zhang et al. 2011). PLK1s 
have been shown to also co-ordinate the more complex meiotic chromosome 
segregation in frogs and flies (reviewed in Archambault & Glover 2009; Zitouni et 
al. 2014). 
Mitotic exit requires the inactivation of the Cdk1-cyclin B complex, which occurs 
through the inactivation of Cdk1 or universal degradation of mitotic cyclins 
mediated by the APC, a multi-subunit ubiquitin ligase. In mammalian cells, 
activation of the APC is mediated through the degradation of its inhibitor, EMI1 
(early mitotic inhibitor 1). This is achieved by the phosphorylating activity of 
mammalian Plk1 which targets EMI1 for ubiquitination and subsequent 
degradation (Hansen et al. 2004; Moshe et al. 2004). A similar function for Plx1 
in Xenopus has also been described (Descombes & Nigg 1998). In yeast, though 
mitotic exit is mediated by completely different complexes (SIN in fission yeast, 
and MEN and FEAR pathways in budding yeast), PLK1 homologues, Plo1 and Cdc5 
in fission yeast and budding yeast, respectively, initiate equivalent kinase 
cascades promoting exit from mitosis (reviewed Lee et al. 2005).    
Cytokinesis is a dynamic process which varies depending on the organism, yet 
the step-by-step complex processes involved follow the same pattern – selection 
of the division site, assembly of the contractile apparatus, co-ordination of 
cytokinesis with the nuclear cycle, constriction of the contractile ring/septation 
and abscission (for reviews see Balasubramanian et al. 2004; Barr & Gruneberg 
2007; Guizetti & Gerlich 2010). Differences in cytokinetic events occur between 
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yeast and mammalian cells. In yeasts, the cleavage plane, referred to as the bud 
selection site or the cortical band in budding or fission yeast, respectively, is 
determined early in the cell cycle which constrains the localisation of the 
mitotic nucleus; whilst in mammalian cells, the cleavage plane is only 
determined during the anaphase to metaphase transition as the central spindle 
is assembled. In yeasts, the process of cytokinesis occurs through septation 
whilst in mammalian cells it occurs through constriction of the contractile ring. 
When temperature sensitive yeast Plo1/cdc5 mutants failed to septate and 
generated a ‘chain’ phenotype, the direct roles for Plo1 and Cdc5 in yeast 
cytokinesis were established (Bähler et al. 1998; Ohkura et al. 1995; Park et al. 
2003; Tanaka et al. 2001). Localisation of human Plk1 to the anaphase spindle 
(Golsteyn et al. 1995) pointed towards the key regulatory function of Plk1 in 
mammalian cytokinesis. Studies involving the use of chemical tools such as small 
molecule mammalian Plk1 inhibitors and analogue sensitive mutants have 
allowed previously unfeasible post-mitotic studies of Plk1 function and have 
together established its regulatory role in cytokinesis (Petronczki et al. 2007; 
Santamaria et al. 2007; Burkard et al. 2007; Brennan et al. 2007). Post-anaphase 
inhibition of Plk1 prevented formation of the actomyosin contractile ring thus 
inhibiting its contraction. Formation of the contractile ring requires the 
activation of the small GTPase RhoA which is brought about by the Rho guanine 
nucleotide-exchange factor (GEF) protein Ect2. This is only possible following 
localisation of Ect2 to the central spindle which has been shown to be mediated 
by PLK1 (reviewed in Petronczki et al. 2007).   
PLK1s orchestrate further cellular functions which also have implications on the 
cell cycle. Plk1 has been implicated in Golgi inheritance during cell division (Lin 
et al. 2000). PLK1s have also emerged as important modulators of the DNA 
damage checkpoint during S and G2 phases (Takaki et al. 2008; Bahassi 2011; 
Zitouni et al. 2014).  
3.3 PLK1 structure and regulation 
Due to their pivotal positions as master regulators of various mitotic and 
cytokinetic activities, PLK1s are subject to tight regulation to prevent cell cycle 
defects. The control of their activities occur in terms of both time and space and 
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is strongly linked with the structure of these kinases which shall be first 
described. 
3.3.1 PLK1 structure  
All PLKs share a conserved structure featuring an N-terminal serine/threonine 
kinase domain and C-terminal polo-box domain (PBD; Figure 3-1; Lowery et al. 
2005). The two domains are joined together by an inter-domain linker (IDL). The 
PLK kinase domains are typical of the catalytic domains of any other serine-
threonine kinases and mediate the catalytic function of PLKs in their structure, 
regulation and function as described below. The phosphopeptide-binding PBDs 
are unique to PLKs. In the majority of the PLK family members, the PBD feature 
two structurally homologous tandem domains, termed polo-boxes that are 
separated by linker regions (Lowery et al. 2005). Exceptions are members of the 
PLK4 subfamily which possess only one canonical polo-box and are 
unconventional in how they regulate and perform their functions (Lowery et al. 
2005). 
 
Figure 3-1 Schematic representation of domains in PLK1. PC – polo-box cap; L1 – linker 1; PB1 – 
polo-box 1; L2 – linker 2; PB2 – polo-box 2. 
Efforts to generate a crystal structure of the full length protein have so far 
proven to be unsuccessful (Lowery et al. 2005; Lee et al. 2005; Johnson et al. 
2008). However, separate crystal structures of either the kinase domain or the 
PBD have been solved (Leung et al. 2002; Cheng et al. 2003; Elia, Rellos, et al. 
2003; Kothe et al. 2007; Bandeiras et al. 2008; Yun et al. 2009) and have greatly 
enabled the modelling of PLK activity and regulation.  
Kothe et al solved crystal structures of the kinase domain of Plk1 (T210V) (Figure 
3-2; inactive kinase; section 3.3.3) complexed with two different non-
hydrolysable ATP analogues, both of which produced similar structures (Kothe et 
al. 2007). The Plk1 kinase domain displayed a typical kinase fold characterised 
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by a bi-lobed structure: an N-terminal lobe (residues 37-131) composed almost 
entirely of anti-parallel β-sheets apart from a single α-helix (termed the “C-
helix”) and a C-terminal lobe (residues 138-330), which is predominantly α-
helical and includes part of the IDL, also known as the C-terminal tail, 
connecting the kinase domain and PBD (residues 306-330). The two lobes are 
connected via a hinge region forming a cleft within which the ligands were found 
to bind, thus highlighting the ATP binding site. The connecting hinge region was 
also found to make conserved backbone interactions with the bound ligand 
highlighting the physiological interactions of the adenine ring of ATP with the 
residues of this hinge region. The C-terminal lobe housed the activation loop (or 
T-loop) which was book-ended with 194DFG (Asp-Phe-Gly) and APE221 (Ala-Pro-
Glu) motifs characteristic of the T-loops of other kinases. The T-loop includes 
phosphorylatable residues such as T210 in human Plk1 that mediate 
conformational changes which, in collaboration with other regulatory events, 
arrange the kinase at various conformational stages of activity/inactivity as 
described below.  
This work was closely followed by the solved crystal structures of the WT (wild-
type) Plk1 kinase domain bound to a designed selective ankyrin-repeat protein 
(DARPin 3H10) which acted as a surface modifier enabling effective crystal 
growth (Bandeiras et al. 2008). The structures reported in this paper largely 
agreed with those generated by Kothe and colleagues. Similar to other kinases, 
activation of the Plk1 kinase domain was found to include conformational 
changes in the C-helix of the N-terminal lobe. Rotational movement of this helix 
forms a salt bridge between one of its own conserved residues, Glu101, and 
another conserved residue also part of the N-terminal lobe, at the back wall of 
the ATP binding cleft, Lys82, which allows the lysine to come in contact with the 
phosphates of bound ATP in a catalytically productive manner (Bandeiras et al. 
2008). Both structures were thought to feature T-loops in their active 
conformation suggesting that the default conformation of this truncated protein 
is in its active state despite the lack of detectable phosphorylation within the 
kinase domain, demonstrating additional layers of regulation mediated by the 
missing PBD.  
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Figure 3-2 Schematic diagram of human Plk1 kinase domain structure. A crystal structure of the 
kinase domain of human Plk1 T210V in complex with nonhydrolysable ATP was obtained. Plk1 
kinase domain core is shown in gray ribbon representation with N- and C-terminal extensions in 
orange. The T-loop is shown in green. Residues V210 in the T-loop (primary phosphorylation site 
T210 in WT Plk1) and S137 (secondary phosphorylation site) are shown as green sticks. Adapted 
from Kothe et al. 2007.  
The structure of the PBD was first published by Cheng et al (Cheng et al. 2003) 
where, following the identification and characterisation of its optimal 
phosphopeptide substrates (Elia, Cantley, et al. 2003), the crystals of human 
Plk1 PBD with and without bound phosphopeptides were obtained and solved. 
The solved structure of human Plk1 PBD revealed a typical fold comprising two 
~80 aa long repeats termed polo-boxes - PB1 (residues 411-492) and PB2 
(residues 511-592) with an N-terminal extension, which links to the kinase 
domain, later termed the polo-box cap (PC; residues 372-410) (Elia, Rellos, et 
al. 2003). Although the two Polo-boxes displayed just 12% sequence identity, 
they shared the same structural folds - a continuous six-stranded antiparallel β-
sheet shielded by one α-helix. The PC, extending from the N-terminus of PB1 
was found to wrap around PB2, packing it against PB1. There was no 
conformational change detected between the bound and unbound PBDs (Cheng 
et al. 2003). Elia and colleagues had also published a structure of human Plk1 
PBD-phosphopeptide complex in the same year (Figure 3-3; Elia, Rellos, et al. 
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2003) and the two were found to largely agree. The two polo-boxes were found 
to pack together to form a 12-stranded β sandwich flanked by three α-helical 
segments – two belonging to PB1 and one belonging to PB2. The PC was found to 
consist of one helical segment followed by a loop and then a short helix which 
connected to the first β-strand of PB1 via one of the two linkers within the PBD - 
L1. PB1 and PB2 were connected via L2, the 2nd short linker chain within the 
PBD. L1 and L2 ran in anti-parallel directions in between the β-strand sandwich 
away from the phosphopeptide-binding cleft. The bound phosphopeptide 
interacted mainly with one β-sheet from PB1, two β-sheets from PB2 and the N-
terminal end of L2 (Elia, Rellos, et al. 2003).  
 
Figure 3-3 Schematic diagram of human Plk1 PBD-phosphopeptide complex. A crystal structure 
of human Plk1 PBD in complex with a pThr-containing peptide (shown as a ball and stick 
representation in yellow) was obtained. Polo-box 1 (PB1) is shown in red whilst polo-box 2 (PB2) 
is shown in purple. The linker regions (L1 and L2) and the polo-box cap (PC) are shown in grey. 
The phosphopeptide binds at one end of a pocket formed between PB1 and PB2. Adapted from 
Elia, Rellos, et al. 2003. 
This structure is unlike that assumed by the PBD of the divergent PLK4 family. 
Structural analysis of the single polo-box of murine Plk4/SAK, revealed that the 
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domain crystallised as an intermolecular dimer featuring a clam-like fold made 
up of two α-helices and two six-stranded β-sheets contributed by the two 
monomers (Leung et al. 2002; Lowery et al. 2005). Although the structure 
assumed by the SAK polo-box dimers broadly resembled the structure formed by 
the two interacting polo-boxes in Plk1, the residues most closely involved in 
phosphopeptide binding by Plk1 are not conserved in SAK (Lowery et al. 2005; 
van de Weerdt et al. 2008). Actual ligands that bind to the SAK polo-box dimers 
remain to be identified. 
As mentioned earlier, the PBD is a phosphoserine (pSer)/phosphothreonine 
(pThr) binding motif. This was determined by the use of a proteomic screen, 
where an immobilised library of partially degenerate phosphopeptides featuring 
pSer and pThr motifs (which resembled the phosphorylating action of Cdks and 
mitogen-activated protein kinases) were used to isolate phospho-binding 
domains that specifically recognised pSer/pThr containing motifs (Elia, Cantley, 
et al. 2003). Through this study the consensus sequence of PBD ligands was 
determined as [Pro/Phe]-[φ/Pro]-[ф]-[Thr/Gln/His/Met]-Ser-[pThr/pSer]-
[Pro/X] where φ represents hydrophobic amino acids and X is any residue. This 
consensus sequence testifies to the key interactions required for PBD binding to 
its substrate. Among other interactions, a His-Lys pincer in PB2 (H538 and K540) 
was found to be vital for mediating binding of peptide substrates via direct 
electrostatic contacts with the negatively charged phosphate group of the 
phosphorylated serine and threonine residues while W414 in PB1 was found to be 
crucial for hydrogen bonding with the serine at the pThr-1 position of the 
phosphopeptide (Elia, Rellos, et al. 2003). In 2009, Yun et al. determined the 
minimal phosphopeptide sequence required to bind Plk1 PBD and to bind Plk1 
specifically instead of PLKs from the other subfamilies. This study revealed that 
having prolines at the pThr-4 and -3 positions are essential for this specificity 
and affinity together with the crucial contribution histidine at the -2 position for 
binding. This study proved that Plk1 localisation and activity can be specifically 
regulated compared to other PLKs via Plk1 PBD substrates featuring the 
described optimal phosphopeptide sequence (Yun et al. 2009).     
The PBD has crucial regulatory roles. By serving as a phosphopeptide binding 
module, it is responsible for the proper subcellular localisation of the whole 
kinase. In addition, it also inhibits PLK kinase activities via its intramolecular 
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interaction with the kinase domain (section 3.3.4). A priming phosphorylation is 
usually required to relieve this auto-inhibition. However, Drosophila Map205 has 
previously been shown to bind strongly with PBD of Drosophila polo or human 
Plk1 in a phospho-independent manner (Archambault et al. 2008). Taking 
advantage of this, Xu et al. have recently co-crystallised individually isolated 
kinase domain and PBD of zebrafish Plk1 in complex with the PBD binding 
domain of Drosophila Map205 (Map205PBM; Xu et al. 2013). This has significantly 
cemented the current model of PLK structure and regulation by providing a 
greater understanding of how the two domains interact with each other.  
Here, the structure of the kinase domain and the PBD were found to be identical 
to those already described earlier, apart from a few key differences accounting 
for the regulatory effects of the kinase domain and PBD being in the same 
complex as had already been hinted at experimentally (see section 3.3.4). The 
interacting surface between the kinase domain and the PBD is contributed by the 
C-terminal tail (linker connecting kinase domain and PBD), helix αD from the C-
terminal lobe together with the hinge region and β1 strand of the N-terminal 
lobe on the side of the kinase domain, and the two linkers, L1 and L2 and the 
tips of β-strands polo-boxes on the side of the PBD. This interface is opposite to 
the phosphopeptide binding groove lending credibility to observations made by 
Elia et al that phosphopeptide binding to the PBD has minimal effect on kinase 
domain-PBD binding (Elia, Rellos, et al. 2003). This paper also provided 
structural evidence for a phenomenon that had already been established 
previously, that kinase domain-PBD binding is auto-inhibitory to PLK kinase 
activity (section 3.3.4). Mutations of crucial residues required for this 
interaction were found to increase the activity of full length zebrafish Plk1. In 
contrast, mutation of residues that have nothing to do with the kinase domain-
PBD interface had no effect on full length zebrafish Plk1 activity. The L1 of the 
PBD was found to impact on the flexibility of the kinase domain’s hinge region 
and interlobe cleft which is known to be required for kinase activity as discussed 
later on. In addition, the IDL was found to also have an inhibitory effect 
potentially by sequestration of the phosphorylatable threonine in the T-loop. 
When the phosphopeptide-bound human PBD (also similar to the apo form; Elia, 
Rellos, et al. 2003) was super-imposed with the kinase domain-bound zebrafish 
Plk1 PBD, a large conformational change in L2 was apparent, indicating its role 
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as the key switch between the on and off states of Plk1. When the PBD inhibits 
the catalytic activity of the kinase domain by staying bound to it, L2 remains in 
an open state. When a phosphopeptide binds to the PBD, the conformational 
change that is brought about in the L2 brings it into its closed state, causing a 
steric hindrance between the L2 and the C-terminal tail of the kinase domain, 
thus releasing it to perform its kinase activity.   
The bound Map205PBM was found to pack against the PBD in a torsion spring-like 
conformation occupying both the classical phosphopeptide-binding site and the 
newly identified binding channel even though a Ser-(pThr/pSer) motif cannot be 
found in Map205PBM. This is in keeping with its role as a sequestering factor for 
Plk1s, targeting them and stabilising their auto-inhibition, until a mitotic kinase 
such as Cdk1 is able to release Plk1 via phosphorylation of the protein 
(Archambault et al. 2008).   
The crystal structure of the kinase domain–PBD– Map205PBM heterotrimeric 
complex has provided a structural framework for understanding how PLK1 is 
regulated and the authors were then able to propose a model for how various 
active/inactive states of PLK1 are brought about (see Figure 3-4; Xu et al. 2013). 
The PBD and IDL inhibit the kinase domain by reducing the flexibility of the 
hinge region or sequestering the activation loop. Phosphorylating T196 (T210 in 
human Plk1) of the activation loop prevents such a sequestration, thus partially 
activating PLK1. Phosphorylation of the conserved serine residue at the end of 
the hinge region S123 (Ser137 in hPLK1) during late mitosis, leads to the 
intramolecular interaction between the kinase domain and PBD being disrupted, 
thus further activating PLK1. This intramolecular interaction can be further 
disrupted when the PBD binds to its phosphorylated target, which further 
relieves the auto-inhibition and also adds the spatial layer of Plk1 regulation. 
These multiple layers of PLK1 regulation allow for multi-level regulation of PLK1, 
which is important to satisfy its multiple functions throughout the whole cell 
cycle. 
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Figure 3-4 Model suggesting multi-level regulation of zebrafish Plk1. Auto-inhibited zebrafish 
Plk1 (top) can be partially or fully activated through phosphorylation of T196 (center; T210 in 
human Plk1) and S123 (center left; S137 in human Plk1), and phosphopeptide binding (center 
right). These events can occur independently or sequentially at different stages of the cell cycle 
and at different subcellular localisations. Dashed orange lines indicate the possible packing mode 
of the IDL. pT – phosphothreonine; pS – phosphoserine. Adapted from Xu et al. 2013. 
Regulation of PLK ensures a) its expression at the right time-points during the 
cell cycle - this is achieved through transcriptional control, phosphorylation and 
proteolysis; and b) its accurate localisation and targeting to downstream 
substrates – this is achieved via its PBD mediated protein-protein interactions. 
Deregulation of the activity of PLK1s is lethal. High expression levels of 
mammalian Plk1 have been directly linked with malignancy of tumours. 
Therefore, Plk1 is widely considered as a potential anti-cancer therapeutic 
target (Strebhardt & Ullrich 2006).  
3.3.2 Control of expression 
The concordant changes in transcript and protein levels of PLK1s suggest that 
their expressions are primarily controlled transcriptionally in the various phases 
of the cell cycle. Evidence of transcription level control of PLK1 expression was 
shown in human cells where Plk1 promoter activation was demonstrated to peak 
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around G2/M phase (Uchiumi et al. 1997). The promoter of mammalian Plk1 has 
been found to feature many regulatory elements which are conserved among 
many mammalian mitotic kinases. One of these is the bipartite element 
CDE/CHR (cell cycle dependent element/cell cycle genes homology region) 
which needs to remain unbound for the promoter to be active. Other activating 
elements such as a GC stretch, CCAAT motif  and FKH-TF binding sites, amongst 
others, have been linked with the stimulation of mammalian Plk1 expression 
(Bräuninger et al. 1995; Uchiumi et al. 1997; Alvarez et al. 2001; for review see 
Martin & Strebhardt 2006). However, FKH-TFs are the only transcription factors 
that have been directly demonstrated to activate PLK1 promoters to date in 
yeast and mammals (Alvarez et al. 2001; Murakami et al. 2010). The initial 
stimuli by which the increase of PLK1 level is achieved, and other factors that 
are downstream of such stimuli, are yet to be elucidated. Most of what is known 
about PLK1 transcription regulation pertains to repression of PLK1 levels rather 
than the upregulation of them.  
Downregulation of PLK1s is an important feature of the G2/M checkpoint which is 
induced upon the detection of DNA damage following replication during S-phase. 
As mentioned earlier, the CDE/CHR element is key for the downregulation of 
mammalian Plk1 expression. Mutations within this element significantly 
diminished cell cycle dependent regulation of human Plk1 expression (Uchiumi 
et al. 1997). The dynamic interactions of the tumor suppressor protein, p53, the 
cyclin-dependent kinase inhibitor, p21, the transcription factor, NF-Y, and Rb 
proteins with promoter elements such as the CCAAT box, p53RE1/2, EF2 binding 
box and CDE/CHR element, and with each other, have been shown to 
orchestrate downregulation of mammalian Plk1 expression following DNA 
damage (Uchiumi et al. 1997; Zhu et al. 2002; Ando et al. 2004; Jackson et al. 
2005; Lin et al. 2014). The DNA damage kinases ATM and ATR (van Vugt et al. 
2001) are also crucial to these pathways. These Plk1 transcriptional control 
pathways promise to be intricate and complex and remain important means by 
which Plk1 transcript levels are upregulated upon entry into G2 and 
downregulated to prevent mitotic entry upon DNA damage. Transcriptional 
regulation of PLK2-4 appears to be different and has been discussed by in detail 
by van de Weerdt & Medema 2006. 
Chapter 3 
 
81 
3.3.3 Activation of kinase activity 
Activation of PLKs by auto-phosphorylation and phosphorylation via upstream 
kinases are crucial ways by which their activities are regulated. Mitotic 
mammalian Plk1 was found to migrate slower upon gel electrophoresis and this 
phenomenon was found to be abrogated upon phosphatase treatment (Hamanaka 
et al. 1995; Mundt et al. 1997). Phosphopeptide mapping suggested Thr210 and 
Ser137 as important phosphorylation sites in human Plk1. The phosphorylation of 
such highly conserved threonine and serine residues in the T-loops (also known 
as the activation loops; see section 3.3.1) of their kinase domains is a conserved 
phenomenon by which the phosphorylating activities of protein kinases are 
regulated. In Plk1, when one such T-loop threonine residue, T210, was mutated 
to prevent phosphorylation (T210V), Plk1 kinase activity was abrogated while 
mutating the same residue to mimic phosphorylation (T210D) increased its 
kinase activity and invoked premature mitotic entry and delayed mitotic exit 
(Jang, Ma, et al. 2002; Jang, Lin, et al. 2002). Ser137 was also investigated as 
another potential regulatory residue. However, this residue was not detected as 
a phosphorylation site in vivo and therefore was thought to be an unlikely target 
for upstream kinases (Jang, Ma, et al. 2002). Several protein kinases capable of 
activating Plk1 have been identified. These include the members of the Ste 20-
like kinase family (Johnson et al. 2008), BORA and Aurora kinase A (Macurek et 
al. 2008; Seki et al. 2008; Bruinsma et al. 2014) which phosphorylate mammalian 
Plk1 at T210. 
3.3.4 Repression of kinase activity 
The ubiquitin-proteasome pathway is a major mechanism through which cellular 
proteins that are no longer needed are targeted and destroyed. PLK activity is 
also regulated through this mechanism as non-degradable Plk1 was shown to 
frequently interfere with exit from mitosis (Lindon & Pines 2004). The dramatic 
fall in human Plk1 activity following mitosis has been attributed to the ubiquitin-
proteasome pathway (Ferris et al. 1998), shown to be mediated by a conserved 
destruction box in Plk1 and linked to the activity of APC ubiquitin-ligase (Lindon 
& Pines 2004; Archambault & Glover 2009). 
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A further Plk1 regulatory mechanism that has been unearthed involves auto-
inhibition through the interaction of the N-terminal kinase domain and the C-
terminal PBD. The PBD of Plk1 was found to interact with the kinase domain 
involving residues that seemed unique to this interaction and was not a 
consequence of dimerisation (Jang, Lin, et al. 2002). The association of the PBD 
with Plk1 inhibited its activity against α-casein, an effect which was not 
repeated when T210 was substituted with aspartic acid. Also, activity of 
truncated Plk1 featuring just the kinase domain was found to be greater 
compared to the full length protein. Since the PBD was shown not to be a 
substrate for Plk1 and, therefore, cannot act as a competitive inhibitor for 
casein, this study was able to conclude that the PBD imposes an inhibitory effect 
on Plk1 kinase activity via intramolecular interactions, and that phosphorylation 
of T210 relieves this auto-inhibitory binding of PBD with the kinase domain of 
Plk1. This inhibition can also be relieved by the PBD binding to an optimal 
phosphopeptide (Elia, Rellos, et al. 2003). The generation of such primed PBD-
substrates thus remain an important point of regulation of PLK activity (section 
3.3.5). In prometaphase and metaphase, Cdk1 acts as the primary priming kinase 
of PBD substrates (Elia, Rellos, et al. 2003; Elia, Cantley, et al. 2003; Barr et al. 
2004; Lowery et al. 2005) whilst other factors such as PRC1 and MKlp2 do the 
same during anaphase and cytokinesis (Neef et al. 2007). Thus the 
phosphorylation of T210 and the binding of the PBD with a primed substrate act 
as intermediate switches which additively activate Plk1 kinase activity. 
Structural studies of human and zebrafish Plk1 constructs have shed light on how 
these switches mechanistically activate Plk1 kinase activity (section 3.3.1). 
3.3.5 PLK1 localisation 
The PBD is essential for targeting PLKs to their substrates. Mutating the PBD of 
mammalian Plk1 disrupted its localisation to the spindle poles and cytokinetic 
neck filaments (Lee et al. 1998) and the importance of the PBD in localising 
PLK1s (to centrosomes, centromeres, the central spindle and the midbody ring) 
was also found to be the case in other organisms (Lee et al. 1999; Song et al. 
2000; Reynolds & Ohkura 2003; Liu et al. 2004). The PBD was also found to 
mediate the different functional specificities of the same protein (Hanisch et al. 
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2006) in addition to the target specificities of PLKs belonging to different 
subfamilies (van de Weerdt et al. 2008). 
The frequent requirement for phospho-priming of PLK1 substrates is one of the 
ways in which its subcellular localisation is regulated (Lee et al. 1998; Elia, 
Cantley, et al. 2003; Lowery et al. 2005). Two modes by which PLK activity 
mediates mitotic progression, via PBD-mediated interactions, have been 
described by Lowery et al. 2005. One of them is referred to as the ‘processive 
phosphorylation’ model where the PBD directly binds to one site of the target 
substrate of PLK, that has already been phosphorylated for this purpose by a 
priming mitotic kinase, and the PLK kinase domain then phosphorylates the same 
substrate on another site. In this case, the kinase activity of PLK is limited to the 
time when its substrate has been primed by another mitotic kinase and has not 
yet been dephosphorylated by phosphatases. Therefore, in this model, the PBD 
functions as the temporal ‘integrator’ of PLK mitotic function in time. Priming 
phosphorylation of Bub1 by Cdk1 which enhances Plk1 interaction with Bub1 
mediating its recruitment to the kinetochores during mitosis, is one such 
example of the processive phosphorylation model (Qi et al. 2006; Elowe et al. 
2007). Claspin binding of the PBD of Plx1 in a phospho-dependent manner 
leading to its subsequent phosphorylation by Plx1 is another such example 
(Kumagai & Dunphy 1996). The second model is referred to as the ‘distributive 
phosphorylation’ model where the PBD binds to a ligand that is separate from 
the target substrate of PLK. In this case, PLKs bind to a scaffold or docking 
protein that is in the vicinity of the substrate to be phosphorylated and, 
therefore, their kinase activities are limited by their proximity to primed 
docking sites. Thus, in this model, the PBD functions as the spatial ‘integrator’ 
of PLK mitotic function in space. The self-regulated recruitment of Plk1 to 
interphase and mitotic kinetochores, where it generates its own docking sites by 
priming PBIP1 to function as a scaffold in order to localise itself in proximity of 
its substrates, is an example of the distributive phosphorylation model of PBD-
mediated PLK regulation (Kang et al. 2006). In reality, it is likely that both 
models work in conjunction with each other. Also, phospho-priming is not always 
required for PBD binding to a substrate (García-Alvarez et al. 2007; Archambault 
et al. 2008) which indicates that the two models do not cover the whole story. 
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3.4 T. brucei PLK 
Graham et al, first characterised PLK in T. brucei (TbPLK). T. brucei features a 
single copy TbPLK gene which is located on chromosome 7 (GeneDB accession 
no. Tb927.7.6310) and encodes a 797 aa long protein sized 86.8 kDa. Amino acid 
sequence alignment of TbPLK with mouse Plk1 and yeast cdc5 revealed amino 
acid homology of 34.4% and 29.6%, respectively, and 50.4% and 54.1%, 
respectively, within the kinase domain (Graham et al. 1998). Sequence identity 
between human Plk1 and TbPLK was found to be 25% for the full length protein 
and 47.5% for the kinase domain (Kumar & Wang 2006). The protein has a typical 
N-terminal kinase domain (residues 43-297) and C-terminal PBD comprising two 
polo-boxes (residues 564-642). TbPLK was also found to feature a poly-
asparagine sequence between the kinase domain and the PBD, which displayed 
length polymorphisms depending on the isolate which could be attributed to 
unequal crossing-over events or polymerase slippage (Graham et al. 1998). The 
TbPLK protein studied in this project has been derived from the Lister 427 
MiTat1.2 strain and is 763 aa long. 
3.4.1 TbPLK functions 
Studies looking into the role of TbPLK in PCF parasites have confirmed its 
importance in the T. brucei cell cycle but not in mitosis. Instead, it has been 
found to be essential for the division of organelles that are intimately associated 
with the flagellum and cytokinesis.  
Among the first studies, those conducted by Kumar and Wang found that 
depletion of TbPLK in PCF cells resulted in enlarged cells and aberrant cell types 
(specifically 2N1K cells). Although the cells were able to progress through the 
cell cycle, progression was seen to be arrested at early cytokinesis. When an 
epitope-tagged version of TbPLK, TbPLK-3HA, was over-expressed, an increase in 
the presence of zoids was observed suggesting premature progression through to 
cytokinesis before the completion of mitosis (Kumar & Wang 2006). For TbPLK to 
carry out this function in initiating cytokinesis, the expression of TbAUK1 was 
supposed to be an essential pre-requisite (Tu et al. 2006). TbPLK did not seem to 
be involved in mitotic entry or exit suggesting the divergence of TbPLK functions 
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from those mediated by its homologues in yeast and metazoans. The, somehow, 
contrasting fact that TbPLK was able to rescue cdc5 knockout temperature 
sensitive yeast mutants (Kumar & Wang 2006) confirms it as a true functional 
and structural homologue of cdc5. The lack of a mitotic role for TbPLK in T. 
brucei could be explained by the differences between the biological contexts of 
T. brucei and other relevant eukaryotic organisms. TbPLK appears to be able to 
bind and phosphorylate the target substrates of cdc5 and this ability could be 
due to substrate availability as mediated by the yeast-specific priming activity of 
upstream kinases.  
Further studies showed that TbPLK is not required for cytokinesis per se, but is 
involved in upstream events that eventually impact on cytokinesis initiation. A 
deeper look into PCF parasites depleted of TbPLK via RNAi showed defective 
basal body duplication which inhibited kinetoplast segregation thus subsequently 
preventing cytokinesis (Hammarton et al. 2007). This link between TbPLK and 
bilobe biogenesis in PCF cells provided further hints at the roles of TbPLK 
involving duplication and segregation of cytoskeletal structures (de Graffenried 
et al., 2008). A microscopy based study conducted by the de Graffenried lab 
confirmed this idea (Ikeda & de Graffenried 2012). TbPLK was shown to 
dynamically localise within the cells through the cell cycle. α-TbPLK antibody 
was found to stain cytoskeletal structures as they were replicating, starting with 
the basal bodies, the FPC, the bilobe and then the anterior end of the new FAZ 
(possibly the flagellar connector). Ultimately, these events were found to 
manage the proper inheritance and positioning of the single flagellum. The 
signal was lost just before the commencement of furrow ingression and 
cytokinesis. The protein appeared to employ the new MtQ as its track for 
migrating through the length of the cell body. This study also suggested that the 
defect in basal body replication did not lie in its duplication (Hammarton et al. 
2007) but in its proper segregation. This discrepancy could be explained by 
differences in the penetrance of RNAi systems used. In all, de Graffenried’s 
study suggests that TbPLK plays a role in basal body segregation, FPC 
duplication, and FAZ elongation. Defects in FAZ formation could also explain the 
cytokinesis defects as FAZ defects could block the determination of cleavage 
points for furrow ingression.  
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A further study employing chemical genetics allowed in-depth dissection of 
TbPLK roles (Lozano-Núñez et al. 2013). PCF cells were modified to exclusively 
express analogue sensitive TbPLK (TbPLKas) from the endogenous locus which 
could then be specifically inhibited by the bulky ATP analogue, 3MB-PP1. Rapid 
inhibition of TbPLKas kinase activity in synchronised PCF cells showed, in 
agreement to the previous study, that TbPLK is directly involved in basal body 
segregation, bilobe duplication and FAZ initiation and elongation. In addition, 
the defect in basal body segregation was found to be caused by the failure of the 
repositioning of the new basal body to the posterior of the cell (see section 
1.3.2). In terms of the precise pathways in which TbPLK is involved to bring 
about the replication of these cytoskeletal structures, there is a lot yet to be 
discovered. TbCentrin2, a component of T. brucei bilobe and flagellum is the 
only recorded in vitro and in vivo substrate of TbPLK (de Graffenried et al. 2008; 
de Graffenried et al. 2013). TbPLK was shown to phosphorylate multiple sites in 
TbCentrin2. Imaging analysis with anti-TbCentrin2 phospho-specific (pS54) and 
anti-TbPLK antibodies showed that S54 is phosphorylated at specific points of 
the cell cycle, especially when TbPLK co-localises with the bilobe. Mutation of 
this residue to alanine failed to complement conditional TbCentrin2 knockout 
PCF cells and generated defects in bilobe duplication and FAZ elongation, 
reminiscent of the defects produced by TbPLK-depleted cells (de Graffenried et 
al. 2013) thus confirming TbCentrin2 as one of the, presumably, many substrates 
of TbPLK in PCF cells.    
3.4.2 TbPLK regulation 
The fact that TbPLK is expressed at specific times of the T. brucei cell cycle and 
is localised sequentially at particular cytoskeletal structures gives the strongest 
indication possible for its strict regulation in time and space, just like its 
homologues. As described earlier, the TbPLK structure features a conserved N-
terminal kinase domain and C-terminal PBD. This hint at the possibility that 
some regulatory features described for other PLKs (section 3.3) are conserved in 
TbPLK. 
Initial structure-function relationship studies on TbPLK revealed that truncating 
distinct domains of TbPLK could alter its localisation. The PBD as a whole was 
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found to be essential for TbPLK localisation in PCF cells (Sun & Wang 2011). This 
study also identified a putative bi-partite nuclear localisation signal (NLS) which 
can be found just after the kinase domain: 315RRRQHSDDPRGHAQGPLPLRRQK337; 
a puzzling find considering that no nuclear role has yet been identified for 
TbPLK. This NLS, in the absence of the PBD, was apparently found to localise the 
truncated TbPLK to the nucleus. A recent study with higher quality images lent 
credence to this hypothesis (Yu et al. 2012). Over-expressed HA-tagged kinase 
domain without the NLS showed a cytoplasmic localisation while the addition of 
the NLS localised it to the nucleus. Addition of the PBD (and linker) to this 
kinase domain+NLS construct resulted in a cytoplasmic localisation, suggesting 
that the presence of the PBD prevents nuclear localisation of TbPLK despite the 
presence of the NLS sequence. These experiments implied the importance of the 
whole PBD in TbPLK localisation. However, the PBD on its own did not appear to 
localise like the full length WT protein but again seemed to be cytoplasmic. 
Altogether, these experiments signalled that the kinase domain and PBD are 
jointly required for accurate TbPLK localisation. 
The obvious question that arises when studying TbPLK regulation is whether 
what is known of PLK1 regulation is conserved in TbPLK. Some of these questions 
were asked in a comprehensive study performed by Li’s group (Yu et al. 2012). 
Endogenous TbPLK was successfully knocked down via RNAi against its 3’UTR 
instead of its coding sequence. This then allowed them to ectopically express 
TbPLK variants which would not be affected by the RNAi system. Expression of 
WT TbPLK was able to complement the RNAi phenotype. Using this coupled 
system, mutants were used to study regulatory features of TbPLK. The conserved 
threonine residue of the T-loop, T198, was found to be important for TbPLK 
activity because mutating T198 to alanine (non-phosphorylatable) failed to 
rescue the RNAi phenotype while mutating it to aspartic acid (phospho-mimetic) 
did. Using the same mutation strategy, phosphorylation of another conserved 
threonine residue, T202 was also found to be equally important for kinase 
activity. Some residues, identified in other PLK1 proteins to be important for 
PLK1 localisation by making direct contact with its bound phospho-peptide 
(Trp414, Leu490, His538 and Lys540 in human Plk1) were not found to be 
entirely conserved. A putative His-Lys pincer (H710 and K712) was identified and 
along with two other residues, Phe561 (aligns with Trp414 in human Plk1) and 
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Trp557 (adjacent residue) were individually mutated to alanine and subjected to 
the same RNAi complementation assay. They were found to play no role in TbPLK 
function or localisation.  
The same study also identified a second in vitro substrate, termed p110, for 
TbPLK, although its identity was not revealed. In vitro kinase assays using pulled 
down kinase domain and PBD indicated that the kinase domain was sufficient for 
in vitro TbPLK binding with p110 and TbCentrin2. Using GST pull-down assays, 
the kinase domain and PBD were found to interact with each other in a manner 
which inhibits the activity of the kinase domain. Altogether, TbPLK regulation 
seems to be conserved (in relation to the regulatory T-loop of its kinase domain 
and the auto-inhibitory activity of the PBD) and divergent (in relation to the role 
of PBD as mediator of TbPLK substrate binding) at the same time. 
3.5 Project aims 
The aims of this study were to characterise how TbPLK activities were regulated 
in PCF cells. The roles the following domains played in regulating TbPLK activity 
were investigated:  
 the residues T198 and T202 in the T-loop  
 the Polo-box domain  
 the destruction box 
At the time of the beginning of this project in 2010, a lot was yet to be 
understood about the structure-function relationship of TbPLK in PCF cells. 
While the project was underway, Yu and colleagues published their study which 
asked many of the same questions that were to be asked in this project (Yu et 
al. 2012). Nevertheless, the decision was made to carry on with the project as 
there were differences in the approach and constructs to be used. This could 
provide new insights and also shed further light into TbPLK regulation, in 
addition to allowing the verification of conclusions drawn by Yu et al. Studies 
were also conducted to understand TbPLK regulation in BSF cells; these have 
been described separately in Chapter 4.   
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3.6 Results 
3.6.1 The expression assay 
To investigate the importance of the putative regulatory domains/residues of 
TbPLK for its kinase activity in vivo, the phenotypic observations made by 
Hammarton and colleagues (Hammarton et al. 2007) were used as the basis for 
the in vivo assay employed in this work. As described earlier, ectopic expression 
of WT TbPLK (Figure 3-5A and B) in PCF cells, but not the kinase dead TbPLK 
N169A protein (Figure 3-5A and B), resulted in a decrease in growth and a rise in 
aberrant cell types (Figure 3-5C, D and E; Hammarton et al. 2007). Upon 
expression of WT TbPLK, an initial rise in 2N1K cells was observed which was 
followed by the appearance of >2N1K cells at later time points (Figure 3-5D and 
E).  
 
Chapter 3 
 
90 
Figure 3-5 Expression of ty-tagged TbPLK in PCF cells. N-terminally TY-1 tagged TbPLK (ka=WT, 
kd=N169A) were expressed in PCF T. brucei with the addition of 1 µg ml-1 tetracycline (+tet) in a 
WT background. Analyses of non-induced cells (-tet) have also been shown as controls (A) 
Western blots were performed on whole cell extracts (1 x 106 cells/sample) taken at 37 h post 
addition of tetracycline to detect expression of TbPLK (PLKty (ka))/ TbPLK N169A (PLKty (kd)) 
using an α-TY antibody. Equal loading was confirmed by Coomassie blue staining of a replica gel 
(bottom). (B) The expressed proteins were immuno-precipitated with anti-TY antibody and used 
in a radioactive kinase assay with alpha- and beta-casein as substrates. WT TbPLK was active 
against alpha-casein and beta-casein while TbPLK N169A did not show any activity. (C) 
Cumulative growth curves were generated. Expression of the WT protein (PLKty (ka)), and not 
the N169A kinase dead version (PLKty (kd)), generates growth defects. (D) The numbers of nuclei 
(N) and kinetoplasts (K) in each PLKty expressing cell (n ≥ 200) following DAPI staining of samples 
were recorded at the indicated time points post addition of tetracycline. (E) Detailed analysis of 
aberrant cells observed when PLKty is expressed. Figure adapted from Hammarton et al. 2007.   
These phenotypes were exploited in this study to test whether ectopically 
expressed TbPLK mutants are active or not in vivo.  The TbPLK mutants were 
tagged to allow their localisation to be tracked. This was achieved by modifying 
pHD675 (Biebinger et al. 1997) to facilitate tagging of TbPLK proteins at their N-
terminus with a YFP tag. First, YFP was sub-cloned (section 2.3.2.7) from 
pHG329 (gift from Chris de Graffenried) as a HindIII-BamHI fragment into pGL202 
(originally pHD675; see Table 2-5 for details; Biebinger et al. 1997) generating 
pHG342. Then a multiple cloning site was added at the 3’ end of YFP to include 
MluI, XhoI and HpaI restriction sites generating pHG366 (sections 2.3.2.7 and 
2.3.2.8; Figure 3-6). TbPLK variants (Figure 3-7) were then cloned as BamHI-XhoI 
fragments into pHG366 (section 2.3.2.7).  
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Figure 3-6 Plasmid map of pHG366. pGL202 (originally pHD675, see Table 2-5 for details; 
Biebinger et al. 1997) was modified to allow expression of N-terminal YFP-tagged proteins and to 
introduce a multiple cloning site (MCS) featuring the restriction sites MluI, XhoI and HpaI. Amp – 
Ampicillin resistance cassette. rRNA – ribosomal RNA spacer. Hyg – Hygromycin resistance 
cassette. For transfection, the constructs were linearised by digestion with with NotI (section 
2.3.2.4).
 
Figure 3-7 TbPLK variants that were analysed in this study.  
The effect of expressing full length TbPLK proteins, featuring an N-terminal YFP 
tag (YFP:TbPLK and YFP:TbPLK N169A), was then analysed via growth curves and 
cell cycle analysis to determine if they would behave as their ty-tagged 
counterparts described in Hammarton et al. 2007. Indeed, expression of YFP-
tagged TbPLK and TbPLK N169A in a WT background, generated results that were 
comparable to those of the N-terminal ty-tagged versions (Figures 3-5 and 3-8). 
Cells expressing WT TbPLK (YFP:TbPLK) displayed impaired growth (Figure 3-8A, 
top panel) whilst those expressing the kinase dead version (YFP:TbPLK N169A) 
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did not (Figure 3-8B, top panel). Samples of cells taken at various intervals 
following tetracycline induction were analysed via DAPI staining (section 2.5) to 
classify cells according to the number of nuclei (N) and kinetoplasts (K) present 
in each cell. YFP:TbPLK expression generated an increase in 2N1K cells at 18 h, 
and multinucleate cells at 24 h (Figure 3-8A, middle panel) whilst expression of 
YFP:TbPLK N169A had no effect on the cell cycle (Figure 3-8B, middle panel). 
These observations are consistent with the results obtained by Hammarton et al. 
The appearance of a growth defect upon TbPLK expression can be explained by 
delayed kinetoplast segregation causing an initial rise in 2N1K cells, resulting in 
delays in cytokinesis, leading to subsequent generation of >2N1K cells at later 
time-points  (Hammarton et al. 2007).  
Western blotting (section 2.4.1.3) (bottom panels of Figure 3-8) confirmed that 
the proteins were expressed at detectable amounts as early as 10 h post-
induction. For the loading control, a cross-reacting band which appeared at 
about 35 kDa was used instead of the one representing EF-1α at about 50 kDa. 
This was because the size of EF-1α was mistakenly thought to be 35 kDa during 
initial experiments. After transfer during western blotting, the blotting 
membranes were often cut to allow separate incubation with different 
antibodies. In this experiment, the membrane was cut in such a way that 
proteins above 45 kDa in size, including EF-1α, were excluded for incubation 
with EF-1α primary antibody. Therefore, it was not possible to employ the EF-1α 
as loading control here. This has been also the case for experiments described in 
Figures 3-10, 3-16 and 3-18, and will all need to be rectified in future repeat 
experiments. 
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Figure 3-8 Expression of YFP-tagged TbPLK and TbPLK N169A in PCF cells. N-terminally YFP-
tagged TbPLK (A) and TbPLK N169A (B) were expressed in PCF T. brucei cells with the addition of 
1 µg ml-1 tetracycline (tet+). Analyses of non-induced cells (tet-) have also been shown as 
controls. Cumulative growth curves were generated (top panels of both sections) and the 
numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of 
samples were recorded at the indicated time points post addition of tetracycline (middle panels 
of both sections). Western blots (bottom panels of both sections) were performed on whole cell 
extracts (1 x 106 cells/sample) taken at 0, 10 and 96 h post addition of tetracycline (t0, t10 and 
t96, respectively) to detect expression of YFP:TbPLK/YFP:TbPLK N169A using an α-GFP antibody. 
Western blots were also probed with α-EF-1α which generated a cross-reacting band at 35 kDa 
that has been used as the loading control. 
Because the cells at t10 appeared to be healthy morphologically with NK 
configurations comparable to those found at t0, the decision was made to image 
cells at this time-point (in this and future experiments with PCF parasites) to 
localise the expressed proteins via fluorescence microscopy (section 2.5). The 
cells were fixed on glass slides for at least 20 minutes in MeOH at -20oC before 
they were rehydrated with PBS, mounted with Vectashield containing DAPI and 
viewed under the FITC channel. YFP:TbPLK displayed varied localisations 
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consistent with previous observations of dynamic localisation. It was mainly 
found to concentrate in an area next to the kinetoplast consistent with it 
localising in the bilobe area, and possibly along the length and at the tip of the 
flagellum (Figure 3-9, top panels). TbPLK N169A showed a similar pattern of 
localisation albeit more diffuse and brighter appearance (Figure 3-9, middle 
panels). PCF cells featuring integrated YFP:TbPLK constructs, prior to induction 
of expression with tetracycline, did not express the protein (Figure 3-9, bottom 
panels). 
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Figure 3-9 Localisation of YFP-tagged TbPLK proteins in PCF parasites. Images show direct 
fluorescence of YFP-tagged TbPLK (top panels) and TbPLK N169A (middle panels) following 10 h 
induction with 1 µg ml-1 of tetracycline. Bottom panels – PCF cells transfected with YFP:TbPLK 
expression construct, prior to induction. Arrows indicate localisation of fusion proteins in the 
bilobe (open arrowheads) and flagellar area (closed arrowheads). Brightfield, DAPI and FITC 
channels are shown (from left to right). Scale bar – 10 µm.  
Previous studies localising TbPLK generally showed the kinase to localise at a 
dorsal mid-point and the anterior tip of the growing FAZ (Umeyama & Wang 
2008; Sun & Wang 2011; Yu et al. 2012). However, a more comprehensive study 
conducted by de Graffenried’s lab has shown TbPLK to dynamically localise at 
the basal bodies, flagellar pocket collar, bilobe, the old FAZ and the anterior tip 
of the new FAZ during the cell cycle possibly using the emerging microtubule 
quartet as a track for movement (Ikeda & de Graffenried 2012). This could 
explain the variation in localisation that was found in YFP-tagged expressed 
TbPLK in this experiment. The more diffuse localisation of the kinase dead 
version is not in agreement with the findings of Yu et al. (Yu et al. 2012) where 
no such change in localisation was observed, but could be due to the higher level 
of expression relative to the wildtype TbPLK as detected by the Western blot at 
10 h post-induction when the cells were imaged (Figure 3-8).  
Now that the ty-tagged TbPLK expression phenotypes described by Hammarton 
et al. were replicated with the use of YFP-tagged TbPLK proteins, the expression 
assay was deemed established. Different YFP:TbPLK mutants were then 
ectopically expressed in order to understand the roles of: 
 the residues T198 and T202 in the T-loop (section 3.6.2) 
 the Polo-box domain (section 3.6.3) 
 the destruction box (section 3.6.4) 
in the kinase activity and localisation of TbPLK. 
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3.6.2 The importance of T-loop residues T198 and T202 
for TbPLK kinase activity in vitro and in vivo. 
In order to determine if phosphorylation of T198, a conserved residue in the T-
loop of TbPLK, is essential for TbPLK kinase activity, YFP:TbPLK T198 mutants 
were ectopically expressed in PCF parasites in a WT background (for cloning 
details, see sections  2.3.2.6 and 2.3.2.7). Expression of YFP:TbPLK, with its 
T198 mutated to the phospho-mimetic aspartic acid (YFP:TbPLK T198D), 
generated growth and cell cycle defects similar to what is seen when the WT 
protein is expressed suggesting that YFP:TbPLK T198D is behaving like the kinase 
active protein (Figures 3-8A and 3-10B). Expression of YFP:TbPLK, with its T198 
mutated to the non-phosphorylatable alanine (YFP:TbPLK T198A) did not have 
any effect on the parasite growth or cell cycle progression which is similar to 
what was seen when the kinase dead YFP:TbPLK N169A was expressed (Figures 3-
8B and 3-10A). This, therefore, suggests that YFP:TbPLK T198A is behaving like 
the kinase dead TbPLK. This means that phosphorylation of T198 is apparently 
important for TbPLK kinase activity. The localisations of both T198 mutants were 
comparable to that of WT YFP:TbPLK (Figures 3-9 and 3-10A and B, bottom right 
panels). The importance of T198 phosphorylation found in this study is in 
agreement with recently published work (Yu et al. 2012).  
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Figure 3-10 Expression of of YFP-tagged TbPLK T198A and T198D in PCF cells. N-terminally YFP-
tagged TbPLK T198A (A) and TbPLK T198D (B) were expressed in PCF T. brucei cells via the 
addition of 1 µg ml-1 tetracycline (tet+). Analyses of non-induced cells (tet-) have also been 
shown as controls. Cumulative growth curves were generated (top left of both sections) and the 
numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of 
samples were recorded at the indicated time points post addition of tetracycline (top right 
panels of both sections). Western blots were performed on whole cell extracts (1 x 106 
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cells/sample) taken at 0, 10 and 96 h post addition of tetracycline (t0, t10 and t96, respectively) 
to detect expression of YFP:TbPLK T198A/YFP:TbPLK T198D using an α-GFP antibody (bottom left 
panels of both sections). Western blots were also probed with α-EF-1α which generated a cross-
reacting band at 35 kDa that has been used as the loading control. Also shown are images 
representing direct fluorescence of YFP-tagged TbPLK T198A and TbPLK T198D following 10 h 
induction (bottom right panels of both sections; from left to right, Brightfield, DAPI and FITC 
channels). Arrows indicate localisation of fusion proteins in the bilobe (open arrowheads) and 
flagellar area (closed arrowheads). Scale bar – 10 µm. 
Yu et al. 2012 also identified a neighbouring threonine residue, T202, to be 
essential for TbPLK kinase activity. This residue has not been identified as a 
phosphosite in the only phospho-proteomic study done in PCF parasites so far 
(Urbaniak et al. 2013) whilst T198 was. However, the same site has been found 
to be phosphorylated in PLK1 proteins from other organisms (Wind et al. 2002; 
Kelm et al. 2002; Dulla et al. 2010). Therefore, the relationship between these 
two residues in mediating TbPLK activity was also investigated.  
In order to do this various YFP:TbPLK T198 and/or T202 mutants in a WT 
background were ectopically expressed in PCF parasites (for cloning details, see 
sections 2.3.2.3 and 3.6.1) and the growth and cell cycle phenotypes were 
determined. Note that the clones analysed for growth and localisation 
phenotypes (Figure 3-11 and 3-13) are not the same as those analysed for cell 
cycle progression (Figure 3-12).  
Expression of YFP:TbPLK T202A did not generate any growth or cell cycle defects 
indicating a kinase dead phenotype (Figures 3-11A and 3-12A). Mutating T198 to 
aspartic acid (YFP:TbPLK T198D T202A) was not able to alter this phenotype to 
resemble a kinase active one (Figures 3-11A and 3-12A). Unsurprisingly, 
expression of the double mutant YFP:TbPLK T198A T202A also demonstrated a 
kinase dead phenotype (Figures 3-11A and 3-12A). Mutating T202 to aspartic acid 
failed to generate a kinase active phenotype, either on its own (YFP:T202D) or in 
addition to T198A (YFP:T198A T202D) (Figures 3-11B and 3-12B). This phenotype 
did not change even with the mutation of T198 to aspartic acid (YFP:T198D 
T202D; Figures 3-11B and 3-12B), which is remarkable as it suggests that TbPLK 
kinase inactivation by T202D cannot even be rescued by the kinase activating 
T198D mutation (see above).   
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Figure 3-11 Expression of YFP-tagged TbPLK T198 and T202 mutants in PCF T. brucei cells. N-
terminally YFP-tagged TbPLK T202A, TbPLK T198A T202A and TbPLK T198D T202A (A); as well as 
TbPLK T202D, TbPLK T198A T202D and T198D T202D (B) were expressed in PCF T. brucei cells 
along with YFP:TbPLK and YFP:TbPLK N169A via the addition of 1 µg ml-1 tetracycline (tet+). 
Analyses of non-induced cells (tet-) have also been shown as controls. Cumulative growth curves 
were generated (top panels of both sections). Western blots were performed on whole cell 
extracts (1 x 106 cells/sample) prepared at 10 and 72 h post addition of tetracycline (t10 and t72, 
respectively) to detect expression of each YFP:TbPLK T198 T202 mutant using an α-GFP antibody 
(bottom panels of both sections). Western blots were also probed with α-EF-1α as a loading 
control. 
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Figure 3-12 Cell cycle analysis of PCF T. brucei cells expressing YFP-tagged TbPLK T198 and 
T202 mutants. Here, a second set of clones were analysed compared to those depicted in Figures 
3-11 and 3-13. N-terminally YFP-tagged TbPLK T202A, TbPLK T198A T202A and TbPLK T198D 
T202A (A); as well as TbPLK T202D, TbPLK T198A T202D and T198D T202D (B) were expressed in 
PCF T. brucei cells with the addition of 1 µg ml-1 tetracycline (tet+). Analyses of non-induced 
cells (tet-) have also been shown as controls. Numbers of nuclei (N) and kinetoplasts (K) in each 
cell (n ≥ 200) following DAPI staining of samples were recorded at the indicated time points post 
addition of tetracycline. 
All of these proteins seemed to show the same varied localisations (Figure 3-13) 
as found with YFP:TbPLK (Figure 3-9) albeit that the localisation was a bit more 
diffuse, which could be explained by their higher levels of expression at the 
same time-point (Figure 3-22) compared to the WT counterpart. 
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Figure 3-13 Localisation of YFP-tagged TbPLK T198 T202 mutants in PCF cells. Images show 
direct fluorescence of YFP-tagged TbPLK T202A, TbPLK T198A T202A and TbPLK T198D T202A 
(A); and TbPLK T202D, TbPLK T198A T202D and T198D T202D (B) following 10 h induction with 1 
µg ml-1 tetracycline (from left to right, Brightfield, DAPI and FITC channels) in PCF T. brucei 
parasites. Arrows indicate localisation of fusion proteins in the bilobe (open arrowheads) and 
flagellar area (closed arrowheads). Scale bar – 10 µm. 
Overall, it appears that mutating T202 has a detrimental effect on the activity 
of TbPLK in vivo. This led onto the question of whether the T202D mutation was 
unable to effectively mimic phosphorylation and if another residue also known to 
mimic phosphorylation, such as glutamic acid (Maciejewski et al. 1995; 
Barrientes et al. 2000), could be used instead. Additional cell lines were, 
therefore, made to express a YFP:TbPLK T202E mutant (for cloning details, see 
sections 2.3.2.3 and 3.6.1). However, this mutant too failed to generate growth 
and cell cycle defects (Figure 3-14) suggesting that this TbPLK variant is also 
inactive in vivo.  
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Figure 3-14 Expression of YFP-tagged TbPLK T202E in PCF T. brucei cells. N-terminally YFP-
tagged TbPLK T202E was expressed in PCF T. brucei cells with the addition of 1 µg ml-1 
tetracycline (tet+). Analyses of non-induced cells (tet-) have also been shown as controls. 
Cumulative growth curves were generated (top panel). Western blotting was performed on whole 
cell extracts (1 x 106 cells/sample) taken at 0, 10 and 96 h post addition of tetracycline (t0, t10 
and t96, respectively) to detect expression of YFP:TbPLK T202E using an α-GFP antibody (middle 
panel). The western blot was also probed with α-EF-1α as a loading control. Numbers of nuclei 
(N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of samples were recorded 
at the indicated time points post addition of tetracycline (bottom panel). 
In order to test if what was observed in vivo could be replicated in vitro, 
recombinant 6His-tagged TbPLK variants (for cloning details, see sections 2.3.2.6 
and 2.3.2.7; for recombinant protein expression details, see section 2.4.2) were 
purified and subjected to a kinase assay where 4 µg of each recombinant protein 
were incubated with radio-labelled (32P) γ-ATP (section 2.4.3) in the presence or 
absence of TbPLK’s favoured in vitro substrate, α-casein (Hammarton et al. 
2007; Figure 3-15). It was found that 6His:TbPLK was highly auto-
phosphorylated, which has been observed previously (May 2010) and that it 
phosphorylates α-casein. This was also accompanied by a change in 
electrophoretic mobility, which could be attributed to the additional phosphate 
groups bound to the protein. 6His:TbPLK T198D was also observed to feature a 
similar change in electrophoretic mobility and was able to phosphorylate α-
casein albeit at a lower scale (Figure 3-15). This suggests that this mutation, 
although to some extent able to mimic phosphorylated T198, is not able to fully 
activate TbPLK and that other factors may also contribute towards TbPLK 
activity in vitro. 6His:TbPLK T198D T202D appears to show slight ability in 
phosphorlyating itself and α-casein, albeit at a much lower scale compared to 
6His:TbPLK and even 6His:TbPLK T198D. However, no detectable change in 
electrophoretic mobility is seen. Altogether, these observations suggest that the 
kinase activity of 6His:TbPLK T198D T202D is highly impaired due to the 
additional mutation of the T202 residue lending credence to what was seen of 
this mutant in vivo (see above). All of the rest of the 6His:TbPLK variants did not 
seem to be kinase active in vitro which is in keeping with what was seen when 
their counterparts were expressed in vivo (see above). 
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Figure 3-15 In vitro kinase activity of recombinant 6His-tagged (N-terminus) TbPLK proteins. 
Recombinant 6His-tagged TbPLK proteins were subjected to a kinase assay in the presence or 
absence of the generic substrate, α-casein. The different reaction mixtures were loaded as 
indicated. The master mix containing no kinase was used as a negative control. Predicted protein 
sizes – His:TbPLK proteins – 87 kDA; α-casein – 30 kDA. Note - WT and T198D versions of TbPLK 
migrate more slowly compared to the other proteins due to auto-phosphorylation. Top panels – 
autoradiograph (32P). Bottom panels – gel stained with Coomassie blue (CBB). 
3.6.3 The role of the polo-box domain 
As described in sections 3.3.4 and 3.3.5, a His-Lys pincer is important for 
interaction between the PBD of the PLK and its substrates. An alignment of PLK1 
proteins from various organisms with TbPLK showed a putative His-Lys pincer in 
TbPLK close to those found in the other PLK1 proteins. To test the importance of 
these residues for TbPLK activity in vivo, they were mutated to alanine 
(YFP:TbPLK H704A K706A; for cloning details, see section 2.3.2.6 and 2.3.2.7) 
and ectopically expressed in PCF cells (section 3.6.1). As seen in Figure 3-16, 
these mutations did not make any difference in the phenotypes obtained when 
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the WT protein (YFP:TbPLK) is expressed. The same growth and cell cycle 
defects were observed (Figures 3-8A, top and middle panels, and 3-16, top 
panels) and the fusion protein showed the same varied localisations as 
YFP:TbPLK (Figures 3-9, top panels, and 3-16, bottom right panel) suggesting 
that these mutations did not affect the functions of the expressed TbPLK in vivo. 
 
Figure 3-16 Expression of YFP-tagged TbPLK H704A K706A in PCF cells. N-terminally YFP-tagged 
TbPLK H704A K706A was expressed in PCF T. brucei cells with the addition of 1 µg ml-1 
tetracycline (tet+). Analyses of non-induced cells (tet-) have also been shown as controls. 
Cumulative growth curves were generated (top left panel) and the numbers of nuclei (N) and 
kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of samples were recorded at the 
indicated time points post addition of tetracycline (top right panel). Western blot analysis was 
performed on whole cell extracts (1 x 106 cells/sample) taken at 0, 10 and 96 h post addition of 
tetracycline (t0, t10 and t96, respectively) to detect expression of YFP:TbPLK H704A K706A using 
an α-GFP antibody (bottom left panel). Western blots were also probed with α-EF-1α which 
generated a cross-reacting band at 35 kDa that has been used as the loading control. Also shown 
are images representing direct fluorescence of YFP-tagged TbPLK H704A K706A following 10 h 
induction (bottom right panel; from left to right, Brightfield, DAPI and FITC channels). Arrows 
indicate localisation of TbPLK H704A K706A in the bilobe (open arrowheads) and flagellar area 
(closed arrowheads). Scale bar – 10 µm. 
Next, the importance of PBD in mediating the kinase activity of the whole 
protein was investigated. As discussed earlier (section 3.3.5), it is known that 
the PBD acts as an important mediator between the kinase domain and the in 
vivo substrates of PLK. In addition, the PBD is known to impose auto-inhibition 
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on the activity of the PLK kinase domain (section 3.3.4). It was investigated 
whether PBD played the same roles in T. brucei. In order to do this TbPLK was 
truncated to feature just the kinase domain (1-312; KD) and its GST-tagged 
recombinant version was expressed and purified (for cloning details, see sections 
2.3.2.6 and 2.3.2.7; for recombinant protein expression details, see section 
2.4.2). Similarly, a TbPLK truncation featuring just the PBD (431-763 aa; PBD431) 
was also expressed and purified as a 6His-tagged fusion protein. The kinase 
activity of GST:KD was first verified via a kinase assay (section 2.4.3) in the 
presence and absence of α-casein (Figure 3-17). GST:KD was shown to be highly 
auto-phosphorylated and to be active against α-casein. Introduction of the 
N169A mutation into GST:KD (GST:KD N169A) abolished its auto- and trans- 
phosphorylating activity. Finally, 6His:PBD431 was added into the same reaction 
mixtures to determine if it imposes any auto-inhibitory activity on full length 
6His:TbPLK or the GST:KD. No evidence of such auto-inhibition was found in 
vitro. On the contrary, 6His:PBD431 itself was found to be a substrate of 
6His:TbPLK and GST:KD.   
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Figure 3-17 The PBD does not inhibit TbPLK kinase activity but acts as a substrate in vitro. 
Recombinant 6His:/GST:TbPLK proteins were subjected to a kinase assay in the presence or 
absence of 6His:PBD431 and the generic substrate, α-casein. The different reaction mixtures were 
loaded as indicated. Predicted protein sizes – His:TbPLK proteins – 87 kDA; GST:KD proteins – 63 
kDA; His:PBD431 – 38 kDA; α-casein – 30 kDA. Note - WT versions of TbPLK and KD fusion proteins 
migrate more slowly compared to their kinase dead counterparts due to auto-phosphorylation. 
Top panels – autoradiograph (32P). Bottom panels– SDS-PAGE gel stained with Coomassie blue 
(CBB). Asterisks on the right of a band indicate degradation products or contaminants found in 
the protein samples. 
On being satisfied that the KD truncation generated is active in vitro, the 
question of whether the lack of a PBD would prevent this protein from localising 
like the WT TbPLK in vivo was investigated. In addition, only the PBD was 
expressed to see if it would generate a dominant negative phenotype indicating 
whether it is able to prevent the endogenous TbPLK from carrying out its in vivo 
activities. N-terminally YFP-tagged KD, KD N169A, PBD431 and PBD431 H704 K706A 
were, therefore, ectopically expressed (for cloning details, see sections 2.3.2.6, 
2.3.2.7 and 3.6.1) and analysed using methods as described earlier for the other 
TbPLK mutants. 
Expression of YFP:KD generated growth and cell cycle defects similar to those of 
YFP:TbPLK (Figures 3-8A and 3-18A) and the protein appears to have localised 
uniformly throughout the cell (Figure 3-19A). This suggests that the YFP:KD is 
unable to localise like the full length protein in the absence of the PBD. Despite 
this mis-localisation, the YFP:KD is yet able to perform its kinase activity and 
targets the same substrates as the YFP:TbPLK evidenced by the similarity in the 
cell cycle and growth phenotypes generated by expressing the two proteins. 
Expression of its kinase dead version, YFP:KD N169A, did not generate any 
growth and cell cycle defects (Figure 3-18B) despite displaying the same 
localisation as the kinase active YFP:KD (Figure 3-19B). It can, therefore, be 
confirmed that it is the phosphorylating activity of YFP:KD and not just the 
presence of the protein, that is generating these phenotypes. Expressing 
YFP:PBD431 and YFP:PBD431 H704A K706A did not have any effect on the growth or 
cell cycle progression of the parasites (Figure 3-18C and D, respectively). This, 
along with observations made earlier regarding expression of the YFP:KD 
variants, confirmed that the PBD is not responsible for the expression 
phenotypes seen with the full length WT TbPLK (section 3.6.1).  
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Figure 3-18 Expression of YFP-tagged TbPLK truncations in PCF cells. N-terminally YFP-tagged 
KD (A), KD N169A (B), PBD431 (C) and PBD431 H704A K706A (D) were expressed in PCF T. brucei 
cells with the addition of 1 µg ml-1 tetracycline (tet+). Analyses of non-induced cells (tet-) have 
also been shown as controls. Cumulative growth curves were generated (top panel of each 
section) and the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI 
staining of samples were recorded at the indicated time points post addition of tetracycline 
(bottom panel of each section). Western blots were performed on whole cell extracts (1 x 106 
cells/sample) taken at 0, 10 and 96 h post addition of tetracycline (t0, t10 and t96, respectively) 
to detect expression of YFP:TbPLK KD N169A/PBD431/PBD431 H704A K706A using an α-GFP 
antibody (middle panel of each section). Western blots were also probed with α-EF-1α which 
generated a cross-reacting band at 35 kDa that has been used as the loading control.  
If the PBD is indeed important for localising TbPLK, it can be expected that the 
expressed YFP:PBD431 would localise like the full length version. This does 
appear to be the case, although the protein seems to have stained the whole 
length of the flagellum and to have diffused further into the cytoplasm (Figure 
3-19C). This localisation did not change with its H704 and K706 residues being 
mutated to alanine (YFP:PBD431 H704A K706A; Figure 3-19D), again suggesting 
that these residues are not important for PBD (and TbPLK) localisation. The 
diffuse staining could be explained by the much higher expression of YFP:PBD431 
and YFP:PBD431 H704A K706A (Figure 3-22). TbPLK is known to localise to specific 
cellular structures as the cell cycle progresses (Ikeda & de Graffenried 2012). It 
can be assumed that it binds specific substrates which are local to these 
structures, e.g. TbCentrin2 in the bilobe (de Graffenried et al. 2013). Therefore, 
it could be possible that the high expression levels of YFP:PBD431 and YFP:PBD431 
H704A K706A might have caused the proteins to bind to all the available 
substrates within the bilobe area and the FAZ – interactions which are probably 
under spatial and temporal control when the full length protein is involved. It is 
important to note that expression of YFP:PBD431 and YFP:PBD431 H704A K706A did 
not generate growth or cell cycle defects within the cells. If YFP:PBD431 and 
YFP:PBD431 H704A K706A did bind all its available TbPLK substrates and docking 
proteins (assuming TbPLK adopts the processive and distributive models of PBD-
mediating phosphorylation of substrates by PLK1 proteins as described earlier), 
then the endogenous WT TbPLK would not have been able to access these same 
binding sites in order to mediate its own cellular functions. However, as 
expressing the PBD431 (and TbPLK N169A) did not generate growth or cell cycle 
defects, it can be assumed that endogenous TbPLK was not inhibited from 
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performing its functions. This could be because the phosphorylating activity of 
the expressed TbPLK by itself (found in kinase active WT TbPLK and KD but not 
the kinase dead versions) is required for such substrate/docking protein binding 
in vivo. Here, in the absence of the kinase activity of the KD, the binding of the 
PBD to the available binding sites alone is ineffective in preventing the 
endogenous TbPLK from accessing the substrates and carrying out its kinase 
activities. 
 
Figure 3-19 Localisation of YFP-tagged TbPLK truncations in PCF cells. Images show direct 
fluorescence of YFP:KD (A), YFP:KD N169A (B), YFP:PBD431 (C) and YFP:PBD431 H704A and K706A 
(D) following 10 h induction with 1 µg ml-1 tetracycline (from left to right, Brightfield, DAPI and 
FITC channels) PCF T. brucei parasites. Arrows indicate localisation of fusion proteins in the 
bilobe (open arrowheads) and flagellar (closed arrowheads) area. Less exposed versions of 
images taken from the FITC channel are also shown to allow clearer localisation of the fusion 
proteins (bottom panels). Scale bar – 10 µm. 
3.6.4 Domains important for TbPLK expression 
Another observation that has been made from the experiments described in the 
section above is that, following tetracycline induction, truncated TbPLK fusion 
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proteins (YFP:KD, YFP:KD N169A, YFP:PBD431 and YFP:PBD431 H704A K706A) were 
expressed at much higher levels compared to the full length variants (Figure 3-
22), despite the same induction and Western blot protocols being used for all 
cell lines. This can also be seen in the fluorescence images of each cell line, 
where the exposure time needed to be reduced for all cell lines expressing 
YFP:TbPLK truncations described above to be able to visualise their localisations 
clearly (Figures 3-19). 
It is known that PLKs feature a destruction box which is important for ubiquitin-
mediated degradation of PLKs (Lindon & Pines 2004; Archambault & Glover 
2009). Common to both the KD and PBD431 fusion proteins, was the lack of the 
IDL region lying between these two domains in the full length protein, and it was 
hypothesised that this region might be important for regulating the expression 
levels of TbPLK in vivo. Following a literature search and alignment of various 
PLK1 proteins, a putative destruction box can be identified within this region - 
375REVLQPISTNLPK387 which appears to be diverged in sequence (337RKPLTVLNK345  
- Plk1; 328RKPLTAINK336 – Plx1; 324RKPLSSLNK332 – zPlk1) preventing its detection 
via BLAST searches. The minimal consensus sequence for destruction boxes is 
known to be RXXL (where x is any amino acid; Liu et al. 2012). In order to test 
the hypothesis that this IDL region is important for regulating TbPLK expression 
levels, further truncations of TbPLK were generated. By adding the IDL region 
(which includes the putative destruction box) to the KD or PBD431, it was hoped 
that the expression levels of these mutants would be lower to that of KD and 
PBD431 alone. The following additional truncated TbPLK proteins were expressed: 
 ΔPBD431 (1-429 aa; up to the beginning of the PBD431) 
 ΔKD+PBD431 (312-429 aa; just the IDL, i.e., from the end of the KD to the 
beginning of the PBD431) 
 ΔKD (313-763 aa; from the end of the KD up to the end of PBD431) 
Two clones of each cell line were analysed and identical results were obtained. 
Therefore, data from just one clone each have been described. N-terminally 
YFP-tagged versions of these truncations were ectopically expressed in PCF cells 
in a WT TbPLK background. Expression of all three constructs failed to generate 
growth or cell cycle defects (Figure 3-20) suggesting that none of them were 
able to perform their kinase activities in vivo. This was expected for 
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YFP:ΔKD+PBD and YFP:ΔKD as they did not contain the kinase domain; however, 
the kinase dead-like phenotype obtained upon expression of  ΔPBD was surprising 
as it still featured the active KD region within the construct. This could be 
explained by the unusual localisation demonstrated by this protein (Figure 3-
20A). This protein can be seen to have exclusively localised within the nucleus 
(Figure 3-21A). Given that this protein was unable to localise to the bilobe and 
flagellar area like WT TbPLK, can explain why no kinase active like phenotypes 
were observed upon its expression in a WT background.  
 
Figure 3-20 Expression of YFP-tagged TbPLK truncations in PCF cells. N-terminally YFP-tagged 
ΔPBD (A), ΔKD+PBD (B) and ΔKD (C) were expressed in PCF T. brucei cells with the addition of 1 
µg ml-1 tetracycline (tet+). Analyses of non-induced cells (tet-) have also been shown as controls. 
Cumulative growth curves were generated (middle panel of each section) and the numbers of 
nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of samples were 
recorded at the indicated time points post addition of tetracycline (right panel of each section). 
Western blots were performed on whole cell extracts (1 x 106 cells/sample) taken at 0, 10 and 96 
h post addition of tetracycline (t0, t10 and t96, respectively) to detect expression of YFP:TbPLK 
ΔPBD/ΔKD+PBD/ΔKD using an α-GFP antibody (left panel of each section). Western blots were 
also probed with α-EF-1α as a loading control. 
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Figure 3-21 Localisation of YFP-tagged TbPLK truncations in PCF cells. Images show direct 
fluorescence of ΔPBD (A), Δ(KD+PBD431) (B) and ΔKD (C) following 10 h induction with 1 µg ml-1 
tetracycline (from left to right, Brightfield, DAPI and FITC channels) PCF T. brucei parasites. 
Arrows and open arrowheads indicate localisation of fusion proteins in the nucleus and in the 
bilobe area, respectively. Scale bar – 10 µm. 
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All TbPLK RNAi phenotypes shown so far have been non-mitotic suggesting that 
TbPLK has no role in the nucleus (Hammarton et al. 2007). However, a function 
can never be thus ruled out as mRNA depletion via RNAi is never 100%. Here, a 
TbPLK fusion protein, which could possibly be active as a kinase, has been shown 
to exclusively localise to the nucleus and yet not induce any mitotic phenotypes. 
A key experiment in the future would be to show that this fusion protein is 
active as a kinase via in vitro kinase assays which would then provide further 
evidence indicating that TbPLK has no mitotic function.  
Even more unusual is the localisation demonstrated by YFP:ΔKD+PBD431. Again, 
this fusion protein localised within the nucleus but this time as discrete bright 
puncta which could coincide with specific nuclear structures (Figure 3-21B). The 
biological relevance of this observation is not clear at present and further 
investigations will need to be made. YFP:ΔKD, on the other hand, appears to 
localise in a cytosolic manner, sometimes with a particular bright staining in the 
bilobe area (Figure 3-21C), somewhat reminiscent of the localisation 
demonstrated by the full length TbPLK variants. Due to this more cytosolic 
nature of the localisation of YFP:ΔKD, it appears to contradict the notion that 
the PBD is the domain responsible for TbPLK localisation. This cannot be 
explained by higher expression levels, as it is expressed at levels equivalent to 
YFP:TbPLK (Figure 3-22). There could be issues with folding; however, this would 
need to be verified. 
Coming back to the question of expression levels, surprisingly, the most highly 
expressed construct of all the TbPLK mutants expressed so far in PCF cells is 
YFP:ΔKD+PBD which is the region that was hypothesised to feature the 
destruction box. However, the addition of this region to KD (YFP:ΔPBD) does 
lower the expression level compared to KD on its own (YFP:KD; Figure 3-22). 
Similarly, the addition of this region (i.e. ΔKD+PBD) to PBD431 (YFP:ΔKD) also 
lowers the expression level compared to PBD431 on its own (YFP: PBD431; Figure 3-
22). The high levels of YFP:ΔKD+PBD could be explained by its inaccessibility to 
the degradation machinery when localised in the nucleus seen in Figure 3-21. 
However, this is yet to be directly proved.   
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Figure 3-22 Western blots of all YFP:TbPLK fusion proteins. Whole cell extracts (1 x 106 
cells/sample) of PCF cells induced with 1 µg ml-1 tetracycline to express N-terminal YFP-tagged 
TbPLK fusion proteins (as indicated) for 10 h were analysed simultaneously via Western blotting 
and probed with α-GFP to allow comparison of expression levels of YFP:TbPLK variants. Western 
blots were also probed with α-EF-1α as a loading control. Right panels – α-GFP stained blot ~5 x 
longer exposed.   
3.7 Discussion 
The repeatable growth and cell cycle phenotypes that were generated following 
the expression of WT TbPLK and its kinase dead version (Hammarton et al. 2007; 
Yu et al. 2012) provided grounds by which the in vivo activity of TbPLK variants 
could be assayed in PCF cells, albeit indirectly. This has allowed pertinent 
questions to be asked addressing the regulatory mechanisms by which this 
essential cell cycle kinase’s functions are controlled. The kinase domain of 
TbPLK is typical of any serine/threonine kinase domain, allowing the hypothesis 
that this domain is activated and inactivated in modes similar to its homologues. 
Indeed, the conserved threonine of the T-loop, T198 (T210 in human Plk1), was 
found to be essential for TbPLK kinase activity. Mutating this residue to alanine 
rendered the kinase inactive in vitro and in vivo. On the other hand, mutating it 
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to aspartic acid maintained the kinase active in vivo and in vitro, although the 
activity was not as strong as for WT TbPLK in vitro. The in vivo results here are 
in agreement with Yu et al (Yu et al. 2012). The difference in the extent of 
kinase activity between the WT and T198D mutant in vitro is in agreement with 
previous unpublished studies carried out in the Hammarton lab (May 2011) where 
similar experiments were performed. In vivo, no difference in the intensity of 
the expression phenotype is seen with the T198D mutation compared to WT 
protein and could be explained by the expressed WT kinase having reached the 
threshold of its kinase activity. An important experiment that needs to be done 
is testing the kinase activity of these (and all other TbPLK variants) expressed 
proteins via immuno-precipitation and subjecting the pulled down proteins to in 
vitro kinase assays. This would allow a direct comparison to be made between 
the activity levels of the different TbPLK variants.   
Phosphorylation of T202 in TbPLK was shown to be just as essential as that of 
T198 for TbPLK activity in PCF parasites (Yu et al. 2012). Its corresponding 
residue in humans, T214, was found to be phosphorylated only at certain times 
during mitosis - it was found to be dephosphorylated after silencing of the 
spindle checkpoint in metaphase (Dulla et al. 2010). This suggested that this 
phosphorylation site may have functions other than regulating Plk1 activity 
which could also be conserved in T. brucei. Indeed, this threonine was found to 
be phosphorylated in other organisms too (Wind et al. 2002; Kelm et al. 2002; 
Dulla et al. 2010). Therefore, one of the aims of this study was to verify the 
essentiality of T202 for TbPLK activity and compare it with that of T198 
phosphorylation. 
Mutating T202 to alanine, aspartic acid or glutamic acid inactivated the kinase in 
vivo and in vitro in ways which could not be fully overcome by coupling these 
mutations with T198D. It is possible that, in this instance, the mutation to 
aspartic acid or glutamic acid failed to mimic phosphorylation, a phenomenon 
which has been reported elsewhere (Littlepage et al. 2002). The structural 
environment of this residue could prevent this mutation from mimicking 
phosphorylation. In humans, T214 is part of the P+1 loop which appears to be 
conserved, sequence-wise, in T. brucei. It has been reported that this residue in 
human Plk1 rotates outward in inactive kinases relative from the position of the 
corresponding residue in active kinase structures, preventing it from forming a 
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hydrogen bond with Lys178 from the catalytic loop, an interaction known to be 
conserved in the active states of Ser/Thr kinases (e.g., Thr201 and Lys168 in 
PKA) (Kothe et al. 2007; Krupa et al. 2004). Therefore, in TbPLK, mutating this 
residue could prevent this hydrogen bonding from taking place, thus preventing 
the kinase from being activated. This is, of course, assuming that the kinase 
domain of TbPLK assumes a structure similar to that of human Plk1. Additionally, 
T202 was not detected as a phosphosite in the only phosphoproteomic study in 
PCF parasites (Urbaniak et al. 2013). Further work needs to be done to settle the 
importance of T202 phosphorylation for TbPLK activity. It is possible that 
phosphoproteomic studies could miss important residues that are phosphorylated 
at specific stages of the cell. The phosphosites of pulled-down endogenous 
TbPLK in synchronised cells could be mapped, thus allowing the identification of 
important regulatory residues at various stages of the cell cycle, which could 
shed light on whether T202 really is an important phosphorylation site. 
Ultimately, a solved crystal structure of active TbPLK and TbPLK T198 and/or 
T202 mutants would provide clearer solutions to resolve this matter. 
The PBD has been shown to be essential for the spatial regulation of PLK 
activities (section 3.3.5). Expressed YFP-tagged WT TbPLK in this study has been 
shown to display a localisation that is consistent with it being dynamic 
throughout the cell cycle, in agreement with the findings of de Graffenried’s 
group (Ikeda & de Graffenried 2012; Lozano-Núñez et al. 2013). YFP-tagged WT 
TbPLK appeared to concentrate around the bilobe region (encompassing basal 
bodies, bilobe, FPC and FAZ; although further co-localisation studies would be 
required to confirm this). This was found to be the case in all full length TbPLK 
T198/T202 mutants, including the ones which inactivated the kinase, suggesting 
that TbPLK kinase activity by itself is unlikely to be essential for its localisation. 
Without a detailed analysis of the relationship between the localisations 
observed and cell cycle stages, it is difficult to identify the smaller details of 
localisation defects following TbPLK mutations. Therefore, it is possible that 
minor localisation defects following TbPLK kinase inactivation have gone 
unnoticed in this study. Such detailed studies enabled de Graffenried’s group to 
observe that inhibited kinase failed to localise to the FAZ following karyokinesis 
(Lozano-Núñez et al. 2013). Also, the fact that these proteins are expressed 
could generate artefacts due to deregulated binding to substrates/binding 
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proteins or other proteins TbPLK wouldn’t necessarily bind to. Even taking these 
caveats into consideration, the significant localisation defects observed upon 
expressing the various truncation mutants of TbPLK have still allowed to build a 
picture of how its domains mediate its localisation. 
The putative His-Lys pincer does not seem to be important for TbPLK 
localisation. This study complements those done by Li’s group (Yu et al. 2012) 
where the PBD of TbPLK was found to possess none of the other conserved 
residues found in other organisms – W414 and L490 in human Plk1. Indeed, the 
putative His and Lys residues of TbPLK were also not found to align well with the 
conserved His-Lys pincer in other organisms (Yu et al. 2012). These residues are 
essential for PBD binding to phospho-peptides (Elia, Rellos, et al. 2003; Elia, 
Cantley, et al. 2003; Yun et al. 2009). Could it be that TbPLK PBD does not bind 
phospho-peptides like PLK1 proteins do in yeast and metazoans? This could 
explain the non-mitotic, divergent function and localisation of TbPLK. The 
YFP:PBD431 as a whole was, however, found to be required for TbPLK 
localisation. YFP:PBD431 appeared to concentrate in the bilobe area and the 
flagellum similar to the full length proteins. YFP:KD, in the absence of the PBD, 
was unable to localise anywhere and remained cytoplasmic even though it was 
still able to function like the WT full length kinase, as evidenced by the similar 
expression phenotypes obtained.  
Further truncation studies shed light on more intriguing aspects of TbPLK domain 
functions which includes a putative bi-partite NLS (Sun & Wang 2011) and a 
putative destruction box in the IDL region that is not included in the KD and 
PBD431 constructs. Addition of this IDL region to the KD (ΔPBD) sequestered it 
into the nucleus. Expression of YFP:ΔPBD protein did not display a kinase active 
phenotype, suggesting the requirement for TbPLK localisation outside the 
nucleus (in the bilobe area and FAZ) to mediate its functions. The localisation of 
YFP:ΔPBD to the nucleus could be explained by the inclusion of the NLS in this 
truncated protein. This was supported by the fact that this IDL region 
(YFP:ΔKD+PBD) on its own also localised in the nucleus, albeit in discrete 
puncta, confirming work by Yu et al (Yu et al. 2012).  
The power of the PBD in regulating TbPLK localisation can be found in the fact 
that addition of the PBD431 to this IDL region (YFP:ΔKD) altered its nuclear 
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localisation to a cytoplasmic one, sometimes concentrating it to the bi-lobe 
region, although it did not completely restore the localisation observed for just 
YFP:PBD431. The reason for the IDL region+PBD431 (YFP:ΔKD) construct for not 
localising exactly like YFP:PBD431 could be due to the tension between the 
competing localising effects of the IDL region (nucleus) and the PBD (bilobe 
region and FAZ). In all, it can be concluded that the PBD is required for TbPLK 
localisation. However, owing to the expressed PBD431’s inability to prevent the 
endogenous TbPLK from accessing its substrates in vivo, it can also be 
considered that there is an additional need for an active kinase domain to allow 
TbPLK to specifically bind its substrates, which is in agreement with the 
observations made by Li’s group (Yu et al. 2012). However, this conclusion 
cannot be conclusively drawn, as it cannot be assumed that the expressed 
YFP:TbPLK proteins are exclusively binding to their physiological substrates. 
Such joint importance of the kinase domain and the PBD in PLK substrate binding 
has been shown previously (Lin et al. 2000); the chemical and structural features 
of both the catalytic and C-terminal domains of Plk1 were required for binding 
to the substrate in question – GRASP65.  
It is intriguing to note that a protein which so far has not shown to localise in the 
nucleus and have any nuclear functions should possess a functional NLS. TbPLK 
mutated to feature alanine, instead of the basic residues which characterises 
the NLS, was still able to rescue endogenous TbPLK depletion by RNAi (Yu et al. 
2012). Expression of nuclear localised truncations (ΔPBD and ΔKD+PBD) in this 
study displayed no growth or cell cycle defects in PCF cells. Altogether, the 
studies done in this project indicate that the NLS plays no role in TbPLK 
function. 
In this study, it has also been shown that the IDL region which possesses the 
putative destruction box, does play a role in TbPLK expression levels. This is in 
keeping with what is already known of PLK1 in other organisms and other cell 
cycle kinases (Lindon & Pines 2004; Archambault & Glover 2009; Liu et al. 2012). 
This, therefore, indicates that TbPLK proteins may be targeted for proteasomal 
degradation. Further experiments could be done to further confirm this 
hypothesis. The arginine and leucine residues of the destruction box could be 
mutated and then expressed from the endogenous locus and compared with the 
expression levels of WT proteins. 
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Future experiments that need to be done, to consolidate the findings described 
in this chapter, have been described in a number of places in the results section 
and above. In addition to these, a few more experiments are also required. It is 
possible that the phenotypes seen following the ectopic expression of proteins 
described here were due to their over-expression. Western blot analyses of 
lysates of WT and TbPLK variants expressing cell lines, using α-TbPLK antibodies, 
would be required to investigate if these proteins were expressed in levels above 
that of the endogenous protein. Also, unless otherwise mentioned, results 
obtained from only one clone have been described for the in vivo expression 
experiments. When conducting further experiments, second clones, which have 
already been generated, will also need to be analysed to demonstrate 
reproducibility.  
TbPLK has been shown to be divergent in its functions but yet, in many ways, 
conserved in the means by which it is regulated. Future studies, characterising 
more of its substrates and how they come to interact with TbPLK would shed 
light on how this kinase mediates its functions in an environment so different 
from its homologues in yeast and metazoans.   
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4 Regulation of T. brucei Polo-like kinase 
in bloodstream form parasites 
4.1 TbPLK in T. brucei BSF parasites  
Previous work carried out by the Hammarton lab has shown that knockdown of 
TbPLK via RNAi in the BSF generates defects in cytokinesis (Hammarton, Kramer, 
Tetley, Boshart, & Mottram, 2007). A rise in 2N2K cells was noted, many of 
which were blocked midway in furrow ingression. No other studies on the role of 
TbPLK in BSF parasites have been published. This difference in phenotypes 
between PCF (section 3.4.1) and BSF parasites could be a result of the 
differences in cell cycle events between the two life cycle stages (section 
1.3.2). In terms of understanding TbPLK regulation in BSF parasites, to date no 
studies have yet been conducted.   
4.2 Project aims 
The aims of this project were to characterise the regulation of TbPLK in BSF 
cells. The questions asked here are similar to those that were asked using PCF 
cells in Chapter 3. In this chapter, how the following domains regulated the 
activity of TbPLK was investigated:  
 the Polo-box domain  
 the residue T198 in the T-loop  
4.3 Results 
4.3.1 TbPLK expression 
The first step was to investigate whether the expression of TbPLK in its kinase 
active (WT) and dead (TbPLK N169A) forms would generate differential cell 
cycle phenotypes compared to those observed with PCF parasites (section 3.6.1). 
In order to do this, the pLew100v5 (kind gift from George Cross; 
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http://tryps.rockefeller.edu/trypsru2 _plasmids.html) plasmid, which allows 
tetracycline inducible expression of genes of interest from the rRNA spacer 
region, was modified to allow N-terminal tagging of the TbPLK proteins with a 
YFP epitope. First, YFP was sub-cloned from pHG329 (gift from Chris de 
Graffenried) as a HindIII-BamHI fragment into the same sites in pLew100v5 
(section 2.3.2.6 and 2.3.2.7 for cloning details). Then a multiple cloning site was 
added at the 3’ end of YFP to include ApaII, XhoI and HpaI restriction sites 
(section 2.3.2.8). TbPLK variants were then cloned as BamHI-XhoI fragments into 
this modified vector (now pHG399; section 2.3.2.7; Figure 4-1). These constructs 
were then linearised and transfected into BSF 427 pLew13 pLew90 (Hygr and 
Neor; Table 2-3) which expresses the TetR driven by a T7 promoter. The TetR 
binds to the operators (adjacent to the rRNA promoter which drives expression 
of the gene of interest) preventing the expression of the gene of interest until 
the addition of tetracycline.  
 
Figure 4-1 Plasmid map of pHG399. pHG316 (originally pLew100v5, see Table 2-5 for details; 
kind gift from George Cross, http://tryps.rockefeller.edu/trypsru2 _plasmids.html) was modified 
to allow expression of N-terminal YFP-tagged proteins and to introduce a multiple cloning site 
(MCS) featuring the restriction sites ApaII, XhoI and HpaI. Amp – ampicillin resistance cassette. 
rRNA – ribosomal RNA spacer. Ble – Bleomycin resistance cassette. GPEET SAS – GPEET splice-
acceptor site. ACT – Actin. Ald – Aldolase. For transfection, the constructs were linearised by 
digestion with with NotI (section 2.3.2.4). 
Expression of YFP:TbPLK in BSF cells appears to give slight growth defects but 
without marked changes in cell cycle progression (Figure 4-2A). On the other 
hand, expression the kinase dead YFP:TbPLK N169A did not give strong 
phenotypic changes either in growth or cell cycle progression of BSF cells (Figure 
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4-2B). Western blotting confirmed that the proteins were expressed at 
detectable amounts as early as 18 h post-induction. For the loading control, a 
cross-reacting band which appeared at about 35 kDa was used instead of the one 
representing EF-1α at about 50 kDa. This was because the size of EF-1α was 
mistakenly thought to be 35 kDa during this experiment. After transfer during 
western blotting, the blotting membranes were often cut to allow separate 
incubation with different antibodies. In this experiment, the membrane was cut 
in such a way that proteins above 45 kDa in size, including EF-1α, were excluded 
for incubation with EF-1α primary antibody. Therefore, it was not possible to 
employ the EF-1α as loading control here and will all need to be rectified in 
future repeat experiments. 
 
Figure 4-2 Expression of YFP-tagged TbPLK and TbPLK N169A in BSF cells. N-terminally YFP-
tagged TbPLK (A) and TbPLK N169A (B) were expressed in BSF T. brucei cells by the addition of 1 
µg ml-1 tetracycline (tet+) to the culture medium. Analyses of non-induced cells (tet-) have also 
been shown as controls. Cumulative growth curves (left panels of both sections) were generated 
and the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining 
of samples (right panels of both sections) were recorded at the indicated time points post 
addition of tetracycline to the induced samples. Western blots (middle panels of both sections) 
were performed on whole cell extracts (1 x 106 cells/sample) taken at 18 and 72 hrs post-
induction (t18 and t72, respectively) to detect expression of YFP:TbPLK/YFP:TbPLK N169A using an 
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α-GFP antibody. Western blots were also probed with α-EF-1α which generated a cross-reacting 
band at 35 kDa that has been used as the loading control. 
A second independent clone of each of these cell lines was also analysed and 
gave the same results (data not shown). However, the difference in phenotypes 
between the two cell lines was not considered to be marked enough to be 
exploited for use in an expression assay as was done with PCF parasites (section 
3.6.1). Efforts were then made to establish an RNAi complementation system 
instead as described below. 
4.3.2 TbPLK RNAi complementation 
The aim here was to determine how well the exogenous expression of TbPLK 
mutants was able to complement knockdown of endogenous TbPLK via RNAi. In 
order to knockdown endogenous TbPLK specifically without affecting expression 
of the exogenous TbPLK variants, the 3’ UTR of endogenous TbPLK was targeted 
via RNAi. Since the TbPLK variants that were expressed using pHG399, used the 
aldolase 3’ UTR, these exogenously expressed TbPLK variants were exempted 
from depletion via RNAi against the endogenous TbPLK 3’ UTR. Also, since the 
stem loop generating RNAi vector, p2T7ti:GFP (LaCount, Bruse, Hill, & Donelson, 
2000), was, like pHG399, bleomycin resistant, it was first modified to replace its 
bleomycin selective marker with a BSD resistance marker (see section 2.3.2.7 for 
cloning details) generating pHG456. This permitted transfection of the same cell 
line with both pHG456 and the modified expression vector pHG399 (section 
4.3.1).     
4.3.2.1 TbPLK knockdown via RNAi targeting its 3’ UTR 
The 549 bases, lying immediately downstream of the stop codon of the TbPLK 
gene, were cloned as a HindIII and BamHI fragment into pHG456 (section 
2.3.2.7). This construct (pHG457) was then linearised with EcoRV and 
transfected into BSF 427 pLew13 pLew90 cells. TbPLK RNAi was induced with 
tetracycline for 24 hours in three independent clones before the cell lines were 
tested for TbPLK knockdown using an α-TbPLK antibody (kind gift from de 
Graffenried's lab; Ikeda & de Graffenried, 2012). In Figure 4-3 it can be seen 
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that all three clones showed good levels of TbPLK knockdown. Clone 1 was then 
selected for further analysis and used for the complementation assay. 
 
Figure 4-3 Western blot analysis of TbPLK knockdown via RNAi of its 3’ UTR. The α-TbPLK 
antibody was used to probe Western blots of lysates of TbPLK 3’ UTR RNAi clones following 24 hrs 
induction with 1 µg ml-1 tetracycline (tet+). Lysates of non-induced cells (tet-) have also been 
included as controls. The cross-reacting band verifies equal loading of lysates.  
4.3.2.2 The RNAi complementation assay 
Previously, in order to investigate the role of TbPLK in BSF cells, RNAi targeting 
the 5’ end of endogenous TbPLK was used to knockdown the protein (Hammarton 
et al., 2007). Following RNAi induction, a rapid growth arrest was noted and a 
considerable increase in post-mitotic (2N2K) cells was observed. This 
accumulation of 2N2K cells suggested that cytokinesis was impaired by TbPLK 
RNAi. Further investigation of these 2N2K cells uncovered an increase in the 
proportion of furrowing 2N2K cells and concomitant decrease in the proportion 
of 2N2K cells which had completed furrow ingression but not abscission over 
time. Altogether, the data strongly suggested that furrow ingression is impaired 
when TbPLK is downregulated in bloodstream trypanosomes.  
This TbPLK RNAi cell line (TbPLK RNAi; Hammarton et al., 2007) and the newly 
generated 3’ UTR RNAi cell line (TbPLK 3’ UTR RNAi; section 4.3.2.1) were then 
compared to determine whether the new cell line acted as expected. The cell 
lines were also induced with three different concentrations of tetracycline (0.1 
µg ml-1, 1 µg ml-1 and 10 µg ml-1; Figure 4-4) in order to test for differences in 
intensities of knockdown which could affect the efficiency of complementation 
by the exogenously expressed TbPLK variants. Reducing or increasing the 
tetracycline concentration generated very small changes, if any at all, in the 
growth phenotypes of the cell lines (Figure 4-4A and B, top panels). Overall, 
TbPLK 3’ UTR RNAi did induce a cell death phenotype (Figure 4-4B). However, 
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the cells appear to grow, albeit at a slower rate, for the first 24 hours before 
their growth is arrested and the cell death phenotype becomes apparent (at 72 
hours), which is in contrast to the original TbPLK RNAi cell line for which the cell 
death phenotype is apparent within the first 24 hours following RNAi induction 
(Figure 4-4A). Despite the milder growth phenotype, the cell cycle defects 
generated by TbPLK 3’ UTR RNAi are comparable to those obtained with TbPLK 
RNAi (Figure 4-4A and B, bottom panels). Both cell lines demonstrate a rise in 
2N2K cells by 6 hours post-induction with a subsequent rise in “other” aberrant 
cell types. Western blot analysis of these cell lines is vital at this point to 
confirm TbPLK knockdown. However, repeated attempts to visualise TbPLK 
staining with the α-TbPLK antibody (as seen in Figure 4-3) on Western blots of 
lysates from the two TbPLK RNAi cell lines were unsuccessful. Nevertheless, the 
TbPLK 3’ UTR RNAi cell line was transfected with the vectors described in 
section 4.3.1 (for cloning details, see sections 2.3.2.6 and 2.3.2.7) to express 
YFP:TbPLK variants (this section, sections 4.3.2.3 and 4.3.2.4).  In these doubly 
transfected cell lines, addition of tetracycline should induce TbPLK 3’ UTR RNAi 
and the expression of YFP:TbPLK variants at the same time.  
First, YFP:TbPLK and YFP:TbPLK N169A were expressed in a TbPLK 3’ UTR RNAi 
background (Figure 4-4C and D, respectively). Expression of YFP:TbPLK, but not 
YFP:TbPLK N169A, was able to partially complement the growth defect induced 
by TbPLK knockdown. Analysis via Western blotting verified expression of these 
N-terminally YFP-tagged proteins. A slight, but not complete, alleviation of cell 
cycle defects was also observed with WT YFP:TbPLK expression (Figure 4-4C, 
middle panel) which was not the case with YFP:TbPLK N169A expression (Figure 
4-4D, middle panel) suggesting that it is the kinase activity of TbPLK and not the 
protein in general that is responsible for the complementation. Varying the 
concentration of tetracycline did not vary the amount of recombinant protein 
expressed and, subsequently, no variations in growth phenotypes were observed 
(Figure 4-4C and D, top panels). These observable differences, in the ability of 
YFP:TbPLK and kinase dead YFP:TbPLK N169A to complement TbPLK 3’ UTR 
RNAi, provided the basis by which the kinase activity of YFP:TbPLK variants 
could be tested. 
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Figure 4-4 Controls for the RNAi complementation assay in BSF cells. TbPLK was knocked down 
in T. brucei BSF cells via RNAi either targeting its 5’ end (A) or 3’ UTR (B). N-terminally YFP-
tagged TbPLK (C) and TbPLK N169A were also expressed in a TbPLK 3’ UTR RNAi background. All 
cell lines were induced with three different concentrations of tetracycline (tet; 0.1 µg ml-1, 1 µg 
ml-1 and 10 µg ml-1) which induced the RNAi and expression. Analyses of non-induced cells (tet-) 
are also shown as controls. Cumulative growth curves (top panel of each section) were generated 
for all cell lines and tetracycline concentrations. The numbers of nuclei (N) and kinetoplasts (K) 
in each cell (n ≥ 200) following DAPI staining of samples were recorded at the indicated time 
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points post addition of 1 µg ml-1 tetracycline to the induced samples (bottom panels (A,B); 
middle panels (C,D). Western blots were performed on whole cell extracts (1 x 106 cells/sample) 
taken at 18 h post addition of tetracycline to the induced samples for 3’ UTR TbPLK RNAi + 
YFP:TbPLK expression (C, bottom panel) and 3’ UTR TbPLK RNAi + YFP:TbPLK N196A expression 
(D, bottom panel).  
4.3.2.3 Role of the KD and PBD 
In order to investigate the importance of the PBD for TbPLK activity, a few 
TbPLK truncations (same as those described in Chapter 3 - KD, KD N169A PBD431, 
PBD431 H704A K706A and TbPLK H704A K706A) were expressed using the pHG399 
vector (section 4.3.1; for cloning details, see sections 2.3.2.6 and 2.3.2.7) in the 
TbPLK 3’ UTR RNAi background (Figure 4-5). Expression of YFP:KD, which 
entirely lacked the PBD and the IDL region, compounded the cell death 
phenotype instead of alleviating it (compare Figure 4-5A with Figure 4-4C). This 
was accompanied by a rise in aberrant cell types, especially 2N1K cells (20% of 
total cells counted at t18 post-induction). Since the expression of the kinase dead 
version of KD, YFP:KD N169A, did not have any effect on the background TbPLK 
3’ UTR RNAi phenotypes (Figure 4-5B), this suggests that it is the kinase activity 
of KD rather than the protein itself that is responsible for the cell death 
phenotype. The dominant negative phenotype could possibly be attributed to 
unregulated kinase activity of the expressed YFP:KD, which would suggest that 
the PBD is required for the negative regulation of TbPLK kinase activity. The rise 
in 2N1K cells seen with YFP:KD expression in the TbPLK 3’ UTR RNAi background 
is similar to what is seen with YFP:TbPLK expression in WT background PCF 
parasites (Hammarton et al., 2007 and Chapter 3). This suggests defects in 
kinetoplast segregation putatively linking TbPLK function to kinetoplast 
duplication in BSF cells.  
Expression of YFP:PBD431 or YFP:PBD431 H704A K706A, which lack the kinase 
domain were, unsurprisingly, unable to complement the TbPLK 3’ UTR RNAi and 
did not compound the severity of the phenotype either (Figure 4-5C and D). 
When YFP:TbPLK H704A K706A was expressed in the TbPLK 3’ UTR RNAi 
background, some alleviation of growth and cell cycle defects were seen 
although not to the same level as with YFP:TbPLK (Figures 4-5E and 4-4C). It is 
possible that the levels of YFP:TbPLK H704A K706A expression is lower than that 
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of YFP:TbPLK explaining the difference in phenotypes. A western blot allowing 
direct comparison of expression levels would help clarify this. If the two proteins 
are expressed at same levels, then these results suggest that the putative His-
Lys pincer might play a role in regulating TbPLK activity in BSF cells.
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Figure 4-5 Analysis of the roles of the kinase domain and the PBD of TbPLK in BSF cells using an 
RNAi complementation assay. N-terminally YFP-tagged KD (A), KD N169A (B), PBD431 (C), PBD431 
H704A K706A (D) and TbPLK H704A K706A (E) were expressed in BSF T. brucei cells, in a TbPLK 3’ 
UTR RNAi background, with the addition of 1 µg ml-1 tetracycline (tet+) to the culture medium. 
Analyses of non-induced cells (tet-) have also been shown as controls. Cumulative growth curves 
(left panel of each section) were generated and the numbers of nuclei (N) and kinetoplasts (K) in 
each cell (n ≥ 200) following DAPI staining of samples (right panel of each section) were recorded 
at the indicated time points post addition of tetracycline to the induced samples. Western blots 
(middle panel of each section) were performed on whole cell extracts (1 x 106 cells/sample) 
taken at 18 h post addition of tetracycline to the induced samples (t18) to detect expression of 
YFP:KD, YFP:KD N169A, YFP:PBD431, YFP:PBD431, YFP:H704A K706A and YFP:TbPLK H704A K706A 
using an α-GFP antibody. Western blots were also probed with α-EF-1α as a loading control.  
A second independent clone of all the cell lines mentioned in this section was 
also analysed and gave the same phenotypes (data not shown). 
4.3.2.4 Role of T198 
In order to investigate the role of T198 in regulating TbPLK activity, YFP:TbPLK 
with its T198 mutated to the non-phosphorylatable alanine/valine was expressed 
in a TbPLK 3’ UTR RNAi background. Neither recombinant protein was able to 
alleviate the growth and cell cycle defects generated by the TbPLK RNAi (Figure 
4-6). Second clones of these two cell lines were also analysed which also 
demonstrated similar phenotypes upon induction (data not shown). Altogether, 
the data suggest that phosphorylation at this residue is essential for activating 
TbPLK kinase activity. In order to provide further evidence for this conclusion, 
numerous attempts were made to generate cell lines expressing YFP:TbPLK 
T198D, but were unsuccessful. Mutating T198 to aspartic acid would have 
mimicked phosphorylation. If it was able to complement TbPLK 3’ UTR RNAi at 
the levels of WT YFP:TbPLK, this could have revealed the importance of T198 
phosphorylation for TbPLK activity. 
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Figure 4-6 Analysis of the role of the TbPLK T198 residue in BSF cells using an RNAi 
complementation assay. N-terminally YFP-tagged TbPLK T198A and TbPLK T198V were expressed 
in BSF T. brucei cells, in a TbPLK 3’ UTR RNAi background, with the addition of 1 µg ml-1 
tetracycline (tet+) to the culture medium. Analyses of non-induced cells (tet-) have also been 
shown as controls. Cumulative growth curves were generated (left panels of both sections) and 
the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining (right 
panels of both sections) of samples were recorded at the indicated time points post addition of 
tetracycline to the induced samples. Western blots (middle panels of both sections) were 
performed on whole cell extracts (1 x 106 cells/sample) taken at 18 h post addition of 
tetracycline to the induced samples (t18) to detect expression of YFP:TbPLK T198A and 
YFP:TbPLK T198V using an α-GFP antibody. Western blots were also probed with α-EF-1α as a 
loading control. 
4.4 Discussion 
The work described in this chapter sheds some light on how TbPLK activity is 
regulated in BSF trypanosomes. Expression of YFP:TbPLK did generate a small 
growth defect in BSF parasites however not to the extent observed in PCF cells 
(section 3.6.1; Hammarton et al., 2007; Yu, Liu, & Li, 2012). Since the 
expression of YFP:TbPLK was robust (Figure 4-2), this suggests differences in how 
TbPLK is regulated in addition to differences already observed in the functions of 
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TbPLK between the two life-cycle stages (Hammarton et al., 2007; Chapter 3). 
The smaller extent of phenotypic changes following expression of YFP:TbPLK 
could indicate that its activity is tightly regulated. On the other hand, it could 
also mean that the downstream pathways are not as responsive to extra TbPLK 
activity. Indeed, the toxicity of expressing just the kinase domain, even in a 
TbPLK RNAi background, suggests that the PBD and the IDL, which are not 
present in the KD protein described here, could be required to negatively 
regulate TbPLK activity. The rise in 2N1K cells when YFP:KD was expressed 
putatively links TbPLK function to kinetoplast duplication reflecting what is 
already known in PCF cells (Ikeda & de Graffenried, 2012). TbPLK knockdown is 
known to inhibit ingression of the furrow in BSF cells during cytokinesis 
(Hammarton et al., 2007). Altogether, there seems to be an indication that 
proper kinetoplast duplication is required for furrow ingression during 
cytokinesis.   
The TbPLK RNAi cell line generated in this study, which targeted the 3’ UTR of 
TbPLK, was confirmed to knockdown TbPLK and generated cell cycle defects 
which were comparable to that of TbPLK RNAi cell line which targeted the 
coding sequence (Hammarton et al., 2007), despite a milder growth phenotype. 
This suggested that targeting the 3’ UTR of TbPLK is enough to silence the gene. 
However, expression of YFP:TbPLK in this RNAi background did not fully abrogate 
the growth and cell cycle phenotypes. The inability of YFP:TbPLK to fully 
complement TbPLK RNAi could be due to off-target effects or effects on the 
expression of genes immediately downstream of TbPLK. However, this strategy 
has previously been successfully used in PCF cells (Yu et al., 2012). The problem 
faced with implementing this strategy in BSF cells could be due to the 
differences in gene regulation between the two life-cycle stages. Nonetheless, 
the partial ability of YFP:TbPLK to complement TbPLK RNAi and the inability of 
YFP:TbPLK N169A to do the same, provided the basis by which the kinase 
activity of TbPLK mutants could be tested.        
The inability of YFP:TbPLK H704A K706A to complement TbPLK RNAi as well as 
YFP:TbPLK does suggests that these residues are partially important for TbPLK 
activity. This is in contrast to conclusions drawn in PCF parasites (Chapter 3) 
again indicating differential regulation of TbPLK between the two life-cycle 
stages. Further work is essential to investigate this further. It is possible that the 
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expression levels of YFP:TbPLK H704A K706A is lower than that of YFP:TbPLK. In 
future experiments, the expression levels of these, and the rest of the proteins, 
in addition to endogenous TbPLK, will need to be verified. Imaging studies 
dissecting the localisation of YFP:TbPLK H704A K706A would help answer if this 
putative pincer is truly essential for TbPLK localisation and substrate binding. 
T198 appears to play the same regulatory role as it does in PCF parasites and in 
other organisms (Chapter 3). Preventing phosphorylation at T198 of expressed 
YFP:TbPLK by mutating it to alanine or valine hinders the ability of the 
recombinant protein to reverse the effects of TbPLK RNAi. Additional studies 
with T198 mutated to aspartic acid which mimics phosphorylation would have 
been useful in confirming these conclusions. The inability in generating BSF cell 
lines which express YFP:TbPLK T198D could possibly be due to the toxicity of 
deregulated, hyperactive TbPLK. Despite tight regulation of these inducible 
expression vectors, perhaps the toxicity of YFP:TbPLK T198D could explain why 
attempts to generate these cell lines were unsuccessful.  
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5 RNAi-based Screening for Protein 
Kinases Involved in the T. brucei Cell 
Cycle 
5.1 RNAi – discovery and mechanism 
The discovery that double-stranded (ds) RNA was able to disrupt gene function in 
C. elegans (Fire et al., 1998) has revolutionized the way in which loss-of-
function studies can be performed. This process, termed RNA interference 
(RNAi), involves dsRNA being cleaved to generate short interfering (si) RNAs, 
which then direct endonucleases towards the cognate mRNAs leading to their 
degradation and, consequently, gene silencing (Hammond, Bernstein, Beach, & 
Hannon, 2000; Zamore, Tuschl, Sharp, & Bartel, 2000). For organisms which 
possess the RNAi machinery, it is an essential part of post-transcriptional gene 
regulation and defence against viruses and mobile elements (Ding, Li, Lu, Li, & 
Li, 2004; Ghildiyal & Zamore, 2009; Schütz & Sarnow, 2006; Umbach & Cullen, 
2009).  
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Figure 5-1 Schematic representing RNAi mechanism. Long dsRNA is cleaved into duplex siRNA by 
DICER endonuclease. The anti-sense strand of the siRNA (now known as guide RNA) along with 
AGO form the catalytic engine of the RISC complex which binds cognate mRNA and cleaves it. 
The machinery responsible for driving RNA interference (RNAi) is now well 
defined (Figure 5-1). The common minimal machinery as understood from 
different model organisms includes: 1) a DICER endonuclease of the RNAse III 
family which cleaves long dsRNAs into duplex siRNAs (Bernstein, Caudy, 
Hammond, & Hannon, 2001); 2) a DICER cofactor which enables siRNA biogenesis 
and loading of one of the strands of the siRNA duplex (now termed as the guide 
RNA; as opposed to passenger strand which is discarded) to 3) an Argonaute 
(AGO) “slicer” endonuclease (Meister, 2013). The AGO-siRNA complex forms the 
catalytic engine of the RNA-induced silencing complex (RISC; Hammond et al., 
2000). Through complementary binding of the single-stranded (ss) guide siRNA, 
RISC cleaves the target mRNA thus silencing it (Elbashir, Lendeckel, & Tuschl, 
2001; Elbashir, Martinez, Patkaniowska, Lendeckel, & Tuschl, 2001). 
The discovery of RNAi has enabled gene function studies in a number of 
organisms and has significantly contributed towards the understanding of their 
biology. The relative ease by which RNAi can be induced has allowed the 
interrogation of gene functions at global scales (Kamath et al., 2003; Mohr, 
Bakal, & Perrimon, 2010). Genome-wide RNAi libraries which efficiently target 
almost every gene are now available for studying model cells and organisms such 
as Drosophila, C. elegans and humans. A variety of biological processes from 
cell-growth and viability (Boutros et al., 2004; Luo et al., 2008; Silva et al., 
2008), signalling pathways (Bakal et al., 2008; Brown, 2005; Nybakken, Vokes, 
Lin, McMahon, & Perrimon, 2005; Z. Tu et al., 2009; Xu et al., 2007) to pathogen 
infections (Agaisse et al., 2005; Karlas et al., 2010; Krishnan et al., 2008; 
Sessions et al., 2009) have been focussed on, not to mention, the cell division 
cycle. High throughput RNAi studies which sought to screen for cell cycle 
regulators in C. elegans, Drosophila and human cells shall be reviewed in the 
next section. 
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5.2 RNAi-based cell cycle screens in other model 
organisms 
The first ever large-scale study screening for cell cycle regulators demonstrated 
the huge amount of effort demanded by such projects. Initial studies restricted 
the screens to a specific cohort of genes reflecting the limitations of the RNAi 
technologies that were available then. Gönczy et al., screened about 96 % of 
predicted ORFs (2232 genes) on chromosome 3 of C. elegans to identify genes 
involved in cell cycle regulation (Gönczy et al., 2000). RNAi was induced by 
micro-injecting dsRNAs into wild-type hermaphrodites. The resulting embryos 
were then analysed via time-lapsed DIC assays and a progeny test. Due to 
decreasing potency of combining dsRNAs (when mixed with increasing volumes of 
different dsRNAs that were known to not cause any observable phenotypes), as 
first experimentally determined in the study, the genes could only be knocked 
down in pairs. This required about 1100 individual experiments, in addition to 
further analyses of “hits” (dsRNAs which gave a phenotype that was detectable 
via the DIC assay). 133 genes needed for the C. elegans cell cycle were thus 
identified, of which 122 genes had never been studied in the organism before, 
demonstrating the power of such studies. In another such study, the protein 
kinase (PK) gene family, was focussed on (Bettencourt-Dias et al., 2004). Again, 
RNAi was the tool of choice. Cell cycle progression determined via DNA content 
analysis using flow cytometry and the quantification of 20 other parameters 
were used to identify kinases required for cell cycle progression and/or mitosis 
in S2 Drosophila cells. Knockdown of a third of the kinome (80/228) was found to 
induce cell cycle defects such as an increase in the proportion of cells in G1, a 
rise in aneuploid cells, an increase in the proportion of cells in G2/M phase and a 
rise in polyploid cells, and the observation was made that compromising 
extracellular stress response pathways can have secondary effects on cell cycle 
progression. Later on, such studies were extended to a genome-wide level in C. 
elegans (Sönnichsen et al., 2005) and Drosophila (Björklund et al., 2006).  
Other efforts in screening for regulators of cell cycle progression have 
concentrated on specific stages of the cell cycle. In one study, factors involved 
in the formation, maintenance and resolution of the Drosophila cytokinetic 
bridge were identified using an RNAi library targeting 7216 conserved genes. This 
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meant that the phenotypic analyses were less complex and more focussed than 
the previous studies described above, where a myriad of parameters were used 
to track a number of types of phenotypes, as many aspects of the cell cycle 
were investigated (Echard, Hickson, Foley, & O’Farrell, 2004). Eggert et al. 
combined genome-wide RNAi screening with that of a library of 51,000 small 
molecules, which included a mixture of commercial “drug-like” molecules, 
natural products and natural product-like libraries to look specifically for genes 
involved in Drosophila cytokinesis and small molecules which specifically 
inhibited them with tight temporal control (Eggert et al., 2004). This time, 
analyses were automated thus reducing the effort required for phenotypic 
analyses. Also, by performing such chemical genetic and genome-wide RNA 
interference screens in parallel, a richer dataset was obtained which allowed a 
systematic dissection of cytokinesis pathways aided by known small molecule 
inhibitors of them. 214 genes were found to be important for cytokinesis of 
which 25 had never been characterised before.  
Automation, again, enabled phenotyping whilst conducting another genome-wide 
siRNA screen in humans (Mukherji et al., 2006). 24,373 predicted human genes 
and 500 “druggable” genes (predominantly enzymes and receptors) were 
targeted in the well-studied osteosarcoma U2OS cells. High-content automated 
single-cell fluorescence microscopy was used to acquire images of the complete 
surface of wells in which the cells were cultured, which were then segmented to 
define DAPI-stained nuclei. Fluorescence intensities, area, and the perimeter-to-
area ratio (PAR), a geometric measure of nuclear shape, were calculated for all 
nuclei and eight descriptors were computed for each sample. 4.7 % genes (1,152 
genes) of the genome were found to alter cell cycle progression, 57 of which had 
never been identified before. Another human genome-wide siRNA screen 
employed HeLa cells and a novel strategy for generating the siRNA library 
(Kittler et al., 2007). This time, endoribonuclease-prepared siRNAs (esiRNAs) 
were used. By enzymatically processing long dsRNAs, a heterogeneous pool of 
siRNAs was generated, which are purported to be more effective in knocking 
down mRNAs than single long dsRNAs (Buchholz, Kittler, Slabicki, & Theis, 2006). 
17,828 genes were targeted and hundreds of genes were identified, which when 
knocked down, caused cell cycle arrest and/or cell division defects. High-
throughput DNA content analysis was employed to initially detect cell cycle 
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arrest and altered ploidy phenotypes and hits were further analysed by 
fluorescence imaging, flow cytometry and time-lapse video 
microscopy. However, there was only 10 % overlap with the genes that were 
identified in the similar study done previously (Mukherji et al., 2006) highlighting 
the problem of the lack of reproducibility which has undermined the reliability 
of such screens. Here, esiRNAs were thought to reduce off-target effects 12-fold 
compared with chemically synthesised RNA suggesting that the data obtained by 
Mukherji et. al is marred by false-positives and false negatives. This poor overlap 
could also be due to poor comparability in the end-point analyses used. 
Problems with reproducibility also seemed to be the case for another genome-
wide RNAi screen done in HeLa cells where mitotic phenotypes were exclusively 
searched for in order to identify candidate genes involved in key mitotic 
processes such as restructuring and segregation of mitotic chromosomes that 
were yet to be discovered (Neumann et al., 2010). Here, ~21,000 genes were 
targeted by multiple siRNAs in cells with fluorescently labelled chromosomes. A 
large dataset of ~190,000 time-lapse movies was generated, which was then 
subjected to computational image processing to quantify about 200 parameters 
in nuclear morphology and, subsequently, to classify phenotypes into 16 
morphological classes thereby identifying 1,249 genes as potential mitotic hits. 
However, overlap of validated hits with other screens ranged from just 6-36 % 
which was attributed to poor comparability. This required following up the 
initial screen with a huge amount of further screens and analyses to eliminate 
false positives and negatives leaving only 572 genes that were confidently 
validated as mitotic genes.  
Similar problems with false positives were also reported in the genome-wide 
RNAi screen performed in S2 Drosophila cells (Björklund et al., 2006) which 
initiated a much needed comparison study to investigate the reasons behind 
these problems (Guest et al., 2011). Here, results from the two screens done in 
Drosophila (Bettencourt-Dias et al., 2004; Björklund et al., 2006) were compared 
and only 24 genes were identified in both screens. An independent RNAi screen 
was then conducted targeting genes which were identified as potential cell cycle 
regulators with the aid of a virtual protein interaction network. The results 
confirmed many of the original phenotypes but also revealed many likely false 
positives and false negatives from the previous two screens making the case for 
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the use of such additional datasets in confirming true hits in the future. Another 
study made the case for supplementing screens with bioinformatics-based 
methods to help reduce off-target effects (Sigoillot et al., 2012).  
Creative use of such genome-wide RNAi libraries has also been used to deliver 
answers regarding pathways regulating specific stages of the cell cycle (or any 
other cellular process of interest) such as centriole duplication and mitotic peri-
centriolar material recruitment (Dobbelaere et al., 2008), alternative splicing of 
mRNAs (Q. Wang & Silver, 2010), the DNA damage response network (Kondo & 
Perrimon, 2011), cell proliferation over time (Zhang et al., 2011) or promotion 
of developmentally programmed cell cycle quiescence (Roy et al., 2014). 
Altogether, these screens have hugely contributed towards the current 
understanding of cell cycle regulation. The power of high-throughput screens lies 
in the fact that many novel genes were assigned functions. This provide starting 
points by which, the current understanding of the complex interacting network, 
required for successfully promoting cell cycle progression, can be further 
enriched. 
5.3 RNA interference in T. brucei 
Around the same time when RNAi was discovered in C. elegans (Fire et al., 
1998), Ngô and colleagues serendipitously discovered a similar phenomenon in T. 
brucei. In vivo expression of dsRNA of the α-tubulin mRNA 5′ untranslated region 
led to rapid degradation of α-tubulin mRNA preventing the cells from undergoing 
cytokinesis (Ngô, Tschudi, Gull, & Ullu, 1998). T. brucei, T. congolense and 
Leishmania braziliensis are kinetoplastids for which functional RNAi pathways 
have been described so far (Kolev, Tschudi, & Ullu, 2011). With the publication 
of its genome (Berriman et al., 2005) and its amenability to genetic 
manipulation such as RNAi, T. brucei has taken centre stage in developing our 
understanding of kinetoplastid biology. 
T. brucei features two DICER-like proteins (TbDCL1 and TbDCL2; Patrick et al., 
2009; Huafang Shi, Tschudi, & Ullu, 2006), one AGO homologue (TbAGO1; 
Durand-Dubief & Bastin, 2003; Huafang Shi, Djikeng, Tschudi, & Ullu, 2004) and 
two RNAi interference factors (TbRIF4 and TbRIF5; Barnes, Shi, Kolev, Tschudi, & 
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Ullu, 2012). TbDCL1 is cytoplasmic (Huafang Shi et al., 2006) whilst TbDCL2 is 
nuclear (Patrick et al., 2009). Both proteins feature RNase III motifs, bind 
dsRNAs and contribute towards the generation of siRNAs; the latest model 
implicates TbDCL2 in fuelling the T. brucei nuclear RNAi pathway and TbDCL1 in 
patrolling the cytoplasm looking to silence harmful retrotransposons and repeats 
(Patrick et al., 2009). TbRIF4 is a 3’-5’ exonuclease and is critical for the 
conversion of ds siRNAs to the ss form required for the generation of the T. 
brucei equivalent of the RISC complex. TbRIF5 is essential for cytoplasmic RNAi 
and acts as a TbDCL1 cofactor (Barnes et al., 2012). These RNAi components 
orchestrate T. brucei RNAi pathways in a canonical fashion. However, unlike in 
higher eukaryotes, T. brucei does not appear to possess an RNA-dependent RNA 
polymerase (RdRp) known to increase the impact of dsRNA gene silencing by 
amplifying dsRNAs (Kolev et al., 2011). This means that the RNAi effect of 
introduced dsRNA is transient and only lasts for one cell cycle (Ngô et al., 1998). 
To circumvent this, stable continuous expression of dsRNA was required which 
greatly influenced the ongoing development of a number of tetracycline-
inducible expression systems in this parasite.   
5.3.1 Development of inducible RNAi systems in T. brucei 
The development of robust, tightly regulated, inducible transgene expression 
systems have been vital in developing RNAi systems for high-throughput screens 
in T. brucei as they were subsequently adapted to stably express dsRNA 
fragments for RNAi induction. The first generation systems developed for 
regulated transgene expression exploited the “strong” Pol1 promoter, EP1 
procyclin promoter, which was modified to include TetO sites (L. E. Wirtz & 
Clayton, 1995). This allowed the control of expression from these constructs 
when introduced into cells that constitutively expressed the TetR. However, the 
use of the EP1 procyclin promoter limited the efficacy of these constructs in BSF 
parasites (Biebinger et al., 1996; Biebinger, Wirtz, Lorenz, & Clayton, 1997). 
These constructs faced further challenges, with reports of low expression of 
regulatory factors leading to high background expression of cassettes, which has 
since been attributed to the tandem arrangement of the dual promoters (one of 
them being the inducible EP1 procylin promoter driving expression of the gene of 
interest and the second promoter being a constitutive promoter, such as VSG 
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promoter or rRNA promoter, driving the expression of the selective marker; L. E. 
Wirtz, Leal, Ochatt, & Cross, 1999). Subsequent efforts to get round these 
problems led to the exploitation of the T7 phage polymerase system which has 
since been widely used in BSF & PCF parasites (E. Wirtz, Hoek, & Cross, 1998; L. 
E. Wirtz et al., 1999), where the constitutive expression of the TetR and the 
resistance marker were driven by T7 promoters and depended on their 
introduction into a T7 RNA polymerase background. Based on these constructs, 
RNAi systems were developed which either depended on the generation of stem-
loop fragments or opposing promoter fragments (LaCount, Bruse, Hill, & 
Donelson, 2000; H. Shi et al., 2000; Z. Wang, Morris, Drew, & Englund, 2000). 
Stem loop systems were found to produce more rapid and efficient mRNA 
knockdown (Durand-Dubief, Kohl, & Bastin, 2003) compared to the opposing 
promoter system. These constructs are still widely used today and continue to 
remain important tools for T. brucei functional genomics. However, challenges 
in achieving high transfection efficiency and reducing inter-clonal variability 
remained, therefore, limiting the success of employing the RNAi systems 
described above to interrogate the T. brucei genome in larger-scale studies.      
The variability between clones in the expression of transgenes has been largely 
blamed on the use of the rRNA spacers as loci for chromosomal integration. The 
intergenic regions of the rRNA loci are transcriptionally silent and, therefore, 
allow stable integration of regulated cassettes. However, T. brucei possesses 
nine rRNA spacers in a haploid genome (Berriman et al., 2005) with differing 
capacities for expression (Alsford, Kawahara, Glover, & Horn, 2005). To 
eliminate these positional effects, using cells with an improved TetR background 
(using the double-TetR system containing two TetR genes; Alibu, Storm, Haile, 
Clayton, & Horn, 2005), the rRNA spacers were screened for strong repression of 
regulated reporter cassettes with high inducible expression levels (Alsford et al., 
2005). A desirable rRNA locus was thus selected and the reporter cassette was 
exchanged for an incomplete HYG-resistance marker cassette (now referred to 
as 2T1 cells). This would allow selection of cells that could stably integrate 
cassettes which possess an over-lapping and complementary HYG selectable 
marker/targeting fragment. Whilst achieving reliable, non-leaky, robust 
expression of transgenes, this strategy also resolved the problem of reported T7 
RNA polymerase toxicity (Alsford et al., 2005) by returning to the use of 
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expression vectors driven by endogenous promoters such as the EP1 procyclin 
promoter and the rRNA promoter. This provided the basis for a very reliable 
system for the generation of RNAi cell lines (Alsford & Horn, 2008; Alsford et al., 
2005). A number of expression plasmids were then generated (Alsford & Horn, 
2008) and the resulting pRPAISL stem loop RNAi constructs were used to generate 
the RNAi library employed in the study described in this chapter (Jones et al., 
2014). 
5.3.2 RNAi based screens in T. brucei 
The success of implementing RNAi in T. brucei has led to a number of medium- 
to high-throughput systematic studies interrogating gene cohorts and even the 
whole genome to develop the current understanding of a variety of trypanosome 
cellular processes and pathways. A group of these studies utilised a gene-by-
gene targeting approach with relative success. The first study (albeit not the 
first RNAi screen in T. brucei) of this kind saw a large collaborative effort where 
210 predicted ORFs, mainly from chromosome 1, were individually knocked-
down using constructs based on the p2T7 opposing promoter RNAi system 
(modified to allow direct cloning of PCR fragments; Alibu et al., 2005), in BSF 
parasites, and the resultant cell growth, viability, and/or cell cycle progression 
phenotypes were assessed (Subramaniam et al., 2006). A large proportion (45 
genes; 23 %) of the investigated genes was found to be required for BSF T. brucei 
proliferation whilst 31 (16 %) of the genes were found to be required for normal 
cell cycle progression. A significant number of essential genes was conserved 
only amongst kinetoplastids which demonstrates the divergence of kinetoplastid 
biology compared to other model eukaryotic organisms and the huge potential to 
identify kinetoplastid-specific drug targets. Other gene-by-gene large scale RNAi 
screens include a study which focussed on proteins featuring the RNA 
Recognition Motif (RRM), where 25 genes (17 in BSF and seven in PCF) were 
found to be required for cell proliferation (Wurst et al., 2009) and another which 
sought to analyse a set of 31 PKs considered to be least studied (Mackey, 
Koupparis, Nishino, & McKerrow, 2011). Here, RNAi of five PKs were found to 
generate growth defects; CRK12, CRK8, CRK1, a CMGC/DYRK Tb927.7.4090 and 
the CMGC/MAPK, Tb927.10.5140 (called ERK8 in this publication; Mackey, 
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Koupparis, Nishino, & McKerrow, 2011), two of which, CRK12 and ERK8, were 
deemed essential for BSF cell proliferation. 
The first study integrating RNAi in T. brucei (and in any other organism!) with a 
forward genetic approach on a global scale was in 2002 by the Englund lab in 
PCF parasites (Morris, Wang, Drew, & Englund, 2002). This was also the first time 
a high-throughput RNAi screen was ever carried out in T. brucei. Here, genomic 
DNA, sheared to an average size of 660 bp was cloned into the modified pZJM 
vector (opposing promoter system to generate dsRNA; Wang et al., 2000). This 
library of RNAi constructs was then transfected into PCF cells multiple times to 
ensure 5 X coverage of the RNAi library. Pools of cells were then screened for 
ConA binding to isolate genes responsible for EP procyclin expression, GPI 
biosynthesis, N-glycan biosynthesis or cell death. It was hypothesised that 
silencing such genes would cause the cells to become ConA resistant. Cells which 
did not bind ConA were then cloned out and target genes were identified via 
sequencing. A glycolytic enzyme, hexokinase, was thus identified, which upon 
further investigation was found to alter procyclin expression. RNAi of hexokinase 
was found to switch procyclin expression from glycosylated EP procyclins to 
unglycosylated GPEET procyclin expression. Modulation of procyclin expression 
was found to be linked to environmental glucose levels. The Englund lab pZJM 
library proved to be an important tool in conducting a number of such forward 
genetic screens in PCF cells. It was used to identify factors involved in 
maintaining the mitochondrial membrane potential by enriching pools of the 
RNAi library for cells featuring a decrease or disruption of mitochondrial 
membrane potential following RNAi induction (Verner, Paris, & Lukes, 2010). It 
was also used to understand the pathways responsible for the toxic activity of 
drugs of interest; e.g. tubercidin. In this study, pools of the RNAi cell line library 
were subjected to tubercidin treatment which led to the identification of a 
hexose transporter important for tubercidin susceptibility (Drew et al., 2003). 
Further analyses implicated the glycolytic pathway as the target of tubercidin in 
PCF cells (Drew et al., 2003). 
Understanding drug mode of action is a subject of huge interest for the purposes 
of drug development. Another study saw the development of a  brand new RNAi 
library of plasmids where the BSF stage-appropriate expression system was used 
to identify genes required for melarsoprol and eflornithine sensitivity which led 
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to the verification of the amino acid transporter 6 (AAT6) as an important player 
of eflornithine toxicity (Schumann Burkard, Jutzi, & Roditi, 2011). Such 
protocols which involve pools of cell lines that are subjected to a selection 
pressure and then cloned, vastly reduce the amount of work required to identify 
individual hits. However, examining RNAi effects in pools would not be 
appropriate for investigating other aspects of trypanosome biology where the 
relevant genes are essential for viability (as these clones would simply disappear 
from the pool) or the end-point analysis requires visual/microscopic phenotyping 
such as changes in cellular/organellar morphology or changes in localisation of 
proteins of interest. In such cases either the RNAi library of cell lines was cloned 
out and then subjected to screening or a gene-by-gene targeting approach was 
employed.  
In one study conducted to identify genes required for kinetoplast integrity and 
maintenance, 1400 PCF cell lines were cloned out from the global pZJM library 
of pooled cell lines. They were then screened for kDNA size reduction/loss which 
led to the identification of p166, a molecular component of the TAC, as an 
important factor required for kDNA segregation (Zhao, Lindsay, Roy Chowdhury, 
Robinson, & Englund, 2008). In another study, a large scale screen of the 
Englund library was carried out to identify regulators of the PCF cell cycle 
(Monnerat, Clucas, Brown, Mottram, & Hammarton, 2009). Here, 200+ individual 
clones were selected via limiting dilution following transfection of PCF T. brucei 
cells with the Englund library of RNAi plasmids. DNA sequence analysis of clones 
excluded those that contained sequences of no interest (and those for which 
sequencing failed), following which only 76 clones were individually analysed to 
determine those which displayed a growth defect following RNAi induction. 16 
cell lines were found to display growth defects following induction. Further 
analyses of these cell lines to identify genes required for PCF T. brucei cell cycle 
did not unambiguously yield novel cell cycle regulators. The fact that none of 
the CRKs or cyclins were identified and that the coverage of the screen was <1 % 
of protein-coding genes, undermined the robustness of the library. The outcomes 
of this study also magnified the limitations of the RNAi technology used, e.g., 
the relatively low transfection efficiency, and demonstrated the urgent need for 
effective high-throughput methods for the phenotypic analyses of such genome-
wide libraries.  
Chapter 5 
 
145 
A solution to counter low transfection efficiency was found when the 
introduction of double strand breaks into the integration site of transfected 
plasmids (such as the rRNA spacer) was found to improve transfection efficiency 
(Glover & Horn, 2009). Capitalising on these findings, the Englund genome-wide 
RNAi library was transfected into BSF cells, that had been induced to feature a 
double strand break at the rRNA spacer of choice (selected to ensure high 
expression levels of transgenes with tight regulation of their expression as 
described in section 5.3.1) using the I-SceI meganuclease system (Baker, Alsford, 
& Horn, 2011). Transformation efficiency was found to have been increased by 
250-fold. The resultant cell line library was then used to elucidate the pathways 
for nifurtimox and eflornithine toxicity in BSF cells by culturing pools in which 
RNAi had been induced in the presence or absence of the drugs. Genomic DNA 
was extracted from resistant populations and the RNAi fragments were 
recovered allowing the identification of target genes via next-generation 
sequencing. In agreement with previous studies, nitroreductase and AAT6 were 
found to be responsible for sensitivity to nifurtimox/benznidazole and 
eflornithine, respectively, thus validating this approach. This approach of 
identifying target genes heralded the paradigm shift in how RNAi libraries could 
be analysed. By integrating next-generation sequencing, a versatile new tool for 
genome-scale functional analysis had now been developed which was 
successfully employed to reveal global knockdown profiles with respect to 
trypanosome growth and development, thus linking thousands of previously 
uncharacterized and “hypothetical” genes to essential functions (Alsford et al., 
2011). This new high-throughput phenotyping approach, termed RNAi target 
sequencing (RIT-seq) has already been successfully adapted to elucidate genes 
targeted by specific compounds such as CpdA (Gould et al., 2013) and current 
drugs used to treat HAT and AAT (Alsford et al., 2011) or pathways involved in 
differentiation induced by a cAMP analogue (Mony et al., 2014), and is a 
powerful new tool which should help advance current understanding of 
trypanosome biology.  
5.4 T. brucei kinome-wide RNAi library 
The kinome-wide RNAi library of individual T. brucei BSF cell lines is another 
tool that has newly been made available as a resource to perform large scale 
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functional analyses of specific gene families (Jones et al., 2014). The advantage 
here lies in the availability of individual cell lines which target specific PKs of 
interest to understand the roles they play in T. brucei biology. By capitalising on 
technologies available, such as the tagged-locus approach to ensure high 
expression levels and tight regulation (section 5.3.1; Alsford & Horn, 2008), to 
overcome the problems of low transformation efficiency and leaky expression 
faced by earlier attempts, a library of independent cell lines which successfully 
target the whole trypanosome kinome with robust, repeatable results was 
generated.  
To set up the library, briefly, as a first step, a high-throughput system was 
established for the generation of the library of RNAi plasmids which individually 
target T. brucei PKs in a tetracycline inducible manner. To do this, the stem-
loop RNAi vector which integrates at a single, tagged rRNA locus of a modified 
cell line (termed 2T1; Alsford & Horn, 2008), pRPaISL, was modified to allow 
integration of amplified gene fragments in a single recombinase reaction (Jones 
et al., 2014). RNAi constructs were made to target 190 PKs, each of which were 
individually transfected into BSF 2T1 parasites, following which two independent 
clones were recovered for analysis. Essential kinases were identified by 
employing a 72 hour cell viability Alamar Blue assay to assess loss of fitness of 
each induced cell line relative to their uninduced counterparts. In this study, 
cell lines which exhibited a loss of fitness following RNAi induction were then 
selected for further analysis to detect proliferation and cell cycle defects via 
growth curve generation and nuclear/kinetoplast configuration of DAPI-stained 
cells, respectively.  
The loss of fitness phenotypes detected in this kinome-wide RNAi library were 
found to have excellent correlation with previous candidate-based gene studies 
(Jones et al., 2014). However, there was one notable discrepancy with published 
literature – PLK. The two clones thought to knockdown PLK mRNA in this library 
unexpectedly did not generate any loss of fitness phenotype. However, 
additional qPCR analysis demonstrated that there was no reduction in PLK mRNA 
upon RNAi induction (Jones et al., 2014), explaining the discrepancy. qPCR of 
another kinase, MKK1, known to be redundant in BSF parasites, also indicated 
inefficient knockdown (Jones et al., 2014), although this kinase is known to be 
non-essential (Jensen, Kifer, & Parsons, 2011). These instances do raise the 
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possibility of other false negative results, arising from inefficient mRNA 
knockdown, being present within the library analysis. Correlation with the 
genome-wide RITseq data (Baker et al., 2011) was also found to be good; 
however, 25 PKs that were ‘hits’ in this screen were not detected by Alsford and 
colleagues raising the possibility of off-target effects (Jones et al., 2014) or false 
negatives in the Alsford study. This could be explained by differences in the 
RNAi constructs used and the phenotypic analyses performed, but further 
validation of the library would be desirable. 
The high correlation of phenotypes generated with published literature provided 
confidence in the effectiveness of this kinome-wide library and, subsequently, 
presented an excellent opportunity to interrogate the T. brucei kinome for the 
role it plays in regulating the T. brucei cell cycle. A popular method used to 
determine the cell cycle profile of a T. brucei cell line is microscopic 
determination of nuclear and kinetoplast configurations following DNA staining 
of cells using DAPI. Since, the nucleus and kinetoplast undergo discrete 
replication cycles in T. brucei, where the kinetoplast undergoes replication and 
segregation slightly ahead of the nucleus, the number of nuclei and kinetoplasts 
present in a cell can be used to determine its current cell cycle stage. A cell in 
G1 phase would have 1 nucleus and 1 kinetoplast (1N1K cell) whilst a cell in G2/M 
phase will have 1 nucleus and 2 kinetoplasts (1N2K) (Figure 5-2). A cell that has 
undergone mitosis but has not yet undergone cytokinesis will have 2 nuclei and 2 
kinetoplasts (2N2K) (Figure 5-2). Any other NK configuration would be deemed 
aberrant and depending on how these cells deviate from normal configurations, 
the type of cell cycle defect can often be determined i.e., mitotic, defects in 
kinetoplast replication/segregation or cytokinetic. In the absence of automatic 
image processing, such phenotyping would be too onerous to be feasible for 
genome-wide high-throughput studies. However, focussing on screening kinases 
deemed essential/required for BSF cell proliferation, such an approach becomes 
possible. An automated microscopic system for conducting cell cycle analysis 
would have been useful, and a recently published study does seem to have 
successfully established such a system in T. brucei (Wheeler, Gull, & Gluenz, 
2012). However, at the time when this project commenced, no such approach 
was available.    
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Figure 5-2 Schematic illustrating the cell division cycle of T. brucei. A cell in G1 phase would 
have 1 nucleus and 1 kinetoplast (1N1K cell). A cell in G2/M phase will have 1 nucleus and 2 
kinetoplasts (1N2K). A cell that has undergone mitosis but has not yet undergone cytokinesis will 
have 2 nuclei and 2 kinetoplasts (2N2K). Adapted from Jones et al., 2014. 
5.5 Project aim 
The aim of this project was to utilise the kinome-wide RNAi library to identify 
regulators of the T. brucei cell cycle. Since cell cycle defects invariably affect 
the ability of cells to proliferate, cell lines which exhibited loss of fitness 
following RNAi induction were focussed on. Due to the divergent nature of the T. 
brucei cell cycle and its regulation, it was anticipated that regulators that had 
never been linked to the cell cycle in other organisms would be identified.   
Chapter 5 
 
149 
5.6 Results 
5.6.1 Screening of RNAi cell lines for PKs involved in the 
T. brucei cell cycle 
Following the determination of cell viability following RNAi induction via the 
Alamar Blue assay (performed by Nathaniel Jones, WTCMP), 50 cell lines showed 
loss of fitness phenotypes (>10 % reduction in Alamar Blue value in comparison 
with uninduced control values, i.e. Alamar Blue ratios of <0.90; Jones et al., 
2014) and were  selected for further analyses. These cell lines were individually 
cultured in flasks and RNAi was induced via the addition of tetracycline. 
Cumulative growth curves were obtained which were then used to determine 
optimal time-points for performing DAPI staining and flow cytometry analyses. 
This was to ensure that the cell cycle profiles were obtained just before, during 
and just after the appearance of the growth defect. During the early stages of 
this screen, generation of growth curves and microscopic slides for DAPI analysis 
were done in partnership with Manuel Saldivia (CSIC, Granada). 
Based on just the growth phenotypes displayed following RNAi induction, the cell 
lines could be classified as showing no growth defect (Table 5-1A), slow growth 
(Table 5-1B), growth arrest (Table 5-1C) or cell death (Table 5-1D), with a strong 
correlation between Alamar Blue ratios and the growth phenotypes determined 
by growth curve (where lower Alamar blue ratios indicate stronger growth 
defects; Figures 5-3 to 5-12). This provided confidence in the Alamar Blue 
methodology that was used to identify PKs that are essential for BSF T. brucei 
growth (Jones et al., 2014).  
(A) No growth defect 
Kinase family Kinase name Gene ID 
Clone 1 Clone 2 
S/R AB ratio S/R AB ratio 
CAMK LDK Tb927.11.8940 S 0.81 S 0.78 
CAMK/CAMKL   Tb927.8.870 S 0.87 S 0.87 
CK1/CK1 CK1 Tb927.3.1630 S 0.87 S 1.02 
CMGC/DYRK   Tb927.10.9600 R 0.85 R 0.81 
Other/NEK NEK16 Tb927.10.14420 S 0.88 S 0.86 
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STE/STE11   Tb927.8.1100 S 0.84 S 0.83 
pseudo Other/ULK   Tb927.11.8150 R 0.83 R 0.77 
aPK-ABC1   Tb927.10.9900 R 0.70 S 0.88 
       (B) Slow growth 
Kinase family Kinase name Gene ID 
Clone 1 Clone 2 
S/R AB ratio S/R AB ratio 
AGC PDK1 Tb927.9.4910 S 0.80 S ND 
AGC/NDR PK53 Tb927.7.5770 S 0.84 S 1.00 
AGC/PKA* 
PKAC1 Tb927.9.11100 
S 0.53 S 0.50 
PKAC2 Tb927.9.11030 
CAMK   Tb927.7.2750 S 0.83 S 0.75 
CMGC   Tb927.11.5340   0.30   0.37 
CMGC/CDK CRK1 Tb927.10.1070 R 0.81 R 0.76 
CMGC/CDK CRK2 Tb927.7.7360  R 0.47 S 0.29 
CMGC/CDK CRK6 Tb927.11.1180 S 0.76 S 0.76 
CMGC/MAPK KFR1 Tb927.10.7780 R 0.42 S 0.55 
Other/AUR AUK3 Tb927.9.1670 S 0.35 R 0.46 
Other/CAMKK   Tb927.10.15300 R 0.79 R 0.77 
Other/WEE WEE1 Tb927.4.3420 S 0.68 R 0.54 
Pseudo-Orphan   Tb927.7.3210 S 0.89 R 0.75 
aPK-PIKK/FRAP TOR1 Tb927.10.8420 S 0.56 S 0.62 
aPK-PIKK/FRAP TOR4 Tb927.1.1930 S 0.71 S 0.92 
       
(C) Growth arrest 
Kinase family Kinase name Gene ID 
Clone 1 Clone 2 
S/R AB ratio S/R AB ratio 
AGC/NDR PK50 Tb927.10.4940 S 0.21 S 0.86 
CAMK   Tb927.7.6220 S 0.77 S 0.84 
CMGC/GSK GSK3-short Tb927.10.13780 S 0.46 R 0.61 
CMGC/SRPK   Tb927.6.4970 S 0.68 R 0.78 
Orphan PK6 Tb927.9.10920 S 0.24 S 0.23 
Other/CK2 CK2A1 Tb927.9.14430 S 0.63 S 0.65 
Other/ULK   Tb927.11.4470 S 0.70 R 0.87 
STE/STE11   Tb927.11.2040 S 0.20 R 0.20 
STE/STE20 SLK1 Tb927.8.5730 R 0.46 S 0.21 
STE/STE20 SLK2 Tb927.9.12880 R 0.32 R 0.78 
pseudo Other/NAK   Tb927.9.6560 S 0.57 S 0.71 
aPK-PIKK/ATR ATR Tb927.11.14680 S 0.43 S 0.82 
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aPK-RIO RIO1 Tb927.3.5400 S 0.84 S 0.98 
aPK-RIO RIO2 Tb927.6.2840 R 0.72 R 0.70 
       (D) Cell death 
Kinase family Kinase name Gene ID 
Clone 1 Clone 2 
S/R AB ratio S/R AB ratio 
AGC   Tb927.3.2440  S 0.69 S 0.62 
CK1/CK1* 
CK1.1 Tb927.5.790 
S 0.16 S 0.16 
CK1.2 Tb927.5.800 
CMGC/CDK CRK3 Tb927.10.4990 S 0.32 S 0.27 
CMGC/CDK CRK9 Tb927.2.4510 S 0.17 S 0.18 
CMGC/CDK CRK12 Tb927.11.12310 S 0.20 S 0.20 
CMGC/CLK CLK1 Tb927.11.12410 S 0.21 S 0.26 
CMGC/CLK CLK2 Tb927.11.12420 R 0.18 S 0.19 
CMGC/MAPK   Tb927.10.5140 S 0.21 S 0.22 
CMGC/RCK   Tb927.3.690 R 0.23 R 0.18 
Other/AUR AUK1 Tb927.11.8220 S 0.19 R 0.19 
NEK* 
NEK12.1 Tb927.8.7110 
S 0.19 S ND 
NEK12.2 (RDK2) Tb927.4.5310 
Other/TLK* 
TLK1 Tb927.4.5180 
S 0.21 R 0.22 
TLK2 Tb927.8.7220 
STE   Tb927.10.2040 S 0.32 S 0.26 
Table 5-1 Summary of the characteristics of investigated RNAi cell lines. For each kinase 
knocked down, the puromycin sensitivity profile (S – sensitive; R – resistant) and Alamar Blue 
ratio (AB ratio) of each independent clone studied are shown. Cell proliferation analysis data for 
Clone 1 of each of the above cell lines are described in this chapter. The growth phenotypes 
displayed by these cell lines are the criteria by which they have been classified in this table – no 
growth defect (A), slow growth (B), growth arrest (C) or cell death (D). Asterisk denotes double 
knockdown cell lines. 
Due to high levels of nucleotide sequence identity shared by some arrayed or 
paralogous PKs, some RNAi constructs were predicted to target more than one 
PK. For most of the cell lines this was already known upfront, such as PKAC1 & 
PKAC2, CK1.1 & CK1.2, NEK12.1 & NEK12.2, and TLK1 & TLK2, and the strategy 
was to generate individual RNAi cell lines if further characterisation was deemed 
to be of interest. As NEK12.1 and NEK12.2 had never been characterised before, 
and because they did generate growth defects upon RNAi induction (Figure 5-3B, 
bottom panels), efforts were made to individually target the two kinases 
(NEK12.1 and NEK12.2 RNAi cell lines were generated by Nathaniel Jones, 
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WTCMP; Jones et al., 2014). Two other cell lines that were assumed to 
knockdown CLK1 and CLK2 individually were found, following analyses of the 
RNAi constructs, to be double knockdown cell lines instead. The RNAi construct 
supposed to target CLK1 targeted CLK2 too and vice versa (see Figure 5-3B, top 
panels for the growth and cell cycle defects generated by one of the original 
double knockdown cell lines). This was because the two RNAi constructs were 
found to target different parts of the identical C-terminal kinase domains of 
CLK1 and CLK2 (Figure 5-3A). In order to address this, new RNAi constructs were 
made (see Jones et al., 2014 for details), this time targeting the non-identical N-
terminal regions of CLK1 and CLK2, and the resulting cell lines were analysed for 
growth and cell cycle defects. CLK1 (not CLK2; as described later on) and 
NEK12.2 (not NEK12.1; as described later on) were found to be solely responsible 
for the growth and/or cell cycle defects demonstrated by the original double-
RNAi cell lines (Figure 5-3B), the results of which (except from the NEK12.1 RNAi 
cell line) have been incorporated in the descriptions later on. In addition to 
these, the analyses of RDK1 and TOR2 RNAi cell lines, neither of which 
demonstrated loss of fitness upon RNAi induction in the initial Alamar Blue 
screen, have also been incorporated.  
Chapter 5 
 
153 
Figure 5-3 In vitro growth and cell cycle analysis of RNAi cell lines simultaneously knocking down 
two protein kinases. A: Schematic illustrating domain structure of CLK1 and CLK2 demonstrating 
that, sequentially, their N-termini are different whilst their C-terminal kinase domains are 
identical B: Cell proliferation and cell cycle phenotypes of CLK1/CLK2 (top panels) and 
NEK12.1/NEK12.2 (bottom panels) double knockdown cell lines. Cumulative growth curves were 
generated (left) and the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) 
following DAPI staining of samples were recorded at the indicated time points post addition of 
tetracycline to the induced samples (right). Analyses of non-induced cells (tet-) are also shown 
as controls.  
Once all these additional cell lines are taken into account, the growth and cell 
cycle analyses of the final cohort of 52 different cell lines representing 55 
different kinases are described below. According to the proliferation and cell 
cycle phenotypes demonstrated following RNAi induction, these cell lines were 
classified as follows: 
 No growth defects and no cell cycle defects - section 5.6.1.1 
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 Growth defects but no notable cell cycle defects - section 5.6.1.2 
 G1/S defects - section 5.6.1.3 
 Mitosis defects - section 5.6.1.4 
 Cytokinesis defects - section 5.6.1.5 
 Kinetoplast duplication defects - section 5.6.1.6 
 Mitosis and cytokinesis defects - section 5.6.1.7 
 Kinetoplast duplication and cytokinesis defects - section 5.6.1.8 
 Unclassified - section 5.6.1.9 
5.6.1.1 Cell lines showing no growth defects and no cell cycle defects 
following RNAi induction 
Nine cell lines (LDK (Figure 5-4A), Tb927.8.870 (Figure 5-4B), CK1 (Figure 5-4C), 
CLK2 (Figure 5-4D), Tb927.10.9600 (Figure 5-4E), NEK16 (Figure 5-4F), 
Tb927.8.1100 (Figure 5-4G), Tb927.11.8150 (Figure 5-4H) and Tb927.10.9900 
(Figure 5-4I) displayed no growth or cell cycle defects following RNAi induction,  
which includes the 8 cell lines described in section A of Table 5-1 (no growth 
defect) and the newly generated CLK2 RNAi cell line as described earlier. This 
point towards the strong correlation which exist between aberrant cell cycle and 
growth defects, thus, demonstrating the appropriateness of choosing to limit the 
cell cycle screen to kinases that are required for the proliferation of BSF 
parasites. 
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Figure 5-4 In vitro growth and cell cycle analysis for cell lines showing no growth or cell cycle 
defects following RNAi induction. A: LDK; B: Tb927.8.870; C: CK1; D: CLK2; E: Tb927.10.9600; F: 
NEK16; G: Tb927.8.1100; H: Tb927.11.8150; I: Tb927.10.9900. Cumulative growth curves were 
generated (left) and the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) 
following DAPI staining of samples were recorded at the indicated time points post addition of 
tetracycline to the induced samples (right). Analyses of non-induced cells (tet-) are also shown 
as controls.  
5.6.1.2 Cell lines showing growth defects but no notable cell cycle defects 
following RNAi induction 
The group of cell lines described in this section are those which displayed growth 
defects, to varying degrees, following RNAi induction which could not be 
attributed to cell cycle defects. Either no cell cycle defects were apparent or 
they emerged only after the appearance of growth defects. Altogether, 19 cell 
lines showed this type of phenotype indicating that the kinases knocked down in 
these cell lines likely play roles that are important but cell cycle-independent in 
BSF T. brucei.  
This group includes two RNAi cell lines which were not hits in the initial Alamar 
Blue screen. One of these is the TOR2 RNAi cell line whose lack of loss of fitness 
upon RNAi induction (Alamar Blue values: Clone 1 – 1.00, clone 2 – 0.92; Jones et 
al., 2014) was found to be contrary to previous reports where incomplete 
knockdown of TOR2 was found to generate a growth defect (Barquilla, Crespo, & 
Navarro, 2008).Therefore, the TOR2 RNAi cell line was analysed via further 
growth curves and cell cycle analysis to reveal that the TOR2 knockdown via 
RNAi does indeed induce a phenotype. However, the phenotype generated was a 
cell death phenotype with no notable cell cycle defects (Figure 5-5A). The 
reason for this discrepancy between the results obtained from the Alamar Blue 
assay and the growth and cell cycle analyses could be due to probable changes in 
the metabolism preventing the loss of fitness being detected by the Alamar Blue 
assay; however, this possibility was not investigated. Also, the findings obtained 
following the growth and cell cycle analyses is in contrast to those of Barquilla 
and colleagues where TOR2 knockdown was found to induce a rise in cells at the 
G2/M phase possibly due to defective cytokinesis although this was not further 
investigated (Barquilla et al., 2008). This discrepancy cannot be fully reconciled 
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at present; however, differences in RNAi constructs used could be a possible 
explanation.  
The second cell line which was not detected as a hit in the Alamar Blue screen 
was the RDK1 RNAi cell line. RDK1 was identified as a negative regulator of 
differentiation (Jones et al., 2014) and, therefore, qualified as a gene of 
interest to potentially play a role in the T. brucei cell cycle. Upon further 
investigation via growth curves and DAPI staining, whilst RDK1 RNAi did generate 
a mild growth defect, it did not cause any cell cycle defects (Figure 5-5B).    
Eight of the 19 kinases within this group were shown for the first time to be 
essential for normal BSF cell proliferation: the newly identified negative 
regulator of differentiation kinase RDK1 (Figure 5-5B; Jones et al., 2014), PDK1 
(a master AGC kinase in other eukaryotes (Pearce, Komander, & Alessi, 2010); 
Figure 5-5C), CRK6 (Figure 5-5D), the MAP kinase KFR1 (Figure 5-5E), the STE 
kinase, Tb927.10.2040 (Figure 5-5F), WEE1 (Figure 5-5G), whose homologues in 
other eukaryotes are required for the activation of the S-phase and G2/M cell 
cycle checkpoints (Vriend, De Witt Hamer, Van Noorden, & Würdinger, 2013), 
the STE-11 type kinase Tb927.11.2040 (Figure 5-5H), SLK1 (Figure 5-5I) and RIO1 
(Figure 5-5J).  
CRK2 and CRK12 have already been individually characterised in the past. 
Knockdown of CRK2 was reported not to result in any growth defects in BSF cells 
(X. Tu & Wang, 2004) which is in contrast to the results obtained here (Figure 5-
5K). CRK12 has been found to be essential for BSF proliferation which is in 
agreement (Figure 5-5L) with another study where the same clone was used 
(Monnerat et al., 2013). Previously, CRK12 RNAi was found to induce a growth 
defect in BSF parasites in the small protein kinase RNAi screen (Mackey et al., 
2011), albeit not as strongly as in the clone described here. In another study, 
CRK12 was again found to be essential for BSF cell proliferation when a 
conditional null mutant approach was used (Merritt & Stuart, 2013); here the 
growth defect generated was as strong as the findings in this study (Figure 5-5L). 
CRK12 was also detected as being essential for BSF proliferation in the genome-
wide RIT-seq RNAi study (Alsford et al., 2011) in addition to eight other kinases 
from this “growth defects but no cell cycle defects” group: TOR2 (Figure 5-5A), 
the CAMK, Tb927.7.2750 (Figure 5-5M), a serine arginine-rich protein kinase 
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(SRPK), Tb927.6.4970 (Figure 5-5N), PK6 (Figure 5-5O), the CAMKK, 
Tb927.10.15300 (Figure 5-5P), SLK2 (Figure 5-5Q), the pseudokinase, 
Tb927.9.6560 (Figure 5-5R), and RIO2 (Figure 5-5S).  
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Figure 5-5 In vitro growth and cell cycle analysis for cell lines showing growth defects but no 
notable cell cycle defects following RNAi induction. A: TOR2; B: RDK1; C: PDK1; D: CRK6; E: 
KFR1; F: Tb927.10.2040; G: WEE1; H: Tb927.11.2040; I: SLK1; J: RIO1; K: CRK2; L: CRK12; M: 
Tb927.7.2750; N: Tb927.6.4970; O: PK6; P: Tb927.10.15300; Q: SLK2; R: Tb927.9.6560; S: RIO2. 
Cumulative growth curves were generated (left) and the numbers of nuclei (N) and kinetoplasts 
(K) in each cell (n ≥ 200) following DAPI staining of samples were recorded at the indicated time 
points post addition of tetracycline to the induced samples (right). Analyses of non-induced cells 
(tet-) are also shown as controls.  
5.6.1.3 Cell lines showing G1/S defects following RNAi induction 
Depletion of two kinases, CRK1 or TOR4, led to slight growth defects (more 
prominent following CRK1 depletion), accompanied by a rise in 1N1K cells 
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suggesting that knockdown of these kinases leads to the cells being blocked at 
G1/S phase (Figure 5-6). These findings are in agreement with previous studies 
where CRK1 knockdown was shown to bring about a rise in G1 phase and 
decrease in S phase cells (X. Tu & Wang, 2004) whilst TOR4 knockdown was 
found to cause an irreversible differentiation of the parasite to the quiescent 
stumpy form (Barquilla et al., 2012). Depletion of each of these kinases was 
previously shown to induce strong loss of fitness phenotypes (within 3 days) in 
the global RIT-seq study (Alsford et al., 2011).  
 
Figure 5-6 In vitro growth and cell cycle analysis for cell lines showing G1/S defects following 
RNAi induction. A: CRK1; B: TOR4. Cumulative growth curves were generated (left) and the 
numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of 
samples were recorded at the indicated time points post addition of tetracycline to the induced 
samples (right). Analyses of non-induced cells (tet-) are also shown as controls. 
5.6.1.4 Cell lines showing mitosis defects following RNAi induction 
RNAi of four kinases (Tb927.11.5340, ATR, CRK3 and AUK1) led to defects in 
proliferation of BSF cells which appeared to be linked to a block in mitosis. 
These phenotypes were described for the first time for the CMGC kinase 
Tb927.11.5340 and ATR, a kinase which, in conjunction with ATM, orchestrates 
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the DNA damage response signalling pathway in other eukaryotes (Lovejoy & 
Cortez, 2009) (top panels of Figure 5-7A and B, respectively). RNAi of 
Tb927.11.5340 and ATR led to a rise in 1N2K cells and subsequent rise in 1N>2K 
cells (Table S1) with the phenotypes being more pronounced following ATR 
depletion (28 % and 6 % of total cell population, respectively, at 72 hours post-
induction; Table S1). The appearance of 1N2K cells and 1N>2K cells could be 
explained by a delay or block in nuclear DNA replication and segregation whilst 
the progression of kDNA replication/segregation continues unimpeded. Flow 
cytometry analyses of propidium iodide (PI)-stained cells showed that 
Tb927.11.5340 and ATR RNAi induced cell lines had undergone DNA replication 
(bottom panels of Figure 5-7A and B) suggesting that it is the progression through 
mitosis, rather than DNA replication, that has been inhibited. In addition, a huge 
rise in cells with 4C DNA content is not seen, suggesting that mitosis is delayed 
rather than blocked in Tb927.11.5340 and ATR RNAi cells.  
CRK3 and AUK1 displayed phenotypes that were consistent with published 
literature (Figure 5-7C and D, respectively). Previously, AUK1 was shown to play 
a role in spindle assembly (Li & Wang, 2006) in keeping with the roles played by 
its homologues in other eukaryotes (Goldenson & Crispino, 2014). Its knockdown 
was shown to generate severe growth defects and a block in mitosis 
demonstrated by the characteristic rise in 1N2K cells (Jetton et al., 2009; Li & 
Wang, 2006). CRK3, a homologue of the mitotic Cdk, Cdk1 (Hammarton, Clark, 
Douglas, Boshart, & Mottram, 2003), was previously shown to be essential for the 
promotion of the G2/M transition (X. Tu & Wang, 2004). Also, knockdown of both 
kinases as part of the genome-wide RIT-seq data analysis (Alsford et al., 2011) 
generated loss of fitness phenotypes. Here, knockdown of CRK3 led to a rise in 
1N2K cells which decreased over time (most likely due to the recovery of RNAi 
refractory cells; Figure 5-7C, right panel) whilst the knockdown of AUK1 led to a 
dramatic rise in 1N2K cells by 3 hours of RNAi induction (Figure 5-7D, right 
panel) further giving rise to 1N>2K cells at later time-points (60 % of 1N2K cells 
at 12 hours post-induction; 11 % of 1N>2K cells at 24 hours post-induction; Table 
S1). Both these results indicate a block in mitosis which is in agreement with 
previous findings.  
  
Chapter 5 
 
166 
Chapter 5 
 
167 
 
Figure 5-7 In vitro growth and cell cycle analysis for cell lines showing mitosis defects following 
RNAi induction. A: Tb927.11.5340; B: ATR; C: CRK3; D: AUK1. Cumulative growth curves were 
generated (left) and the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) 
following DAPI staining of samples were recorded at the indicated time points post addition of 
tetracycline to the induced samples (right). Analyses of non-induced cells (tet-) are also shown 
as controls. Flow cytometry profiles for 50,000 propidium iodide labelled cells at the indicated 
time-points were also obtained for Tb927.11.5340 (A – bottom panels) and ATR (B – bottom 
panels). The DNA content of each peak is indicated. 
5.6.1.5 Cell lines showing cytokinesis defects following RNAi induction 
Knockdown of seven kinases (Tb927.7.6220, Tb927.3.690, Tb927.3.2440, 
Tb927.10.5140, PKAC1 & PKAC2 and PK50) generated growth defects that could 
have been due to defects in cytokinesis. Among these, the essentiality of the 
CAMK, Tb927.7.6220, for BSF proliferation had never been described before 
(Figure 5-8A). The growth defect induced following RNAi of Tb927.7.6220 was 
found to coincide with a slight rise in 2N2K cells and was followed by a 
subsequent rise in >2N>2K cells (Figure 5-8A; Table S1), indicating that whilst 
the nucleus and kinetoplast are able to replicate and segregate, the cells are not 
able to divide to generate progeny. This phenotype was also observed following 
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the knockdown of the rest of the kinases in this section thus indicating their 
putative roles in T. brucei BSF cytokinesis (Figure 5-8). 
The CMGC/RCK kinase Tb927.3.690, the AGC kinase, Tb927.3.2440, the CMGC 
kinase, Tb927.10.5140 and PKAC1 & PKAC2 were already identified as being 
essential for BSF proliferation in the global RIT-seq screen (Alsford et al., 2011). 
Knockdown of Tb927.3.690 generated a spectacular rise in 2N2K cells within 24 
hours (32 % of total cell population at 24 hours post-induction; Table S1) which 
was followed by a rise in cells featuring multiple nuclei and kinetoplasts (Figure 
5-8B). This suggests that the cells that were unable to undergo cytokinesis in the 
first place, continued to replicate their nuclei and kinetoplasts leading to the 
subsequent rise in cells with multiple nuclei and kinetoplasts. Such a phenotype, 
therefore, firmly indicates the essential role of Tb927.3.690 in BSF cytokinesis. A 
similar phenotype was also observed following the depletion of Tb927.3.2440 
albeit at a later time-point and with a less dramatic rise in 2N2K cells (Figure 5-
8C; Table S1). In both cell lines, the majority of the cells were abnormal by 48 
hours. Tb927.10.5140, which generated a similar rise in 2N2K cells and 
subsequent rise in cells with multiple nuclei and kinetoplasts (Figure 5-8D; Table 
S1) had already been identified as essential for BSF proliferation in the mini-
RNAi screen conducted by Mackey and colleagues (Mackey et al., 2011) whilst 
PKAC1 & PKAC2 and PK50, also generating similar cell cycle defects (Figure 5-8E 
and F), have been individually studied elsewhere (Kramer, 2004; Ma et al., 
2010). 
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Figure 5-8 In vitro growth and cell cycle analysis for cell lines showing cytokinesis defects 
following RNAi induction. A: Tb927.7.6220; B: Tb927.3.690; C: Tb927.3.2440; D: Tb927.10.5140; 
E: PKAC1 & PKAC2; F: PK50. Cumulative growth curves were generated (left) and the numbers of 
nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of samples were 
recorded at the indicated time points post addition of tetracycline to the induced samples 
(right). Analyses of non-induced cells (tet-) are also shown as controls.  
5.6.1.6 Cell lines showing kinetoplast duplication defects following RNAi 
induction 
Knockdown of CRK9 or CK2A1 (also known as CK2α) led to growth defects that 
could be attributed to defective kinetoplast replication or segregation (Figure 5-
9). Following knockdown of each kinase, a substantial rise in 2N1K cells was 
observed (13 % at 48 hours post-induction compared to 1 % before induction for 
CRK9; 19 % at 48 hours post-induction compared to 1 % before induction for 
CK2A1; Table S1) with no equivalent rise in 0N1K cells (or ‘zoids’). This indicates 
the completion of mitosis before the kinetoplasts have replicated/segregated. In 
both cases, no subsequent rise in >2N1K cells are observed, suggesting that there 
is a delay, rather than a block, in kinetoplast replication/segregation (Table S1). 
Both of these kinases were classified as essential for T. brucei BSF proliferation 
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in the global RIT-seq study published in 2011 (Alsford et al., 2011). They were 
also both previously studied on a candidate gene basis.  
CRK9 was knocked down in two separate studies in the BSF stage. CRK9 
knockdown was found to be lethal (Badjatia, Ambrósio, Lee, & Günzl, 2013) 
which was in contrast to an earlier report (Gourguechon & Wang, 2009) which 
could be explained by the different RNAi plasmids used (Badjatia et al., 2013). 
CRK9 was found to play important roles in the spliced leader trans-splicing 
process required for mRNA maturation in BSF parasites (Badjatia et al., 2013). 
Previous studies on CK2A1 localised it to the nucleolus and showed that it 
associated with NOPP44/46 (Park, Brekken, Randall, & Parsons, 2002), a 
nucleolar RNA-binding protein required for ribosome biogenesis (Jensen, 
Brekken, Randall, Kifer, & Parsons, 2005). 
 
Figure 5-9 In vitro growth and cell cycle analysis for cell lines showing kinetoplast duplication 
defects following RNAi induction. A: CRK9; B: CK2A1. Cumulative growth curves were generated 
(left) and the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 200) following DAPI 
staining of samples were recorded at the indicated time points post addition of tetracycline to 
the induced samples (right). Analyses of non-induced cells (tet-) are also shown as controls. 
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5.6.1.7 Cell lines showing mitosis and cytokinesis defects following RNAi 
induction 
Three cell lines representing four kinases (CLK1, GSK3-short and TLK1 & TLK2) 
were found to give putative mitosis and cytokinesis defects upon RNAi induction. 
All of the kinases mentioned in this section were also shown to be essential for 
BSF cell proliferation in the genome-wide RIT-seq study (Alsford et al., 2011) 
CLK1 has previously been found to be essential for BSF parasite proliferation and 
to be inhibited by the drug, hypothemycin previously known to target CDXG 
kinases in humans (Nishino et al., 2013). Here, depletion of CLK1 also resulted in 
a cell death phenotype and the characterisation of CLK1 was further extended in 
this screen. CLK1 depletion caused a dramatic rise in 1N2K and 2N2K cells by 6 
hours post-induction (29 % and 11 %, respectively, compared to 11 % and 11 % 
before induction, respectively; Figure 5-10A, top right panel). By 12 hours, the 
majority of the “other” cells comprised 2N3K and 2N4K cells (8 % of total cell 
population; Table S1). These “other” cells at later timepoints proved difficult to 
classify due to difficulties in differentiating discrete kinetoplasts and nuclei 
(Table S1). The initial rise in 1N2K cells suggests defects in mitosis (see section 
5.6.1.3), and when the appearance of cells with two nuclei at the same time is 
also taken into account, an indication is given that these defects could be 
causing delays in mitotic progression rather than its complete block. The initial 
rise in 2N2K cells and the subsequent rise of cells with multiple nuclei and 
kinetoplasts suggest a block in cytokinesis. Flow cytometry analysis revealed a 
decrease in the 2C peak and an increase in the 4C peak at 12 hours post-
induction suggesting that the cells are able to replicate their DNA but either are 
unable to undergo karyokinesis and/or cytokinesis (Figure 5-10A, middle panels). 
In order to analyse the cytokinesis defects further, >200 2N2K cells were scored 
to determine their cytokinesis stage (Figure 5-10A, bottom left panel). A decline 
in the number of cells presenting visible cleavage furrows was observed 
suggesting that CLK1 plays an important role in the entry into cytokinesis or the 
early progression of furrow ingression during cytokinesis. CLK1 was also found to 
be essential for T. brucei BSF survival in a mouse model (experiment conducted 
by Ryan Ritchie, WTCMP), validating it as a potential drug target (Figure 5-10A, 
bottom right panel).  
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Depletion of GSK3-short also generated a cell death phenotype accompanied by 
a concomitant rise in 1N2K and 2N2K cells (24 % and 13 %, respectively at 35 
hours post-induction compared to 13 % and 5 %, respectively before induction; 
Figure 5-10B, top panels) and flow cytometry analysis (Figure 5-10B, bottom 
panels) revealed that DNA replication proceeded normally. Similar to the reasons 
described for CLK1 above, the data indicates a delay, rather than a block in 
mitosis. However, unlike CLK1, depletion GSK3-short does not seem likely to 
block cytokinesis completely owing to the fact that a dramatic rise in aberrant 
cells was not seen to the extent seen following CLK1 knockdown. Previous 
studies had also established the essentiality of GSK3-short in BSF cell viability, in 
agreement with the findings here, in addition to its potential as a drug target 
(Ojo et al., 2008). 
Whilst TLK2 has yet to be individually characterised in BSF parasites, RNAi based 
studies on TLK1 have shown it to interact with the components of the 
chromosomal-passenger complex (CPC), to play roles in mitotic spindle 
formation and chromosome segregation and, therefore, to be essential for BSF 
cell viability (Li, Umeyama, & Wang, 2008). In this study by the Wang lab, flow 
cytometry analysis of TLK1 knockdown cells saw a rise in the 4C peak and a 
decrease in the 2C peak, i.e. the cells were able to replicate their DNA but 
unable to undergo mitosis/cytokinesis. DAPI analysis shed further light on the 
mechanics of these cell cycle defects, where a rise in 1N2K cells indicated that 
the replicated nuclear DNA was not being segregated suggesting, at the very 
least, that delays occurred during mitosis. Here, the joint knockdown of TLK1 
and TLK2 also led to a huge rise in 1N2K cells (Figure 5-10C, top right panel), 
which comprised 43 % of the total cell population at 36 hours post-induction 
(compared to 9 % before induction; Table S1). However, this was also 
accompanied by a concomitant rise in 0N1K (11 % and 13 % at 24 and 36 hours 
post induction, respectively, compared to none being found before induction; 
Table S1) and 1N>2K (9 % and 12 % at 36 and 48 hours post induction, 
respectively, compared to none being found before induction; Table S1) cells - 
phenotypes that were not reported in the Li et al. study (Li et al., 2008). These 
0N1K and 1N>2K cells could have been generated from cells that were unable to 
undergo mitosis but completed cytokinesis nonetheless. These “extra” 
phenotypes suggest that the additional depletion of TLK2 brings about further 
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delays in mitosis, and promotes unchecked cytokinesis despite them. Flow 
cytometry analysis at 36 hours post-induction revealed a shift of the 4C peak to 
the right, indicating that many cells were polyploid and contained DNA that had 
been replicated repeatedly but had not been segregated appropriately (Figure 5-
10D, bottom panels). Additionally, there was a rise in <1C peak, consistent with 
the increase in zoids observed by DAPI analysis. Altogether, the data suggest 
that TLK1 and TLK2 may play separate roles in promoting mitosis and TLK2 may 
also play an inhibitory role at the mitosis/cytokinesis checkpoint without which 
cytokinesis proceeds unchecked despite unsegregated nuclear DNA. 
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Figure 5-10 In vitro growth and cell cycle analysis for cell lines showing mitosis and cytokinesis 
defects following RNAi induction. A: CLK1; B: GSK-short; C: TLK1 & TLK2. Cumulative growth 
curves were generated (left) and the numbers of nuclei (N) and kinetoplasts (K) in each cell (n ≥ 
200) following DAPI staining of samples were recorded at the indicated time points post addition 
of tetracycline to the induced samples (right). Analyses of non-induced cells (tet-) are also 
shown as controls. Flow cytometry profiles for 50,000 propidium iodide labelled cells at the 
indicated time-points were also obtained for CLK1 (A – middle panels); GSK3-short (B – bottom 
panels) and TLK1 & TLK2 (C – bottom panels). The DNA content of each peak is indicated. For 
CLK1 (A), an analysis of the cytokinesis stage of 2N2K cells was also conducted (n ≥ 200) (bottom 
left panel) in addition to analysing the proliferation of the CLK1 RNAi line in mice (bottom right 
panel). 1×105 trypanosomes were inoculated into 4 mice and RNAi was induced with doxycycline 
(dox, as indicated) in 2 mice 48 hours later. Uninduced mice were culled as indicated ( ) when 
their parasitaemias rose above 108 cells ml−1 (in vivo mouse experiments were conducted by Ryan 
Ritchie, WTCMP). 
5.6.1.8 Cell lines showing kinetoplast duplication and cytokinesis defects 
following RNAi induction 
Five cell lines representing six kinases (PK53, AUK3, CK1.1 & CK1.2, 
NEK12.2/RDK2 and Tb927.11.4470) presented growth defects following RNAi 
induction which may be attributed to joint defects in kinetoplast 
replication/segregation and cytokinesis. Three of these kinases have already 
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been studied on a candidate gene basis. Also, five kinases - CK1.1, CK1.2, AUK3, 
RDK2 and Tb927.11.4470, have all been shown to be essential for BSF cell 
proliferation in the genome-wide RIT-seq study (Alsford et al., 2011). 
Knockdown of PK53 generated a slow growth phenotype (Figure 5-11A, left 
panel). Cell cycle analysis via DAPI staining following RNAi induction revealed a 
slight rise in 1N2K cells in addition to “other” cells, a lot of which were either 
2N1K cells (9 % of total cell count at 48 hours post-induction) or “unclassified” 
cells (where discrete nuclei or kinetoplasts could not be clearly visualised) and 
small proportions of 0N1K, 1N0K and 2N0K (Figure 5-11A, right panel; Table S1). 
The rise in 2N1K cells, and the absence of equal number of zoids, indicates a 
delay in kinetoplast replication/segregation whilst the types of “other” cells 
generated suggest defects in cytokinesis. These findings do not exactly concur 
with what has already been published. PK53 RNAi was previously found to induce 
a stronger growth defect accompanied by a clear rise in 2N2K cells, many of 
which appeared to possess a visible cleavage furrow suggesting a block in 
progress to abscission (Ma et al., 2010). This difference in phenotypes could be 
due to differing levels of knockdown which has not been investigated during this 
study. 
AUK3 RNAi (Figure 5-11B, right panel) resulted in the generation of large 
numbers of “other” cells by 18 hours post-induction, the majority of which were 
0N1K, 1N0K and 2N1K cells (6 %, 2 % and and 9 % of total cell count, 
respectively; Table S1). Later at 48 hours post-induction, the majority of the 
“other” cells were 1N0K and 2N1K cells (13 % and and 11 % of total cell count, 
respectively; Table S1). Also prevalent were cells with multiple nuclei and 
kinetoplasts, i.e. >2N>2K cells, at the later time-points (Table S1). The initial 
appearance of 0N1K and 1N0K and 2N1K cells could be explained by inaccurate 
furrow ingression leading to the generation of these cells from 2N2K cells. On 
the other hand, the detection of 2N1K cells and the subsequent generation of 
>3N1K cells (2 % of total cell population at 35 hours post-induction; Table S1) 
suggest delays in kinetoplast division. The subsequent appearance of >2N>2K 
cells also suggests that the parasites were unable to undergo cytokinesis 
effectively.  Altogether, these data suggest delays in kinetoplast division and/or 
cytokinesis or inaccurate furrow ingression which cannot be fully resolved 
without further investigations.  
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CK1.1 and CK1.2 have also been previously studied individually. Knockout of 
CK1.1 was found to have no effect on BSF parasites whilst CK1.2 RNAi was found 
to be lethal (Urbaniak, 2009). Here, the joint knockdown of CK1.1/CK1.2 
supports these findings as they also generate a cell death phenotype (Figure 5-
11C, left panel). DAPI analysis of induced cells revealed a huge rise in 2N2K cells 
(Figure 5-11B, right panel; 38 % and 23 % of the total cell population at 24 hours 
and 34 hours post-induction, respectively, compared to 12 % before induction; 
Table S1) with a concomitant rise in 2N1K cells (16 % and 14 % of the total cell 
population at 24 hours and 34 hours post-induction, respectively, compared to 1 
% before induction; Table S1). When this is considered in combination with the 
fact that no substantial numbers of zoids or 1N>2K cells or cells with multiple 
nuclei and kinetoplasts were generated, the data, therefore, suggest delays in 
kinetoplast replication/segregation and cytokinesis rather than delayed mitosis 
or blocked cytokinesis. Similar phenotypes were also observed following 
knockdown of RDK2 or Tb927.11.4470 (Figure 5-11D and E, respectively), albeit 
on a smaller scale (for RDK2) or with a milder rise in 2N1K cells (for 
Tb927.11.4470; 9 % of total cell population at 48 hours post-induction compared 
to 1 % before induction; Table S1), which leads to the same conclusion being 
drawn for the roles of RDK2 and Tb927.11.4470 in the BSF parasite’s cell cycle. 
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Figure 5-11 In vitro growth and cell cycle analysis for cell lines showing kinetoplast duplication 
and cytokinesis defects following RNAi induction. A: PK53; B: AUK3; C: CK1.1 & CK1.2; D: RDK2; 
E: Tb927.11.4470. Cumulative growth curves were generated (left) and the numbers of nuclei (N) 
and kinetoplasts (K) in each cell (n ≥ 200) following DAPI staining of samples were recorded at 
the indicated time points post addition of tetracycline to the induced samples (right). Analyses 
of non-induced cells (tet-) are also shown as controls. 
5.6.1.9 Cell lines showing growth defects and/or cell cycle defects that were 
unclassified following RNAi induction 
The knockdown of two kinases generated ambiguous results which prevented 
them from being classified into a specific cell cycle phenotypic class. Knock 
down of Tb927.7.3210 generated a slight growth defect (Figure 5-12A, left 
panel). At 30 hours post-induction of RNAi, a large proportion of the cell 
population comprised of aberrant cell types (Figure 5-12A, right panel). This 
generation of “other” cells, however, was not maintained at later time-points 
confounding unambiguous classification of this phenotype to a distinct cell cycle 
defect. Knockdown of TOR1 generated a stronger growth defect but was 
accompanied by a reversal in cell cycle defects (such as the rise in 1N2K and 
2N2K cells seen at 12 post-induction of RNAi) similar to that seen following 
Tb927.7.3210 RNAi induction (Figure 5-12B, right panel). Both of these, 
Tb927.7.3210, which is a pseudo-orphan kinase, and TOR1, exhibited loss of 
fitness proliferation phenotypes in the global RIT-seq study (Alsford et al., 
2011). A previous study investigating TOR1 function also found it to be essential 
for cell growth (Barquilla et al., 2008). It was thought to be part of TORC1 
signalling which is required for proper RNA Pol I localisation, protein synthesis 
and maintenance of appropriate cell growth. 
Chapter 5 
 
181 
 
Figure 5-12 - In vitro growth and cell cycle analysis for cell lines showing growth and/or cell 
cycle defects that were unclassified following RNAi induction. A: Tb927.7.3210; B: TOR1. 
Cumulative growth curves were generated (left) and the numbers of nuclei (N) and kinetoplasts 
(K) in each cell (n ≥ 200) following DAPI staining of samples were recorded at the indicated time 
points post addition of tetracycline to the induced samples (right). Analyses of non-induced cells 
(tet-) are also shown as controls. 
5.7 Discussion 
Compared to the outcomes of a previous cell cycle screen (Monnerat et al., 
2009) which did not lead to the identification of any novel direct cell cycle 
regulators despite the use of a genome-wide RNAi library, the screening of the 
kinome-wide RNAi library of individual cell lines here has been a greater success. 
Thanks to the efficiency and robustness of the library, the majority of the 
previously known cell cycle kinases were detected and many novel cell cycle 
regulators were identified. 25 PKs were detected as potential T. brucei cell 
cycle kinases; this represents 13 % of the T. brucei kinome, demonstrating the 
importance of protein phosphorylation in T. brucei cell cycle regulation. At least 
15 of these putative cell cycle kinases were detected for the first time – the 
CMGC kinase Tb927.11.5340, ATR, the AGC kinase, Tb927.3.2440, the CAMK, 
Tb927.7.6220, the CMGC, Tb927.10.5140, the CMGC/RCK kinase, Tb927.3.690, 
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CRK9, CK2A1, CLK1, GSK3-short, TLK2, CK1.1 & CK1.2, AUK3, RDK2 and 
Tb927.11.4470. Almost all of the rest of the kinases reproduced phenotypes, 
when knocked down, that are in agreement with published literature, thus 
raising the confidence level of the findings of this screen. Nevertheless, further 
analyses are required to confirm these phenotypes and further verify their 
functions. RNAi of a number of these putative cell cycle kinases induced rapid 
cell death signifying their potential as drug targets. These include the CMGC PKs 
CRK3, CRK9, CLK1, Tb927.10.5140, Tb927.3.690, the AGC kinase Tb927.3.2440, 
CK1.1, AUK1, RDK2 and TLK1/2 with CLK1 now being genetically validated as one 
in a mouse model. 
Of the PKs implicated in cell cycle regulation, the majority were deemed to be 
involved in just cytokinesis or in combination with kinetoplast duplication or 
mitosis with surprisingly few in G1/S (Figure 5-13). In other organisms, 
progression through G1 phase and G1/S transition is tightly regulated and involves 
multiple kinases required to induce the commitment point to enter the cell cycle 
(e.g. START in yeasts) and begin DNA replication (section 1.3.4.1). Here, the 
relatively short list of kinases thought to regulate G1 progression and G1/S 
transition suggests that G1 progression and transition into S phase is less tightly 
regulated in T. brucei. On the other hand, it could be that these kinases are 
harder to detect via RNAi or that there is much greater redundancy of function 
between kinases involved in G1. The two putative G1/S kinases identified in this 
study might represent two decisions the cell needs to make whilst at G1: 1) 
should the cell differentiate into the quiescent stumpy form stage; 2) should the 
cell commit to entering the cell cycle. Depletion of TOR4 was shown to cause 
irreversible differentiation of BSF cells to the G0 stumpy form stage (Barquilla et 
al., 2012) which was reflected by the rise in 1N1K cells in this study (section 
5.6.1.3). TOR4, therefore, would be part of the pathway which decides whether 
the cell should differentiate into the quiescent stumpy stage cells. Depletion of 
CRK1 also led to a rise in 1N1K cells. Previous studies showed a rise in G1 cells 
and a decrease in S phase cells (X. Tu & Wang, 2004) suggesting that the 1N1K 
cells seen here are also in G1 and have failed to progress through to S phase. 
Further studies monitoring early cell cycle events, such as basal body 
duplication, would help verify if the pathways involving CRK1 activities are 
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upstream of those which induce re-entry into the cell cycle and do indeed play a 
role in the START equivalent in T. brucei. 
What is also remarkable is the relatively high number of kinases identified to be 
jointly involved in kinetoplast duplication and cytokinesis suggesting a link 
between the two events. This link could be explained by what has already been 
shown in PCF parasites where the replication of cytoskeletal structures such as 
basal bodies and flagellum are closely linked with cytokinesis (section 1.3.2; 
Ikeda & de Graffenried, 2012; Lozano-Núñez, Ikeda, Sauer, & de Graffenried, 
2013; Wheeler, Scheumann, Wickstead, Gull, & Vaughan, 2013). The importance 
of the placement of the growing flagellum in establishing the furrow has already 
been shown (Wheeler et al., 2013). Indeed, when the types of aberrant cells 
generated following the RNAi of these PKs are closely looked at (section 
5.6.1.8), misaligned furrows seem to be the cause of their generation giving 
credence to this hypothesis. 
The PKs, CLK1 and GSK3-short, both of which upon RNAi induction generated a 
similar phenotype, i.e. concomitant rise in 1N2K and 2N2K cells, were thought to 
be involved in mitosis and cytokinesis simultaneously suggesting that these 
kinases are involved in pathways which link these two events. In the case of 
TLK1 & TLK2 dual knockdown, cytokinesis was found to progress inappropriately 
despite delayed mitosis. A possibility could be that, with CLK1 and GSK3-short on 
the one hand and TLK1/TLK2 on the other, represent the two sides of mitosis to 
cytokinesis transition as promoters and repressors, respectively.  
The long list of kinases implicated in BSF T. brucei cytokinesis indicates a 
potentially highly complex regulatory network involved in orchestrating this 
event. The majority of these kinases do not have cell cycle related homologues 
in other organisms indicating the possibility of novel pathways being involved in 
BSF cytokinesis regulation which is not surprising considering the unique cell 
structure of this parasite compared to other eukaryotic model organisms (section 
1.2.2). Furrow analysis, as was performed for CLK1 RNAi cells (Figure 5-10A), 
could be extended to the rest of the cell lines which presented with cytokinetic 
defects following knockdown in order to specify which stage of cytokinesis has 
been perturbed. 
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Further screens could be done in order to specify the cellular event at which 
these kinases function to promote cell cycle progression. In cell lines which 
present kinetoplast duplication defects, early events such as basal body 
duplication could be followed with the use of organelle specific markers such as 
anti-Centrin2 antibody (de Graffenried, Anrather, Von Raußendorf, & Warren, 
2013) to identify regulators of basal body duplication. There lies a huge 
potential to extend this library of individual RNAi cell lines to a genome-wide 
scale. Such a study promises to deliver potential novel cell cycle regulators and 
enrich current understanding of the cell cycle regulatory network. Automation of 
end-point analyses of cell cycle screens in T. brucei, such as the methodology 
developed by Wheeler et al. (Wheeler et al., 2012), would be essential before 
undertaking such a project. Automated microscopy would also present us with 
the opportunity to scrutinize various other aspects of the cell cycle, apart from 
the nucleus/kinetoplast configuration, such as the morphology of the nucleus or 
the kinetoplast etc. Other genome-wide approaches could involve employing the 
RIT-seq approach (Alsford et al., 2011) on a pooled RNAi library following sorting 
based on DNA content which would identify genes which cause a block at various 
stages of the cell cycle. Whilst such a method could be successful in identifying 
regulators at the G1/S or the G2/M transitions, other more subtle phenotypes, 
such as those indicating defects in kinetoplast duplication or cytokinesis, would 
be missed and further screening would be required. 
Whilst the findings of this screen build on our current understanding of the T. 
brucei cell cycle, limitations do exist. An absence of cell cycle phenotype upon 
RNAi induction does not necessarily eliminate cell cycle functions. Redundancy 
between PKs could mean that depletion of one would not have a detrimental 
effect on cells. Subtle effects on the cell cycle or insufficient knockdown could 
prevent a kinase from being detected. Transient knockdown would allow cells to 
recover and the potential cell cycle functions of kinases to remain undetected. 
The major challenge at present lies in placing confirmed T. brucei cell cycle 
regulators in signalling cascades and effector networks, the understanding of 
which still remains incredibly poor. Phosphoproteomic and chemical genetic 
approaches could enable the initial identification of potential substrates of these 
kinases. Such studies, however, would need to be followed up with individual 
characterisation of potential interactions. Shared phenotypes upon induction of 
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RNAi of some kinases, even those thought not to be directly involved in cell 
cycle regulation, could indicate that they are involved in the same pathway and 
be used as reference points to assemble signalling cascades. The fact that a high 
proportion of trypanosome PKs are differentially phosphorylated between the 
bloodstream and procyclic form (Nett et al., 2009; Urbaniak, Martin, & 
Ferguson, 2013) adds to the burden of work required to thoroughly dissect T. 
brucei cell cycle regulation. It cannot be assumed that what is true for one life-
cycle stage would be true for the other.  
 
Figure 5-13 Schematic representation of BSF T. brucei cell cycle and protein kinases implicated 
in the regulation of indicated stages of the cell cycle. Protein kinases in red font – novel cell 
cycle functions identified in this study. Adapted from Jones et al., 2014. 
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6 General Discussion 
Protein kinases (PKs) are an important group of enzymes that are vital 
participants of signalling cascades. They are required for the regulation of 
pathways by acting as signal processors, signal transducers and effectors. By 
post-translationally modifying other proteins, via phosphorylation, they alter the 
enzymatic activity (when relevant), localisation and binding ability/specificity of 
their substrates. It is not surprising that PKs play such an important role in a 
complex cellular process, such as the cell division cycle, which entails 
environmental sensing, requires strict regulation and involves dynamic structural 
changes.  
The unusual features of T. brucei cellular architecture (e.g. the fixed 
longtitudinal arrangement of its single copy organelles or the subpellicular 
corset of microtubules which define the parasite’s shape) and cell cycle 
mechanisms (e.g. ingression of a cleavage furrow along the length of the cell for 
cytokinesis) implies divergent regulatory pathways compared to other well-
studied eukaryotes, the majority of which are yet unknown. Whilst T. brucei 
homologues of conserved eukaryotic cell cycle regulators are useful starting 
points for studying the T. brucei cell cycle, such approaches are limited in their 
scope. The divergent nature of trypanosome cell biology has meant failure in 
detecting putative homologues with known cell cycle functions (e.g. CENP-A; 
Akiyoshi & Gull, 2013) and, conversely, structural conservation of proteins not 
equating with shared function (e.g. PLK in T. brucei is not known to have a 
mitotic role yet, unlike its homologues in other eukaryotes; Chapter 3 and 4). 
Nevertheless, the absence of a putative homologue does not necessarily mean it 
does not truly exist. It is possible the same role is performed by a 
protein/proteins with diverged sequences(s), which renders them undetectable 
by current homology search algorithms. It is also possible that other non-
homologous/kinetoplastid specific proteins are fulfilling the same roles. This 
makes the case for the importance of conducting detailed characterisation of 
individual proteins, such as PLK (Chapter 3 and 4), and also for employing 
forward genetic approaches, such as the cell cycle screen described in this thesis 
(Chapter 5), in understanding the T. brucei cell cycle. 
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6.1 T. brucei PLK 
PLKs in model eukaryotic organisms are one of the major regulators of the 
eukaryotic cell division cycle. Crucial roles of PLKs, especially members of the 
PLK1 subfamily, include progression through mitosis. T. brucei PLK (TbPLK) 
however, has yet to display mitotic localisation or function, demonstrating its 
divergent role in this protozoan organism. Nevertheless, it was able to 
complement temperature sensitive yeast knockout mutants confirming it as a 
functional homologue of the yeast PLK1 member, Cdc5. Divergence in function 
may simply be due to the differences in the cellular environment, although this 
needs to be investigated further. Detailed dissection of TbPLK function 
identified its role in the faithful segregation of the basal bodies, the bilobe, the 
Golgi and the FAZ, the impairment of which leads to defective kinetoplast 
duplication and flagellum inheritance in procyclic form (PCF) cells (de 
Graffenried et al., 2008; Hammarton et al., 2007a; Ikeda and de Graffenried, 
2012; Lozano-Núñez et al., 2013). Studies investigating its role in bloodstream 
form (BSF) parasites indicated its role in kinetoplast division which could also be 
linked to defective basal body segregation, although this has not been looked 
into (Hammarton et al., 2007a). Knockdown of PLK in BSF cells also gave the 
additional phenotype of impaired ingression of the cleavage furrow thereby 
linking BSF kinetoplast duplication and cytokinesis together. Further 
investigations are needed to define this link. 
The focus of part of the studies reported here have been to understand how 
TbPLK activity is regulated. Considering that TbPLK features largely conserved 
domains, i.e. N-terminal kinase domain and C-terminal polo-box domain, the 
working hypothesis was that the regulatory features of PLK1 members, as 
identified in other eukaryotes, have also been retained in T. brucei. Studies 
were conducted in both PCF and BSF parasites although the majority of the work 
focussed on the insect stage cells. This was due to the already established 
expression assay demonstrated in PCF cells (Hammarton et al., 2007a) that had 
not yet been attempted in BSF cells. Expression of wild-type (WT) TbPLK in PCF 
cells was found to generate growth and cell cycle defects whilst expression of 
the kinase dead version did not. This provided the basis by which the kinase 
activity of TbPLK variants could be assessed. Also, modification of the expression 
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vector, to add a YFP tag at the N-terminus, allowed localisation of the expressed 
proteins.  
6.1.1 Procyclic stage 
Overall, the experiments carried out in PCF parasites demonstrated that some 
aspects of PLK1 regulation are conserved in TbPLK. A conserved threonine 
residue, T198, in the regulatory T-loop of the kinase domain, was shown to 
require phosphorylation for the kinase activity of the protein. Another conserved 
threonine residue, T202, was also shown to be essential for TbPLK kinase 
activity; however, the question of whether phosphorylation of this residue is the 
means by which it regulates TbPLK activity could not be answered directly in 
these experiments. Indeed mutating this residue at all seemed to obliterate the 
activating capability of T198, suggesting T202’s dominant role in maintaining 
TbPLK kinase activity. Since T202 is part of the highly conserved regulatory T-
loop of the kinase domain, a closer look at the available structures of this region 
in other homologues could provide the answers needed.  
Further experiments employing truncation of TbPLK demonstrated the joint 
importance of the kinase domain and PBD in the spatial regulation of TbPLK. The 
localising role of the PBD is conserved in PLKs studied so far. The additional 
requirement for an active kinase domain for appropriate localisation could be a 
structural issue. It also means that TbPLK, similar to its metazoan counterparts, 
is likely to phospho-prime its own substrates before binding to them and that 
this is a major mode of TbPLK spatial regulation. However, none of the residues 
required for phospho-peptide binding are conserved in TbPLK. Also, a putative 
His-Lys pincer required normally required for susbtrate binding by homologues 
does not appear to be essential for TbPLK kinase activity. This suggests a 
divergent mode of TbPLK PBD-substrate binding making a strong case for 
elucidating TbPLK’s protein structure to provide the answers needed.  
TbPLK was also found to possess a putative destruction box and experiments 
involving further truncations indicated that this domain is functional and that 
TbPLK might be subjected to proteosomal degradation as a means to temporally 
regulate its presence. This could be cell cycle dependent and further studies 
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would be needed to explore this possibility. The discovery of a functional NLS 
motif as a result of the truncation studies raises the question of whether TbPLK 
does localise in the nucleus in a manner yet to be detected and if this motif has 
a functional role at all.  
A significant proportion of the questions addressed in these studies in PCF cells 
were covered in reports (Sun and Wang, 2011; Yu et al., 2012) published during 
the course of this research project undermining the impact of this study. 
Nonetheless, the majority of the findings of these reports have been 
corroborated here, despite differences in methodologies. However, some 
discrepancies do exist, notably in the questions regarding the importance of 
T202 phosphorylation in TbPLK. It is difficult to reconcile this at the moment and 
further studies are needed to do so.              
6.1.2 Bloodstream form 
Expression of TbPLK in BSF cells, both WT and kinase dead versions, had no 
effect on their growth or cell cycle. This meant that an expression assay could 
not be set up as was done in PCF parasites. Therefore, another approach was 
needed to ask how TbPLK is regulated in the bloodstream stage. To do this, 
attempts were made to set up an RNA interference (RNAi) complementation 
assay. Ectopic expression of WT TbPLK only partially rescued the debilitating 
growth and cell cycle defects generated by TbPLK RNAi. This limited the scope 
of the assay. Also, efforts to confirm knockdown of endogenous TbPLK in the cell 
lines featuring ectopic expression of TbPLK variants in TbPLK RNAi background, 
via Western blotting, were not successful and would need to be addressed in 
future studies. Nevertheless, assuming that knockdown of endogenous TbPLK 
was successful, some general observations could be made. The T198 residue is 
important for TbPLK activity in BSF parasites. However, without analysing the 
effects of T198D mutation (which mimics phosphorylation), it could not be 
directly verified if it is the phosphorylation state of this residue which modulates 
TbPLK activity. Evidence of differential regulation of TbPLK between the two 
life cycle stages was also seen. The putative His-Lys pincer seems to be required 
for TbPLK regulation in BSF cells but not in PCF parasites. Also, BSF cells seem to 
be more sensitive to deregulated TbPLK compared to PCF parasites. This could 
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be due to the differences in the roles cell cycle regulators, such as TbPLK, play 
in the two life cycle stages as a result of differences between their cell cycle 
mechanisms. 
6.2 T. brucei cell cycle regulation by protein kinases 
The advent of RNAi in trypanosomes, and the publication of T. brucei genome 
(Berriman et al., 2005), has enabled rapid discovery of potential cell cycle 
regulators and effectors, including PKs. The success of the screen conducted as 
part of this study (Chapter 5) in identifying known/novel cell cycle regulators 
reflects the huge improvements made in these RNAi systems to make them more 
robust, efficient and reliable. Modifying the existing pRPAISL for rapid 
recombineering to generate stem-loop RNAi constructs has enabled the 
production of a library of a couple of hundred RNAi plasmids individually 
targeting the whole complement of the T. brucei kinome (Jones et al., 2014). 
The pRPAISL system was designed for use in BSF cells that were adapted to ensure 
stable transfection of constructs into a single rRNA locus, thus enabling reliable 
knockdown of most of the targets (Alsford and Horn, 2008). The resulting 
kinome-wide RNAi library of BSF cell lines, therefore, promised to be a reliable 
resource for identifying cell cycle PK regulators at this clinically relevant life 
cycle stage. PKs that were considered to be important for BSF growth and 
replication, following an Alamar Blue screen of the library (Jones et al., 2014), 
were then analysed via growth curves and DAPI staining to identify PKs required 
for cell cycle progression. Many known regulators in BSF and a number of novel 
PKs were identified, satisfying the objectives of this screen. Closely following 
the types of aberrant cells (based on their nuclear and kinetoplast 
configurations) generated, has been greatly informative in identifying how these 
potential regulators are involved in enabling BSF T. brucei cell cycle progression. 
25 PKs belonging to the AGC, CMGC, CK and ‘Other’ families were identified to 
be required for a number of cell cycle stages: G1/S transition, kinetoplast 
duplication, mitosis and cytokinesis. A number of kinases were found to 
potentially have joint roles in mitosis and cytokinesis or kinetoplast duplication 
and cytokinesis thereby hinting at putative links between these processes. 
Individually characterising these kinases, with aims to uncover their interacting 
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partners, would shed light on how BSF T. brucei ensures the timing of its cell 
cycle events. Signalling pathways which promote T. brucei cell cycle progression 
are largely unknown and grouping proteins thought to be involved in similar cell 
cycle functions would be good starting points in uncovering such pathways. 
Efforts need to be made to go beyond identifying generalised putative cell cycle 
functions, to specify the mechanisms by which these PKs, and other proteins, 
impact the cell cycle. Conditional knockout systems can be a useful method for 
dissecting how individual PKs are themselves regulated and to characterise their 
interactions with other proteins (de Graffenried et al., 2013). Chemical genetics 
or the use of selective inhibitors can be used to dissect the temporal role of PKs 
as cell cycle regulators (Lozano-Núñez et al., 2013) and, in conjunction with 
phosphoprotemics, can be used to identify downstream substrates. Phosphosite-
specific antibodies could be developed to systematically interrogate the kinome-
wide RNAi library for PKs which phosphorylate a residue of interest. 
Technologies such as TAP-tagging (Monnerat et al., 2013) and BioID (Morriswood 
et al., 2013) are other effective tools that can be used to identify interacting 
partners.  
The divergence and essentiality of many of these cell cycle regulators makes 
them attractive targets for novel drug development. Follow up work developing 
in vitro activity assays and determining protein structures is important to enable 
their progression through the drug development pipeline. The collective findings 
of candidate gene based studies so far have reported the functional differences 
of cell cycle regulators between the procyclic and bloodstream life cycle stages; 
e.g. TbPLK (Hammarton et al., 2007a), Wee1 (this study and Boynak et al., 2013) 
or CRK9 (Badjatia et al., 2013; Gourguechon and Wang, 2009). It is already 
known that differences in cell cycle mechanisms exist as evident by the fact that 
the dissociation between mitosis and cytokinesis seen in PCF cells is not found in 
BSF parasites. Therefore, extending the cell cycle screen performed here and 
carrying out follow up studies in the PCF stages would be hugely informative in 
understanding such differences.    
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